{
    "5bc844fc-e852-4270-bfaf-36ea9eface3d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "所有初级试验参与者都没有接受任何口服卡佩西塔宾、口服拉帕蒂尼布Ditosylate或cixutumumab IV,但所有次级试验受试者都接受了这些药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "86b7cb3d-6186-4a04-9aa6-b174ab764eed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "甲状腺数超过10万/mm····························································································································································································",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18,
            22,
            23,
            24
        ]
    },
    "dbed5471-c2fc-45b5-b26f-430c9fa37a37": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "与心脏有关的不良事件在初级试验和次级试验中都记录了。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9,
            10
        ]
    },
    "20c35c89-8d23-4be3-b603-ac0ee0f3b4de": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "具有突发双边乳腺癌(T1 N1 M1)的成年患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            3,
            4,
            5
        ]
    },
    "f17cb242-419d-4f5d-bfa4-41494ed5ac0e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "激光治疗是在每个小组的初级试验和次级试验,以及新辅助化疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "fc5c4554-7ce9-4c16-b374-a3cd9d15b021": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT01027416",
        "Statement": "患者必须已经参加特定临床试验才能参加初级试验或次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "96b77cdd-aa9f-4770-8447-8a04d9ca5da7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "临床阶段II(T2N1)侵入性乳腺癌的患者不符合初级试验的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            4,
            10
        ]
    },
    "c73faed2-371b-4238-bf7d-293fae380203": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "初级试验和次级试验有以催眠疗法为基础的干预,次级试验在其干预中也使用了疼痛药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8765009d-ffc4-4395-ab7a-11ecdfd43a40": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "阿黛尔是一名85岁的妇女,患有II级历史上确认的ER+乳腺癌,ECOG为0;她有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            6
        ]
    },
    "0ad7293d-df35-42e8-881d-f2afc3f7d3fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02606708",
        "Secondary_id": "NCT02504424",
        "Statement": "只有初级试验的患者获得40.5 Gy的治疗,二级试验的患者根本不接受放射治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "2bc1e094-41a1-46d9-9b0c-b5a47f23323d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "某些饮料被禁止在进行初级试验的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "83b83400-1439-462d-bba3-42817b5b1fa1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "在初级试验中,大多数CHF病例是在1群中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6,
            14,
            20
        ]
    },
    "c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "初级试验的候选人必须有6个月以上的预期寿命。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            19,
            9
        ]
    },
    "17a821f8-5e68-4bf7-ac01-3f96ddfc5187": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Statement": "符合初级试验资格的患者必须居住在美国。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d76d6c7f-ba39-483c-a89e-152af5ae2878": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "二级试验和初级试验的1组患者不接受相同的AIMRT剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "65f3e755-3e23-4e84-a218-87922759094d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "初级试验服用了28天,而次级试验服用的是介入4周期21天。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d3590771-806b-4754-a455-38113bfedfca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "初级试验的候选人必须具有足够的结肠和肝功能,并且不能目前接受阿米奥达龙或在过去28天内接受阿米奥达龙。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61
        ]
    },
    "941b960f-8d57-4830-9d4c-8e96765ba76c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "初级试验和次级试验都给每个HER2+患者投放Bevacizumab。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "f79a9011-0a68-4255-a40f-5d73af412bf0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "二氧化碳作为干预的一部分在一项初级试验中的研究组中使用,而不是在二级试验中的研究组中使用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "在初审或次审中没有完成自杀,但在次审的1组中有一个尝试。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "57f3a264-9119-4931-9f9c-9cb20e945973": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "初级试验是测试化疗治疗,而次级试验是测试物理治疗课程。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "589e2f5b-9286-465b-8162-bb1549cd5ece": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "在初级试验中的两组中,至少有4名患者获得了完全响应(CR)或部分响应(PR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "8275f846-59b6-404d-a6d8-e01335279f1a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "在初级试验中,不到四分之一的患者经历了不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Statement": "初级试验的两个群体通过皮下服用接受他们的治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "18d9991c-ca96-4bab-93af-77654857a07f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "初级试验不接受1级疮患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            17,
            19
        ]
    },
    "6fb9056d-277c-4dc2-9b45-d7661bb41831": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "初级试验的群体1的参与者接受乳房检查,而次级试验的群体1的患者接受6mg的雌激素作为乳房检查的补充剂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "52b23601-2276-4634-96c7-8b6e55596085": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "初级试验中的一个患者经历了喉咙背部的临床显著炎症。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "95e05332-4926-4381-90a4-87941269e7bf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "超过5%的初级试验参与者获得了部分反应(PR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "20d51467-b059-4f39-b636-d32f2dc692da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "初级试验和次级试验至少部分通过口头进行干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "15c83d26-f9ba-44cc-a920-6941781cdd8b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "中性衰竭影响了初级试验1组中的大多数患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "e100212f-5bef-4f84-a3c1-d18a6b3e8355": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "初级试验的时间范围比次级试验更短,这两个试验在评估中使用相同的衡量单位。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            9
        ]
    },
    "56d2a387-49dd-49b9-93bb-bcb092bf2714": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "该初级试验正在测试一款名为89Zr-trastuzumab的新型放射传感器,以评估其用于可视化HER2+损伤的用途。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2485a3e1-7520-47d2-b941-32ebf91e5b65": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "初级试验的参与者被分配一个干预,取决于他们之前的治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b97d9465-db14-43af-9451-4b824e67abb8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "初级试验和次级试验对他们的群体使用不同的纳入标准,因此患者可能有资格参加一个群体,而不是另一个群体。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "798c0983-5265-47ea-bfcd-735738793482": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "一名患者最近正在接受Tamoxifen治疗乳腺癌,他们被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            11
        ]
    },
    "127e9179-6781-4b9a-abe9-080d2ffad591": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "无论是初级试验还是NCT0306117都没有使用化疗或放射疗法进行干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "阿加莎上周过了50岁生日,她有乳腺腺癌,没有转移性疾病的证据。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "16dc5a77-5758-4d19-9801-6e9932d9fbc9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "主要试验1组中的几名患者以口服药丸作为药物服用方法为首选。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "2ed770a0-fe98-4029-9511-ad04a94a1a69": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "在初级试验中,小组 2 比小组 1 患有 Leukopenia 的患者多,而在次级试验中,小组 1 患有 Leukopenia 的患者比小组 2 患有 Leukopenia 的患者比例最高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            14,
            19
        ],
        "Secondary_evidence_index": [
            0,
            3,
            12,
            15
        ]
    },
    "b4c97206-66fd-468b-8388-fac076222c10": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "与小组 2 相比,初级试验的 1 个小组中有 7 个更多的贫血病例和 1 个更多的散发性血管内凝固病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            12,
            13,
            14,
            15
        ]
    },
    "6e22d118-af77-41bd-bd47-9385779f33aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "有几种类型的手术和治疗方法,禁止那些希望参加初级试验的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "ccc5362a-33d0-4f1b-be46-d31729ba9194": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "初级试验中Talazoparib组中最短的PFS比该组的PFS平均短一个多月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "fa530b28-9142-49f2-aa80-4d04fa532910": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "初级试验组2的参与者接受对麻疹区域的绑定,但没有复杂的退缩物理疗法。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "初级试验的第1群组中没有任何患者有血小板缺陷,而第2群组中的任何患者都没有Pyrexia。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "41cf791e-ed7a-48e5-af84-eefc9fa41ba7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "在初级试验中,所有不良事件都同样普遍,而在二级试验中,酒精中毒被报告为最常见的事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "d417aa7b-6d2c-46f8-812c-426ea60e0328": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "初级试验中只有3起不良事件发生了两次以上。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "2744cc0a-86e9-4764-ae1c-f10f635dc283": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "主要试验中的大多数Letrozole组患者在24个月后出现了脊椎骨质矿物密度下降。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2e4717fd-b349-48a3-b751-88674dfaaa18": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "在初级试验中,1组患者必须对标准疗法失败或不耐受,或没有标准疗法可用,2组患者必须对标准疗法反应良好。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b0c65cd7-8cad-404d-8704-ee074e480f57": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "初级试验和次级试验不具有任何重叠的纳入标准,除非最低年龄为18岁。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            20,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            51,
            54,
            55,
            56,
            51,
            58,
            59
        ]
    },
    "28e20650-e100-4e30-a319-5eceb69a979d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "初级试验中的1名患者患有毒性肝炎。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "8cf0c320-9486-4531-9212-bb3284b734f1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "二级试验是对其干预的DLT进行测试,而主要试验是通过使用SentiMag和SiennaXP来评估淋巴结检测的有效性。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "34a75478-e7cc-495e-86c3-d0accdaf1ddd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "初级试验的参与者必须年满18周岁,已 histologically confirmed stage 4 乳腺癌,ECOG < 2 和预期寿命超过 6 个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            6,
            7,
            8
        ]
    },
    "47780450-1202-4934-8e50-b29416b124f5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "所有初级试验的参与者都接受了相同的Letrozole剂量,而二级试验的所有患者都接受了相同的Tamoxifen剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "在初级试验中观察到2例严重的背痛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "c5e6497a-2e2f-4663-97fd-e73ba8904b0c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "在二级试验和初级试验的所有小组中,只记录了一例心肌炎和血栓症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "c4dd814d-f525-465f-abe1-a7975771d57e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "重量低于45公斤的初级试验小组1的参与者比45公斤以上的参与者获得了500万单位/m2的IL-2,但所有参与者将每周3次服用甲基酮6剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "cfd93077-87c5-458b-8712-e1896929309d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "初级试验中的一个患者有异常低的红细胞,白细胞和血小板细胞。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ]
    },
    "a3faaf85-62c6-430f-acf2-9c5992ee5221": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "在初级试验中,所有不良事件均为普遍,而在二级试验中,疾病的进展被报告为最常见的事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "低于5%的初级试验小组1有高血糖,0%的二级试验患者被记录为高血糖。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "335936e4-9eaa-43b3-84fe-6f112c0d0226": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "辐射治疗和治愈触摸疗法用于初级试验和次级试验的所有群体。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "19921113-538e-4fd2-81a6-6053f2dd6459": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "在初级试验中,DLT的患者比在初级试验中,在小组2中多出38%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "6a013bb4-0688-4f02-96c5-062f3ca67ae1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "总体而言,初级试验的1群体中有5倍的不良事件,而不是2群体。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "c103a786-0b1d-4124-aa5d-4945ded2c384": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "初级试验和次级试验不研究PFS、PBR或DLT。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "2746a75c-7f01-4dc3-a05e-5c7499e75555": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "最多有3级癌症的患者有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61
        ]
    },
    "df64a4c5-08f3-40c7-a4e7-2a6271bc9e53": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "以前有皮肤癌恶性患者被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            13
        ]
    },
    "682f5e80-75c4-4a36-9bc1-b389a98ad160": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "初级试验中的1组患者中没有患有低血压。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "7028841e-28e6-4fd3-a27c-2ae2e7dc7b52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "只有白人和亚洲患者有资格参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "348c9273-6aa1-43a8-840d-3cf080874669": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "总体而言,在初级试验的两组中,至少有2名患有发烧的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "dfe6228e-6bfb-49d3-b0b4-397aab177bea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "我们无法比较初级试验的两个手臂之间的结果,因为在1组中没有患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9f424ebb-63b8-4930-b2c1-cd46fff4d706": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "初级试验中,只有一个患者群体对基准的激素中介变化是积极的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "c1f8c7fb-22de-4501-af86-d9eb59542ae3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "初级试验的2号群体中,与1号群体相比,患有稳定性疾病的患者更多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "6630047b-7ebc-4435-8203-cf6bbe6b6ee7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "左腹部排泄比例 > 50% 是参加初级试验所需的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18
        ]
    },
    "039c3fc2-f798-4d97-b904-9aa7d363eeef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "患有子宫颈癌的患者有资格参加初级试验和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            12
        ],
        "Secondary_evidence_index": [
            6,
            10
        ]
    },
    "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "初级试验要求参与者接受PTR。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "f8028143-35d1-4cc3-895a-acb577db4715": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "初级试验中的1组参与者和次级试验的所有参与者服用了1毫克阿纳斯特罗佐尔和40毫克西姆瓦斯塔丁POQD。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "907f7e56-b6ec-4a43-bf3a-14f93c644bc1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "患有慢性病毒性肝炎的18岁以上女性患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            8,
            16
        ]
    },
    "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "根据Gail模型,在未来5年内和她的一生中被归类为患乳腺癌的高风险的女性有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "a41bf7b0-9a09-4ce0-8832-f13758581f20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "初级试验的凝聚体1记录了比凝聚体2更多的光学不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "5f2d2015-eaf9-45a8-9583-fddbc9807287": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "初级试验的1组患者中,不到0.25%的患者患有 hyperbilirrubinemia。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "609ddd08-ebd5-4661-be43-874b65dbfe52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "患有痴呆症或精神分裂症的患者可能有资格参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            4
        ]
    },
    "b6ac985d-87ae-4e0f-83e1-38033c1db5cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "初级试验和次级试验使用ECOG来评估潜在候选人的绩效状态。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            2
        ]
    },
    "43ff9425-5e6e-4a85-a8ca-0c0c67a96623": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "超过5%的初级试验参与者获得了客观响应(OR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "b3ccde30-cdfc-4e18-aee0-8b3a921dde39": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "每个患者在初级试验中都被给予tipifarnib PO,以及帕克利塔克尔,多克索鲁比辛水氯化物和 acyclophosphamide IV,但只有一小组参与者接受轴心淋巴节分解。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "8697a59e-0f1c-452a-b15a-6d24e2df387f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "初级或次级试验中的任何患者都没有自杀。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "4ab74186-5f4e-4139-af05-d4a9871a251d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "史蒂芬已经和丈夫一起生活了31年,她有资格参加初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            6
        ]
    },
    "082ee581-f420-4892-b098-ce82c6ad0210": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "在初级试验中记录的所有不良事件都与心脏有关。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "7bf084eb-873a-4011-9b98-3a899ee582ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "更年期前和后女性可以进入初级试验,只要他们没有之前的激素替代疗法。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "初级试验和次级试验正在测试完全不同的干预方式,但使用相同的21天周期。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "ERBB2阳性肿瘤的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "f6c85ce8-e0fc-4186-a961-6207dd4cacd2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "大多数以Eribulin Mesylate治疗的初级试验患者没有报告完全响应(CR)或部分响应(PR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "5bdd61d9-aadf-4944-afe3-a04242d9c2b2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "入侵性乳腺癌,直径小于4厘米的患者被纳入初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "b8ce7d6a-d707-48e0-816c-de7ac3a63823": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "菲奥娜的妹妹34岁被诊断患有管道癌症,因此菲奥娜可能有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "53d88010-e7d7-41c7-b20d-6328c8e507d1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "对于初级试验中的一些不良事件类型,没有记录的病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8257bf5c-fae6-44c0-a86d-293746fdc468": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "初级试验的1号群体有比2号群体更多的肝脑病和肺炎病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "HER2阳性乳腺肿瘤的患者有资格参加初级试验,但被排除在二级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "974225b7-9089-499c-9550-0a7207fd28b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": "初级试验的干预不需要患者在研究期间接受任何医疗治疗,而在次级试验中,所有患者都接受放射治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "6f533f52-c8e4-4983-8968-69af03a9e34a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Statement": "细胞学确认的乳腺癌患者,其本地复发性疾病是具有治愈意图的辐射易受的,不符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "690b8562-7d68-4642-bacb-601f227bb763": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "初审没有干预部分。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "75f94edd-dbde-4a19-be18-e67c767f6d8f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "初级试验的干预部分没有描述对2组的干预剂量、频率或持续时间,但1组每天服用安慰剂两次,持续两个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "初级试验中,至少有部分反应的患者比二级试验中的任何一个群体的比例更高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "34ee4f66-e6f7-458c-964c-12fa730a9d56": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "初级试验的两组都应用本地干预,大约每四到六个小时每天进行一周的研究。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "9b0451fe-f760-46d3-b555-0a9b83546e73": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "初级试验记录的呕吐人数是二级试验的半数。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "b9304415-073d-476e-a056-cb2a747d56fa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "初级试验的 2 组仅在 1 到 4 周期服用 Doxorubicin,然后在研究周期 5 期间服用 Doxorubicin, cyclophosphamide, Herceptin 和 docetaxel。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "6e365e33-16b8-43e1-99b5-49dfed6f7b13": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "只有中国女性患有第4阶段或不可治愈的局部复发性乳腺癌,才有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "初级试验中的群体1的参与者比群体2的参与者接受了更多的Dasatinib和Paclitaxel。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "27acc6d7-c12d-4a38-9133-a5c8429dd264": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "初审记录了23起不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "5919a080-2f0d-4c3b-9b03-10df80b2e680": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "初级试验中没有任何不良事件,影响了特定患者群体的10%以上。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "91f6e62a-97e7-49fa-8509-7ff8c1f0155e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "纯管道癌症(DCIS)或瘤的患者有资格参加二级试验和初级试验,并且可以与其他药物试验一起参与这些试验,最多3次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7,
            12
        ],
        "Secondary_evidence_index": [
            0,
            9
        ]
    },
    "b351a091-d5fb-49f9-a864-5c89c6316b1b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": "患者必须具有 histologically 或 cytologically 确认的 PR + 侵入性乳腺癌, 主要肿瘤 直径 > 2 cm 参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d5ca2086-8404-42d1-bf45-5370f3d4e8e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "在初级试验中出血的病例比在次级试验中多出 16.67%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "4c038972-20a9-4031-a1cd-ba00e9dd0908": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Secondary_id": "NCT00617539",
        "Statement": "在初级试验中,Dasatinib,70mg,两次每日结果比Dasatinib,100mg,每日更好的PFS中间值。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "82d6275a-97e6-4d13-84eb-5f7c2585db8b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "在初级试验和次级试验的两组患者之间,只有一个患有心脏衰竭的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "286e74e5-74ed-4d42-b32d-f1398c514d37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "每日服用40毫克(mg)初始剂量和每周服用10分钟的Vinorelbine 25 mg/meter2(meter=m)静脉注射的初始试验中至少有一名受试者服用过胶囊胶囊阿法提尼布的口服治疗(meter=m),PFS超过9个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "634642da-db6d-49cc-a999-67f46e91dbca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "初级试验和次级试验没有重叠的包括或排除标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            20,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            51,
            54,
            55,
            56,
            51,
            58,
            59
        ]
    },
    "a529e364-2da7-4067-acb6-9fb2f0adf08b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "在过去2周内接受T细胞转移治疗的患者将被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            8
        ]
    },
    "317e00ae-9d17-4f85-8787-602cc2548fdb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "从乳腺肿瘤传播到骨髓的癌症患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ]
    },
    "de955acc-ce0e-4416-9884-644a06971603": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "初级试验和次级试验的2组是试验组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4956f0d0-4df4-4de3-9a46-6073927485c3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "二级试验的患者群比初级试验多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9ca0cc75-58b3-451d-abcc-378526744ca4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "患者必须在进入前进行MRI扫描,无论是二级试验还是初级试验,对于初级试验的患者还需要进行脑部MR和PET成像,研究入学后。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6,
            2
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "6efb001b-5ed3-470b-a206-7768a1adf597": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Statement": "历史上确认的侵入性管道乳腺癌将导致从初级试验中排除,但不会从次级试验中排除。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            10
        ]
    },
    "70dd1a42-6e40-4880-80a8-45dfd4941ce4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "初级试验使用3周的循环为SB-715992的管理。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "85f43677-b680-4127-b1da-7e1cc966e4b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "并非在初级试验和次级试验中的所有受试者都将接受4-8mCi Tc-99m sestamibi。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4cccea8a-22ae-4813-96df-b902850f4991": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03136367",
        "Statement": "任何年龄的女性都可以参加初级或次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "8574ecd7-4da7-49b0-a273-de495bc1fee7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "恶心和死亡是初级试验1组患者中最常见的两种不良事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "01b82c51-dd3d-430b-9523-0e93a9eb9c1a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "初级试验记录了许多患有胸痛的患者,而次级试验只观察到一个患有腹痛的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "93149dfc-667b-48d3-a46d-ad48b15e701f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "初级试验的1和2组记录了每个类型的不良事件的确切数量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "d080eec7-412f-4a44-8c56-91e0ec459acc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "初级试验是第二阶段试验,其中所有参与者将接受局部氟基诺尼酸 0.05% 奶油,每天两次在两周内应用于他们的生殖器。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fd18a599-f94a-478a-975f-854a4210ccad": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "初级试验有5年的干预期,次级试验的持续时间仅在排水器被清除后一天。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            5,
            10,
            5
        ]
    },
    "ac9ca070-80b2-4913-97d8-06d1b90fcfce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Secondary_id": "NCT02005887",
        "Statement": "二级试验和初级试验都具有安慰剂手臂和试验手臂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8,
            9,
            3,
            4,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "19f5ff0d-3419-4f27-a7e5-6c7291c3cd21": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "在初级试验的持续时间内,帕里蒂克被给予Fulvestrant剂量的增加。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "009d23bb-2179-4ce3-927d-4dedca6b32a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "以前接受过贝瓦西苏马布治疗的患者不符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            22,
            24
        ]
    },
    "5152d810-7669-4fb2-a66b-a0a1d6026af5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "二级试验和初级试验都使用病理完整反应(pCR)作为其结果衡量,并使用6个月的时间框架。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e8f4a600-0296-47d4-903b-2fa840ebcf28": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "第三阶段宫颈癌患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "3fa8b747-b48d-4fb4-995d-38a23c64ccb3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "初级试验中的2名患者有症状,但能够吞下修改的饮食;有症状,无法口服食物或水分,或有与生命危险的后果相关的症状。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "b9c294c3-93b7-4681-be02-285f9e5cd867": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "在初级试验和次级试验中的所有群体中,仅在一个群体中使用了欧米茄3脂肪酸。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9df90d78-d857-4e1d-a650-e47f7b6b68d6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "初级试验的2号群体接受了比1号群体更高的Ixabepilone剂量,频率较高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "有结果部分表明,初级试验中没有有0不良事件的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "92ac6e0c-8427-454d-9218-36eda1c580a7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "初级试验和次级试验的干预措施是如此不同,以至于无法或无益地比较它们。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "f0aff1fc-4a67-4b28-a974-a4a67a5c930f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "在初级试验中,最小和最大PFS之间的无进展生存差异超过14周。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Secondary_id": "NCT00256243",
        "Statement": "未愿意签署并给出参加初级试验或次级试验的书面知情同意的患者将被拒绝参加。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            11
        ]
    },
    "96ab702d-cfe1-48fb-b348-a7c7b8db3f16": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "接受TNBC诊断后,初级试验的A臂患者生存的平均时间为6个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "6224d2de-c62b-4b43-8517-475eaa565491": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "初级试验中的大多数患者至少经历了一次不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "95154c62-9f79-4d80-90fd-2f61612285b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Secondary_id": "NCT01702571",
        "Statement": "总共,在初级和次级试验中,超过5名患者经历了Earache。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "2f6243a9-af40-426d-9a6a-a5c5708cf1b4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "初级试验和次级试验记录了相同数量的恶心病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            7
        ]
    },
    "837f0588-22fc-4069-b2bc-297b3f6aabf7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "初级试验的候选人不需要满足特定的预期寿命标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            19,
            9
        ]
    },
    "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "初级试验中的患者不会像二级试验中的患者一样注射Herceptin®(trastuzumab)或帕克利塔克尔。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e7b47e19-9cd0-4121-a79a-ee223e7f3ab7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "患者必须有超过半年的预期寿命才能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "初级试验中的30%的患者对感染产生了危及生命的反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "d72ecaae-c132-480c-af5e-87c58dd26082": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "在二级试验和初级试验中观察到的唯一不良事件是内宫颈癌。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "80245791-4a95-4682-bd5f-856694c9f52f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "患有HER2负性肿瘤的患者有资格参加初级试验,但不能参加二级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "二级试验和初级试验不要求参与者属于特定种族,能够说特定语言或超过一定高度的门槛。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "f0da58e6-e937-41ac-b53a-d46ec8a28d11": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "初级试验的干预1要求参与者每天服用300mg的alpelisib。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5a74a63a-3912-44f0-9e83-4e6b678cbe90": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02685566",
        "Secondary_id": "NCT03076190",
        "Statement": "初级试验和次级试验有相同数量的研究组,并正在测试全场数码乳腺癌的有效性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "43f03ba4-ef03-4f57-b059-3d9267f0dcf8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "18岁以下的患者,希望参加初级试验,必须在入学前停止任何抗肿瘤激素治疗,并有3个月以上的预期寿命。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7,
            8,
            13
        ]
    },
    "6e106caf-2522-4022-898d-64b82093d77a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "20岁以上的女性没有先前进行化疗,以治疗目前的癌症,有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5
        ]
    },
    "7f8a918c-fab8-4129-8178-0cda7d0441e1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "初级试验的2个小组在整个研究周期中接受了多克索鲁比цин,循环磷酸胺,赫塞普丁和多塞塔克塞尔。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "初级试验中至少400名受试者每日服用40毫克(mg)初始剂量服用胶囊胶囊阿法提尼布的口服治疗,每周服用Vinorelbine 25 mg/meter2(meter=m)的10分钟静脉注射,9个月内出现PFS。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "2bd65df6-4f1d-461c-93f5-f2ddbfde57b6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "未经解释的三十八摄氏度以下发烧的患者可纳入二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            25,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "0290bc2d-9cd3-44ab-9b04-385f19527c42": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "患者必须有管道癌症,可以通过触摸感受到才能符合初级试验的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "505afbf8-b2b4-4b12-99c5-e0feef473248": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "二级试验和初级试验既不使用临床效益率作为其结果衡量,也不使用相同的时间框架。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "患有 histologically 确认的新诊断阶段 0 双边乳腺癌的患者不能参加初级试验,但仍然有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2e540abd-06e3-483d-bd69-6eb5d2275e9e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "初级试验和次级试验的患者每天服用口服药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "d905f4cb-32aa-41b8-8f61-40578d8ea9ae": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "初级试验中的两个群体中至少有2名患者感到恶心。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            12,
            13,
            25
        ]
    },
    "45510043-7931-493b-8251-41b0be9aabbd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "在初级试验中,有2例患有静脉脉脉搏心脏病的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "e7037f34-bd2e-402e-a19c-48073781885a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "初级试验的1组患者中有10人患有低血压。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "5275a332-46c1-4941-8850-26a8033012e3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "只有先前被诊断出患有癌症并在治疗结束后没有癌症迹象的人,只要他们超过20岁,才可以参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "二级试验和初级试验都使用MRI和Letrozole进行干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b02f43d7-44bb-4219-9a08-fd70e7cc9b87": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "患者必须有确认的更年期状态,定义为超过一年没有月经,如果他们要参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "1a6661e0-343f-4056-b568-611e7cc7750c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "目前接受放射治疗或生物治疗的任何乳腺癌患者都被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            14
        ]
    },
    "ec97c90e-f904-4cf2-9567-8525edf747cf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03196635",
        "Secondary_id": "NCT01943916",
        "Statement": "初级试验和次级试验都评估了患者辅助成像干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7a129a1e-20d9-4f5a-a921-d30957460e27": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "二级试验和初级试验不测试癌症治疗的相同方式。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "在初级试验的两组中,治疗期间至少出现1个不良事件(AE)的参与者比例差异小于1%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "a1c99d5b-d53a-4195-ad5f-5e1b48c22078": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "虽然在二次试验中血管细胞压症患者的百分比远高于初级试验的群体1中,但由于群体大小的显著差异,无法进行强有力的比较。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0203435e-03a0-4c41-afdf-6c497d8908c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "左腹部排泄率大于50%的男性被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18,
            9
        ]
    },
    "e6388dc2-b096-467d-8b70-fd5346dd581a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "在初级试验和次级试验中,任何不良事件的最高发生次数为2。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "93511e52-1c12-4dee-858e-13b10793e2a6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "二级试验在其干预中仅使用放射治疗,而初级试验在研究的第一天为其患者群体提供干细胞移植。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "cb932dbf-4c98-4488-b189-1286442968b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "子宫颈癌患者在现场被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "0b9aa7e8-5912-44db-b9b0-6a84df769e19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "初级试验中没有患有鼻鼻子反应的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "570ab6bb-b23c-4955-b6b0-d756d1b69c0e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "细胞学上确认的,转移性,早期阶段侵入性乳腺癌的患者,Allred分为3有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "daf105f8-58e8-47d7-b0a2-5949620b0a2b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "初级试验在相同的频率和相同的皮肤区域上施用安慰剂和尿酸/乳酸霜。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c4b671ae-4701-43a3-ada1-659c265d1f3a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "为了参加初级试验,参与者必须知道他们在哪里,是什么日子。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "0a17a404-ed1d-4c31-a192-509b68198ea8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "在初级试验中发生了牙齿不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "无论是初级试验还是次级试验都不要求参与者在佩戴Fitbit活动监控设备时练习瑜伽。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e8b86ef4-3ce8-4d81-a632-f30672c80ff5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "在初级试验中,患者接受 Perflutren Lipid Microspheres 注射,而在次级试验中,患者被植入Meso BioMatrix Acellular Peritoneum 矩阵。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "879f2f14-38a8-419a-bae0-e62ed81eb9dd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "初级试验的1号群体接受了LA-EP2006的2号群体剂量的不到60%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2ec46285-dd0c-4420-b9f6-e44a1ac74f20": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Secondary_id": "NCT01940497",
        "Statement": "初级试验或次级试验中观察到0例Tibia或Fibula骨折。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "f8afffdc-649b-4921-942a-66b804a3717f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "为了有资格参加初级试验,患者必须没有先前的辐射,安特拉西克林或系统抗癌治疗,并且必须有T1-4,N1和M1双边乳腺癌。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            13,
            14,
            15,
            19
        ]
    },
    "65f22210-47dd-4865-99e2-ddd414dddb08": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "总共超过82%的初级试验患者在5年后报告无复发生存。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "ff8a1e0d-d2ee-4687-b429-5b3b6081edc6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR 1.35 足以参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "初级试验的2组病人中的一名病人碰撞了他的摩托车。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "0aa3c085-b9c6-4918-a5d0-eabc55bdd177": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "在小组2中有超过10个不良事件的病例,而不是初级试验中的小组1中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ]
    },
    "333c2723-e2e8-4c68-9591-36b7f169ff26": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "初级试验的1号群体中比2号群体更高的百分比显示出发烧的迹象。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "1fa01b9a-1288-404c-ad58-8dcf3db3264c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "初级试验的Arm A的59%获得了最佳的整体反应,分类为至少6个月的完整或部分(确认)肿瘤反应或稳定疾病。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ed272c3f-37a1-4db7-8990-bf226f8c9822": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "在初级试验中,Diplopia的病例数量与二级试验中的贫血数量相同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "b1497cf4-6b06-4227-b679-19e2ac5fb5c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "初级试验研究了CTX/IMQ/RT和Epothilone对中枢神经系统(CNS)无进展生存(PFS)的影响,治疗开始后9周。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "186d5a67-1309-4abc-b31a-de026c5b8bda": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "诊断出内膜肿瘤的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10
        ]
    },
    "6b86f306-f989-4676-8f5e-c4c8a6aa4258": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "初级试验参与者将接受Lapatinib、WBRT或Herceptin。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0e8e4a92-b104-4192-ad36-33b683f94216": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "在初级试验中,与9mg和18mg组的结果差异不到5%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "初级试验有局部干预,而次级试验有口头和IV干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "03a8a787-2bf3-43e5-9c9e-7bd9c3278751": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "在初级试验中,Letrozole组的所有患者在3年后出现了脊椎骨质矿物密度下降。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "7d7a9a69-533a-4480-b2e7-aa59eb8a738b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "完成反应(CR)或部分反应(PR)的参与者的百分比在HER2阳性组在初级试验中比在ER+和/或PR+组中高出6倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "c6fc8336-7c74-443e-9548-3bbafe21fc37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "在初级试验中,不到10%的患者或复发或死亡。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9035000f-d87b-439f-882a-e6e30694e391": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "目前处方的糖尿病患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            18
        ]
    },
    "522ca0ec-aeb0-4083-a274-ab58c2cddb8a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "与初级试验不同,二级试验不测试激素解放激素类似物或医疗设备。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "46d65581-7a0a-423b-907e-662c1f5843cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "在初级试验中,抑郁症的病例比脱水的病例增加了4%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            6
        ]
    },
    "f4ea6e98-75e1-43a0-8202-548bb7ceb66c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "初级试验的干预需要患者在几周的时间内接受多个治疗应用,而次级试验的干预只应用一次。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c3a618d6-2c2e-4ed6-bfe7-88d28ec18240": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "初级试验组一的患者的中位TTP为NA。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "932728c5-2e7f-401f-be64-e90597ff2ce2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "初级试验的群体2比群体1的群体2中出现了更多的胚胎病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "54ad9406-852c-40fc-bd0e-8e7e81eacc71": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "初级试验的参与者无法达到16小时、17小时或20小时的最大血浆浓度。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "7021a4a9-b474-4568-a3b8-015a50c9d9cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "患者必须有三重负渗透性乳腺癌才能参加二级试验或初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "24eced44-40b2-4365-abd3-42eb13220cf0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "在初级试验中使用的干预中没有放射治疗或教育部分。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "3e2dda3a-815f-4681-a470-009d9f9b30d6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "初级试验是测试放射治疗干预,而次级试验是测试一款新的手持医疗器械。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "1a293e7c-691f-4f93-bab8-6bf5d9b3f904": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "初级试验和次级试验的干预是相似的,因为他们正在测试相同的药物,但他们不使用相同的剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "a87e6e20-c7d0-4941-9933-204fab99b299": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "接受Lapatinib治疗的初级试验的参与者不到三分之一在6个月的试验治疗后达到无进展生存率。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "6c3427a8-27a1-459c-9fbc-175649210868": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "在初级试验的1号群体中,比2号群体中观察到的过敏反应多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "883bec6a-bce2-4e60-9304-49a056e66df7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "一个女性的血球含量 > 10.0 g/dl,绝对中性细胞数 1,733/mm3,血小板数 = 100,000/¬ ̈ μl 和总 bilirubin < 1.2 x ULN 是适用于初级试验的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12
        ]
    },
    "8720143a-2611-4502-a5ee-da4e641df918": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "在初审或次审中没有出现过超越案件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "0fdda7a2-4119-40a7-84f3-6c5c6077df49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "在初级试验中的A和B群中,血清25(OH)D大于或等于30 ng/ml的妇女没有接受每周的胆固醇补充剂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "e7eae332-6b6a-41e0-aa31-86a781fd373f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "心脏不良事件的数量是初级试验的1组中失眠症的两倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            8
        ]
    },
    "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "在初级试验中,低剂量氧化物比高剂量氧化物少400毫克/天。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            14,
            15
        ]
    },
    "c09b9f7c-2d22-4c44-a79d-32929530dd9e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01735175",
        "Secondary_id": "NCT01216319",
        "Statement": "二级试验和初级试验都是测试生物设计干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6f143256-52e4-40b7-950c-5c892f8632b9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "在初级试验中,PFS在5个月的比例最高的患者群体是IIIB阶段的患者,最糟糕的是IV阶段的疾病患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "d2718f05-1d35-4c84-a054-06a3fe4a0a9c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "为了被纳入初级试验,患者必须至少有1个单维可测量的损伤,并必须满足某些特定大小条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5,
            8
        ]
    },
    "7f49cafd-3a27-4fc8-872d-914b9176442e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia是初级试验1组患者中最常见的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "初级试验的1组患者中观察到有同等数量的中性衰退和泛细胞衰退。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            4
        ]
    },
    "3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "患有4级癌症治疗前5年以上的放射治疗的患者不符合初级试验或次级试验的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            26
        ]
    },
    "4ab00376-83a4-467e-8a1e-6b8b1643a8f0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "黑人男性和ECOG <=2, ANC >1.5 x 10^9/L,PLT >100 x 10^9/L和没有先前的血栓的历史,有资格参加初级试验,但被排除在次级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10,
            12,
            15,
            25
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "初级试验中的任何患者都没有记录为心脏相关不良事件,而二级试验中的许多患者经历了几种不同的心脏相关问题。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "407369fa-92ba-4994-8a0f-d372995f3241": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "无论是初级试验还是次级试验都不需要参与者练习瑜伽。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "05e50a3d-d5b2-4fe6-9709-c884c89c5f71": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "初级试验和次级试验都评估响应率,但初级试验研究CNS响应,而次级试验研究肿瘤响应,此外,他们测试不同的治疗方法。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "59fd53e4-b38c-4018-bafc-6fd7f7becebe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "初级试验中的1名患者患有阻塞他们的血管的血栓。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c17eaeab-4e99-4cc4-8681-ae6ccddba572": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "初级试验中没有细胞炎、恶心或贫血病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "621d06ac-12dd-42c2-a012-15c1d94a4f0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "初级试验的候选人必须有足够的肾脏和肝脏功能,并不能目前接受阿米奥达龙或在6个月内接受阿米奥达龙。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            27,
            28,
            38,
            43
        ]
    },
    "021e79d2-ce70-43cf-aac9-fa8d4c8d3770": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "在初级试验的患者群体中,观察到3种不同类型的感染,这些是肺炎,尿道和运动员脚。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "06aa0fbc-fe49-4715-88cc-507646f6323f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "初级试验中的两个群体之间的区别在于,群体1参加了哈塔瑜伽,而群体2不参加瑜伽。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "21947261-bbef-4d3a-adda-02bb4a91a3ca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "二级试验和初级试验都接受患有乳腺 progesterone 受体(PgR+)腺癌的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "71daae7c-3ee5-4451-91e2-273d8ff55aae": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "二级试验与初级试验相比,出现不良事件的患者总数较低。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "每个患者在初级试验中至少经历了1个不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "7d22937b-9823-45fa-a914-261f993e4d64": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "在整个初级试验中,一个病人出现了视力问题。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "507a4189-4905-4752-8348-d715a5ce3962": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "初级试验的1号群体中观察到的过敏反应比2号群体多3次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "24001e83-6a8c-4f67-9c24-55dc285c4cc2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "初级试验结果表明,与安慰剂相比,CoQ10降低了患者经历的疲劳水平。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d179396d-94fe-465f-a4f1-e7c3291a0a9a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "filgrastim是初级试验中通过皮下注射给予的唯一药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "4b893eeb-80a4-4a83-8df5-b5c668ce55b1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "二级试验中的更多患者患有肢体肿瘤,而不是初级试验中的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "44cd16f5-6638-4d82-9121-1941eb8ce4b5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "总体而言,初级试验的1组不良事件比2组不良事件多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "50ac2c53-3b63-4507-8712-41f8c257b4da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil、epirubicin 和 cyclophosphamide (FEC) 用于二次试验的两组,但不用于初级试验的 1 组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "14607d45-9aef-458d-89cc-d47c62c23322": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "患有历史上确认的三负性乳腺癌的患者,没有已知的大脑转移,也没有任何早期的自身免疫疾病或心脏功能障碍的历史,可能有资格参加二级试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            22,
            15,
            33
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "d2961e96-bd3b-4994-aa7e-2b310eb6204e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "初级试验中至少有1名参与者表现出肝功能不良的迹象。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "8a5d7285-f4be-4e50-9057-19f74bcc410b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "在初级试验中,患者每3周服用最多200mg IMGN853 IV。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "512990dd-45d2-4b31-b571-66735ff02308": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "有4种不同的不良事件,其中在1组中记录了0例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "383db144-4bcd-4ebc-989c-b6ae7d282026": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "胃肠道出血在二级试验的2组患者中比初级试验的1组患者中更常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "bfa07fb7-f8cb-4215-9bca-ddee8b3bea73": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "主要试验1组中的大多数患者因未知原因死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "228e80ab-84d6-4b60-9960-dcdcbd78c03c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "患有80%至120%的FEV1的患者不符合初级试验的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "b7caad28-5fb2-4eb6-845e-8315cff97318": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "前期激素治疗(s)在转移或辅助环境不必要的患者在初级试验中,也不适当的器官功能或特定种族或种族背景。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "73c37b9c-e7ba-4c90-b26e-23b7a65509c4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T2 N1 M0乳腺癌可接受初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d5b81f6c-821a-4db5-8810-9cc47a952913": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "知情同意对于进入初审是必需的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "cdba382e-894b-4f79-a8e2-ff818746adc5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "在初级试验中,百分之百的患者经历了不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0093175a-38cb-4f63-b391-709ac48158b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "患有过度表达HER-2肿瘤的患者有资格参加二级试验,但不能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "19106207-4fa2-4cc4-8e22-6e5330bf05ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "在初级试验中记录的任何不良事件都没有发生过一次以上。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "a015685e-f744-4bb2-a6d3-893f081d6dcc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "初级试验和次级试验均使用21天的周期进行干预,最多分别为10周期和4周期。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b9578bae-6640-4ef1-ba2c-899b45c602ee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "初级试验中的所有患者都必须喝4杯水,无论是碱性水还是蒸水,取决于他们所处的群体。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "405369ef-d216-4d81-a04f-46f36f466a19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "初级试验的1组有更多的尿路感染和脊椎骨折病例,而不是2组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10,
            11,
            14,
            24,
            25
        ]
    },
    "e424c65e-7c6f-43a4-95e4-6beb705d9903": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "二级试验的1组患者的百分比高于初级试验的1组患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "初级试验的安慰剂组的平均保留比多尼佩齐尔氢氯化物PO QD组更好。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "患有非可触摸的乳房损伤和0可触摸的轴心淋巴结的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            12
        ]
    },
    "6843daf8-8136-4973-9bf2-62a622d5a890": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "在初级试验中,参与者根据他们的HIV诊断进行干预,而在二级试验中,干预被随机分配。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            5,
            6,
            7
        ]
    },
    "2687b547-c225-4838-bbcd-99212a74d815": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "初级试验和次级试验的患者没有出现相同的副作用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "fadf7710-6e4d-49d6-82fc-4f3137b5e26b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "仅在初级试验的1组患者中观察到一个不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "初级试验中的所有不良事件发生在2组患者中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "6c0896ac-db42-45b4-a6e2-620a27fd321a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "在初级试验中,低剂量氧化物比高剂量氧化物少5%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            14,
            15
        ]
    },
    "3a80ba8a-265f-4931-a9a8-b7e00e372599": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "在初级试验中记录的所有不良事件发生在1组患者中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "df4b98f2-7ca9-4855-8d94-d62407ff8535": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "初级试验只有一个测试小组,而次级试验有测试和控制组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "5d2542fa-5482-4aff-af29-80875a0a9dcc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "初级试验记录了患者群体内的直肠出血,而次级试验记录了阴道出血。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "5deb8ebd-fbd2-4d84-8ad2-a1248426908b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "HIV+ 患者均被排除在二级试验和初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            14,
            18
        ],
        "Secondary_evidence_index": [
            12,
            26
        ]
    },
    "5f4880ac-1ce2-4b89-841b-a9918720b6ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": "为了符合二级试验和初级试验的资格,患者必须满足以下所有条件:碱性磷酸酶 < 2 x ULN、阿斯巴达氨基转移酶 <= 1.5 x ULN 和血球素 > 10 g/dL。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            13,
            14,
            9,
            10
        ],
        "Secondary_evidence_index": [
            17,
            18,
            20,
            23
        ]
    },
    "b3aabfaa-23cb-4a75-8416-761d8574f0a4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "初级试验的1组患者可以从40mgPO到50mgPO的Afatinib单治疗剂量逐渐增加。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f697c2d8-e0dd-476e-8ff4-dffe053076f8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "初级试验的Trastuzumab手臂报告了54%的pCR率,这比Lapatinib手臂的pCR率达到45%的结果更差。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f2c0f753-1775-42af-94f0-b87b20156e65": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "初级试验和次级试验在其干预中不使用化疗、放射疗法或乳腺检查。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "17b31c1d-db62-4628-b390-02da22512079": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "与 aromatase 抑制剂相关的肌肉骨骼症状的患者,如1级或以上的肌肉骨骼疼痛或感官神经病症,有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5,
            6
        ]
    },
    "2e6e1044-8b4a-41f7-8319-85fc5bba4482": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "放射治疗用于初级试验和次级试验的所有群体。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "二级试验中的1组MRSA感染,初级试验中的4组MRSA感染。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "0c0324d2-0672-45cb-b715-e51e48786afb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "初级试验的干预部分不描述干预剂量、频率或持续时间。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b3bd3522-8731-448a-bade-a5a350697a98": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "初级试验中的9名患者患有与血液中白细胞数量低相关的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "8607e8c1-6e99-49be-a63e-e707856c805a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "每个患者在初级试验中接受3种不同的药物,而在二级试验中,患者被给予支持表达型群体心理治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1c26e1a7-9d77-46ff-b1c6-179ece7c190f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "平均而言,初级试验的两臂患者经历了同等时间的4级中性衰竭。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "0a156ee2-eb90-40d2-9802-27b9b4a42ff3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "在初级试验的2和3组中,只有1例黄。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "82895f11-37bf-4d03-8de2-84818d93cce0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "初级试验和次级试验有完全不同的不良事件报告。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "f94643de-7122-4a58-972d-b0bb7e59d441": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "初级试验共有3名患有胰腺癌的患者,二级试验有0名。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "1485315b-3169-42a3-a672-6f7963d49a51": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "二级试验和初级试验的每个参与者都接受实验室生物标志物分析。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "b4ef27ca-52b4-4af3-9b60-e9e0285e0e86": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "潜在的参与者将被考虑,无论他们的乳腺癌的激素敏感性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7
        ]
    },
    "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "卡诺夫斯基指数为72的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "426196d8-44ab-4c5c-8f81-5cb12345ad69": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "初级试验对其群体使用不同的纳入标准,次级试验对所有群体只使用一套纳入标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "bcf433b6-4029-4d00-9ccf-d8d94f1722d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Secondary_id": "NCT00005908",
        "Statement": "初级试验和次级试验只记录了一种类型的急性不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "1268edfc-cce2-4f07-9fbb-392341b7f399": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "初级试验中的Ridaforolimus + Dalotuzumab + Exemestane组中间PFS超过5个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "58ccfd13-aa6d-4604-bf3d-c69270fe50d2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Statement": "初级试验中的1名患者在与特定CTCAE术语无关的事件中死亡。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00509769",
        "Statement": "主要试验和次试验中的大多数患者经历了不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "8c84c96f-1635-40dc-839b-fc937ed566a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "具有可测量的疾病的患者仅有资格参加初级试验的第二阶段。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6
        ]
    },
    "7b48355e-3b9c-4cca-b7fa-1cbd612d1523": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "在初级试验的2组中没有出现不良事件,该事件发生在5%以上的患者中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "3d188d93-13c6-48f3-b231-dcdeef81080e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "骨外转移的存在是初级试验的排除标准的一部分。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d7e81d80-5cbf-4969-be00-4fdf17aa4eb9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "MM-121 和 Paclitaxel 的较低剂量用于初级试验的群体1,而不是群体 2。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "2206dc2a-93da-4c11-b110-81f9c39af807": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "一个女性的血球含量 > 10.0 g/dl,绝对中性细胞数 1,733/mm3,血小板数 = 100,000/¬ ̈ μl 和总比利鲁bin > 1.6 x ULN 是适当的初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12
        ]
    },
    "6173faf3-f845-4cf1-94a9-756d1bff48bb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "初级试验中有一名患者在血液中的颗粒细胞数量显著下降。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            17
        ]
    },
    "512c72ab-f1b3-450d-8167-6e0d8d2bf5dd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "只有一个小组的初级试验需要在每个周期前接受手动淋巴排泄。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "超过十几名初级试验参与者被归类为乳房和节点的病理完整反应(pCR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "87987ebb-6799-4d1d-8529-d33c6b7799f8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "接受每日1000mg拉帕提尼布和4mg/kg的加载剂量,然后每周2mg/kg的初级试验中,有64名参与者在12周后至少经历了接近完整的病理反应,或者更好。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "bf94f208-a29b-4d8f-92a7-3cb8241ce344": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Secondary_id": "NCT00896649",
        "Statement": "黑人女性不能参加次审或初审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ],
        "Secondary_evidence_index": [
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "c68f6822-24fa-44b5-bf63-c272a8031fab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "患者必须具有 AST 或 ALT < 1.5 ULN 才能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            20
        ]
    },
    "54a459cf-f01a-4abc-a8cf-0efebc01c694": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "初级试验和次级试验没有记录相同类型的不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "dd4b5a08-c033-4429-81d0-1ad59596edbd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "甲状腺炎和糖尿病患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "d97ebc59-ab4b-462a-9057-12f4fc46df56": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "初级试验中的患者以相同的频率接受伏里诺斯塔特,并通过与二级试验相同的服用途径接受6 - 梅尔卡普托普林。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2e4c7d0b-f1a2-4204-bac3-7445852fd916": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "初级试验和次级试验干预涉及各种扫描,如CT,PET,MRI和剂量测量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "所有初级试验参与者和次级试验中的1组参与者都没有接受任何口服卡佩西塔宾、口服拉帕蒂尼布Ditosylate或cixutumumab IV,但次级试验的2组接受了所有这些。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4546c169-cc5c-4e03-bcce-31d491ed18e0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "初级试验仅记录心血管不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "1bb3badf-41c6-4741-90f0-367473ce254d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "儿童和文盲成年人不能参加初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ]
    },
    "87953ba3-3e94-421c-b426-b716562b8b5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "患有阶段2B、病理确认的PR阳性乳腺癌的患者可以参加初级和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "847b4dbe-428f-431c-8916-2a9c0c80cce4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "剂量在二级试验和初级试验的干预部分中指定。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9c00b318-0a3a-43c9-a6cd-2983c07be393": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "初级试验中没有患有异常心率的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "cbfe14a5-5169-4de3-b69f-13b489be949a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "初级试验和次级试验不使用循环干预措施。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "在初级试验的群体1和群体2之间达成剂量满意的治疗计划的参与者的百分比存在显著差异,Gy的增加具有巨大的影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "在初级试验的1号小组中,低血压的患者比在次级试验的1号小组中多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "eae76b80-107c-4469-b06f-73d5f7a4c1d5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "重型吸烟者(每天吸烟5支以上)有资格参加二级试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "6cf7d10e-902e-4f78-85f6-e06d63e1cd0e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "在接受Lapatinib 1500 mg治疗的初级试验受试者中,不到50%的受试者在第12周没有进展性疾病。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "91ad45ae-6714-4c27-ac1a-d8ff8e89684f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "一名双边乳房切除手术的女性患者将被排除在初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6
        ]
    },
    "91cf53f9-7233-49ee-a619-c027f6db67ac": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "只有男性才有资格参加初审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "78894316-fc7d-4d61-a2d4-9ea369bfce20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "初级试验的1组患者患有Erysipelas的两倍比细菌腹泻。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            11,
            12
        ]
    },
    "889e6622-1614-4f6c-a47c-e7caad6e154f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "初级试验的1号和2号小组有相同数量的贫血和中性衰竭患者,但1号小组比2号小组有1个更多的白血病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            4,
            5,
            14,
            17,
            18,
            19
        ]
    },
    "4577d986-d7e5-4b5d-9852-b944a6f7f252": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "二级试验和初级试验接受同一年龄段的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            15,
            16,
            17
        ]
    },
    "e83b56ba-d129-4cde-976d-2865e67ef4a3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "初级试验研究肿瘤反应,而次级试验调查骨质矿物密度的变化。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "eee75423-9a61-4a57-8baf-8f91b9562486": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "初级试验中的大多数患者都患有肾结石。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "9e046221-7d4b-4681-a374-96793350927d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "二级试验组1的ORR高于初级试验的Everolimus + Letrozole群和Trastuzumab群。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "5448c6b8-244c-4a42-bbef-e1a1a2e254e2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide、Doxil 和 Trastuzumab 在次要试验中使用,但在初级试验中没有使用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "更年期前的患者被排除在二级试验中,但有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "8d450d42-4eb1-4edb-be76-b2885964aa90": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Secondary_id": "NCT00656019",
        "Statement": "细胞学确认的乳腺癌患者,其本地复发性疾病是具有治愈意图的辐射易受的,不符合二级试验的条件,但有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "2674e194-3113-4a11-b2cc-f089d960d194": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "初级试验在其干预中不使用特拉斯图苏马布、塔莫克西芬或埃克斯梅斯坦。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a7232387-b266-4bfb-8df8-ca9789188500": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "初级试验的 1 组与 2 组相比,患有不良事件的患者多出 25%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "2e317381-2704-4d06-a793-1d2b29139969": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "总的来说,在初级试验中,只有一个参与者没有达到病理完整反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "030316a2-fb48-469d-9c55-04cdc9a37fb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "主要试验参与者在研究期间每一天都服用萨拉卡蒂尼布。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2c723e02-14d8-4a80-a95f-517e904bbbad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "初级试验中没有参与者超过1年的无进展生存期,但几名患者有1个月以下的PFS。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "8befa03f-c3da-4950-8d27-491ea06b51ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "患者的食欲在初级试验中没有受到影响,但在次级试验中至少有一次受到影响。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "32424458-a3e2-440a-9693-6a2f8d4aaddb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "初级试验中的 Abraxane + Capecitabine 组有 61 多名完全响应 (CR) 消失的患者; 部分响应 (PR) 至少减少了最长直径的目标损伤的总和比 Abraxane 单独组的 30%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "a2b25229-c003-49c3-8b0b-94b68f756d3c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "初级试验没有记录他们的患者的任何皮肤感染。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "728721c4-6376-4ab8-9e4a-af8596bd1ab3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "激光治疗仅用于初级试验的1组,二级试验的2组都没有使用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "c7151ad6-bcac-48e1-ba1e-e6f56a043804": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "初级试验和次级试验都记录了胆囊炎的病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "4f71e33c-4f0f-4952-bb03-52402be5f9f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "初级试验中有1例(1.45%)的血管细胞压缩症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "ef675459-a7d9-4ea1-8963-c95682c38d15": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "T4 N1 M0乳腺癌的参与者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8
        ]
    },
    "f9df9e45-eb68-4257-801e-b086a89374b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "女性患者LVEF > 50%,之前曾接受以下药物之一的治疗;特拉斯图苏马布艾曼辛,帕克利塔克尔,阿布拉克桑或拉帕蒂尼布仍然符合初级试验的条件,但被排除在次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "94fc10ff-65e1-4b0a-8ff3-1cc48db3433e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "初级试验没有使用整体反应率、肿瘤反应率或无进展生存率作为其结果测量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "958721dc-e374-4fd1-abb9-071add70bde3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "根据初级试验的结果,帕克利塔克尔的MTD大约为120mg。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "19c0b2c7-e45c-4740-b25d-f6e738b59893": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "初级试验的2个小组记录了1个 thrombocytopenia事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            13
        ]
    },
    "7bcfca9e-1b09-45d4-8165-cb6ac96b8815": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "二级试验记录了比初级试验更多的 gastrointestinal不良事件总发生。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e3a8be03-20e4-460d-9ebc-f958a515ac45": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Statement": "初级试验中不到5名患者经历了Earache。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "f1096271-3160-4483-9246-ba0d96735efb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "不到5%的初级试验参与者达到CR或PR。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "329b6871-2edc-4142-a4af-e7f8cef118ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "更多初级试验参与者在周期8后经历了1级心脏毒性事件,而不是3级事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "67522762-9423-4e3d-bf75-247f84ba7f05": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": "为了符合二级试验和初级试验的资格,患者必须满足以下所有条件:碱性磷酸酶 < 2.5 x ULN、阿斯巴达氨基转移酶 <= 1.5 x ULN 和血球素 > 10 g/dL。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            13,
            14,
            9,
            10
        ],
        "Secondary_evidence_index": [
            17,
            18,
            20,
            23
        ]
    },
    "efd37946-54f3-4813-b63d-6d7df6123677": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "总共3名初级试验的患者对感染产生了危及生命的反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "dcf62f43-04b7-4acb-b444-2d805238a8b1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "在初级试验中,Herceptin 组的患者达到部分病理反应的比例比 CT-P6 和 ZA 组高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "83dc7b9a-b863-4f81-88fb-763afc3b79e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "初级试验中没有受试者被要求服用任何药丸,而二级试验中的一半受试者必须每周服用一片药丸。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "d446920a-2b8e-4452-b9f2-17d2771dbb07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "初级试验的1组中最常见的不良事件是中性衰竭。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "aa710138-bf2a-4a7f-8014-4513fa1f448b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "初级试验和次级试验的组合1均有不到30%的不良事件发生率。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "患者必须每周锻炼不到2小时才能参加初级试验,但这不是二级试验的要求。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "6a71c114-2e38-4d57-8f8b-8252d9c62cbe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "初级试验的1组中有4例发烧性中性衰竭,0例心力衰竭。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            5
        ]
    },
    "4333aaa3-dbe4-4275-a982-881fe25c96c0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "初级试验的手臂2在没有疾病进展或不可接受的毒性的情况下,在21天的周期中接受剂量密集的化疗最多3次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "d605b820-2915-4b19-b9cd-ca7850645f83": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "初级试验的1组中,只有6名患者出现了静脉变异。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "d6de70df-d113-4bc8-9d3b-b71f31937ebe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "继承BReast CAncer基因1或2的有害变体的人有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            13
        ]
    },
    "9f897b29-7cfa-414c-8cf6-212a68ec2216": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": "二级试验或初级试验都不要求患者在干预期间接受任何形式的医疗治疗,他们只是测试咨询的有效性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "0d0deba5-c7bd-489b-a49d-c6af9a5cd92a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "初级试验的安慰剂组比测试组表现更好,因为较低的PFS是理想的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "4606f64f-64cc-4d73-a8be-75701c97008d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "初级试验的2组患者接受了血浆移植。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "40bef815-18ed-4db5-8108-9a1cdbdd0a13": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "足够的血液,肝脏和肾功能是不必要的参加初级试验. 但是,怀孕是必需的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "5c676007-9ea4-4f80-82dd-89293237cb07": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "初级试验没有使用整体反应率、肿瘤反应率或偏好分数作为其结果测量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a6682883-ace7-4d83-a35c-956928fdc75a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "二级试验和初级试验不要求参与者具有特定种族、性别、身高或能够说特定语言。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "1a271e29-477b-4819-a472-5c7c7df99e70": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "在初级试验中记录了2例血液分析病例,在次级试验中没有。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "060e833e-384f-48f0-8e56-ebd95f55f221": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "初级试验中没有 Cellulite、 Vertigo 或 Anaemia 病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ac193d32-156e-48bf-bc6b-d613691f869c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "初级试验只记录了三种类型的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "d79173da-5e59-4150-99bd-f1c20118dddc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "所有初级试验的参与者都必须最近接受 echocardiography。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "50559f15-636d-4265-8f8c-4aad016c6c50": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "更年期后女性有资格参加初级试验,更年期前女性有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2
        ]
    },
    "a5af6d2b-4cea-40aa-acdc-59fab5362b3e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "具有雌激素受体的乳腺癌患者被纳入初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "7e89b190-b8f7-4281-b0f1-0e65dcebf402": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "初级试验的1组患者接受Exemestane的频率是2组患者接受Cytoxan的两倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "6036d341-9c6a-49fc-a2f4-19c0e2399f4c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "在初级试验的 2 组中,管心脏病的病例比管心脏病的病例要多得多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            22,
            23
        ]
    },
    "a84afa25-2741-4a08-9e6c-4049f5feca48": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "基于Phosphoinositide 3-kinase抑制剂治疗的患者有资格参加初级试验,如果此治疗已于5年前结束。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6
        ]
    },
    "09e4c746-642a-4a5d-a267-25258a3f2ec0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "初级试验和次级试验不具有相同的干预时间。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "99855d11-e2e4-4a0e-b40e-2264ff128ac5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "初级试验记录了每个类型的不良事件的相同发生次数。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "54fe69c7-5a67-49b1-8bc5-c975133e2bb7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "初级试验中的患者在IV中服用Zometa的剂量低于二级试验中服用Ado-trastuzumab emtansine的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "76362fd3-3a07-4aa3-a072-b9075d2ea791": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "初级试验中没有一个患者患有心脏衰竭(积极治疗期间)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "064b39e9-e9d8-4c51-a76a-ad150bb127f1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "初级试验共有3名患有胰腺相关不良事件的患者,二级试验有0名。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "67a628d7-d883-44b9-b351-901f20fd5d0a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "二级试验和初级试验在研究的第一天给他们的患者群体干细胞移植。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "78c60212-28f7-4306-9f63-549be04687b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "只有两种类型的不良事件,白血病和贫血,发生在初级试验的1组患者中超过1%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "a72e1259-50be-48e5-bdf8-296040cbf7ce": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "阿斯巴达氨基转移酶超过正常水平的2倍以上的患者均被排除在二级试验中,但符合初级试验的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            18
        ],
        "Secondary_evidence_index": [
            23
        ]
    },
    "19cfd511-8582-4116-8d51-7ec4a6221022": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "0/49 初级试验中,HER2表达的转移性或不可复发性乳腺癌的参与者对QTcF的最大变化为 < 60ms。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "3f012bd3-bb89-414b-9dd9-35cef524a69a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "根据初级试验的结果,与每周帕克利塔克尔结合的达萨提尼布的MTD大约为120毫克。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "5eafb3a1-473a-4270-848d-173e5dca9466": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "患有白血病、肝炎或疮的患者不能纳入初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "ed956644-5228-4915-b706-1cedb0462577": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "初级试验参与者被催眠治疗,这在二级试验中根本不使用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "02158762-9490-46a1-b494-0589885fd4ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "初级试验没有记录任何与心脏相关的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "初级试验中 enterovesical fistula 的发生率高于次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "7ec286e9-f519-41da-848d-a0bc5a50c0ee": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "剂量在二级试验的干预部分中明确,而在初级试验中则不明确。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d0af59a9-04ae-4922-97eb-dc29f5bc44e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "初级试验和次级试验使用完全不同的药物和技术进行干预,但它们都需要现场训练的放射科医生进行评估。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5d4cbb15-ea50-4394-b1b9-ab4553b5b275": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": "在初级试验中,患者每天服用一次Pazopanib,直到疾病进展或不可接受的毒性。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "初审中 CHF 案件的所有 4 个都是在 1 群中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            14,
            20
        ]
    },
    "78a5162d-140a-4631-b776-5c284446b5ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "初级试验和次级试验具有完全不同的不良事件配置。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "633ef768-9e9b-4336-9142-8d4ce7ee2342": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "在初级试验中,左心室系统功能障碍的患者比二级试验的患者多10倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            12,
            19
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "7c5b29bc-ac37-48bb-abb1-a102174f79ef": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "初级试验的1和2组接受50毫克不同的药物,从1日到21日口服",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "所有没有进展的参与者(经过16周的治疗)在初级试验中,在阿法提尼布50毫克与莱特罗索尔组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "初级试验记录了比次级试验更多的癫痫发作,尽管其总群中患者人数不到十分之一。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e852619c-312a-470f-8b77-149e79f69a3f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "在二级试验和初级试验中,测试群体的结果比对照组更好。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "27160f45-e4cb-48be-8cf2-c23ced4578c0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "在初级试验的两组中,最常见的不良事件是Anaphylaxis,总共影响了超过10名患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "e4b65e9f-10f6-4424-95d2-837e29587a63": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "二级试验和初级试验都接受患有乳腺腺癌HER-2/新过度表达的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "患有 T1N2M0, T2N1M0, T3N1M1 和 TxN1M0 肿瘤的患者适合进行初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "7796fe1b-1952-4339-90f3-47b051ebe927": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "初级试验的2组患者中的一名患者出现了持续超过7天的中性热症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c7df7b38-068b-48a8-b805-b8ebb3e854e6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "初级试验和次级试验没有记录相同的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "39227bbb-0e26-4ba0-94a7-762376541889": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "多焦点乳腺癌患者不能接受初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Secondary_id": "NCT02679755",
        "Statement": "初级试验和次级试验有不同的群体数量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fd15ddaf-1abc-4551-a5b3-08217b975e36": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "具有直径超过70毫米的侵入性乳腺癌患者被纳入初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "067f4671-0720-4980-a0fa-8d01d31daa9a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Secondary_id": "NCT01421017",
        "Statement": "由于初级试验和次级试验使用非常相似的结果指标,我们可以很容易地比较和对比他们的结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "026e7eb7-37fd-4aae-b74f-dacf905db262": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "初级试验报告了与二级试验相比经历不良事件的患者数量的10倍以上。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a79fc503-215f-40d4-9cc1-e101cec3a9c9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "完全活跃且能够在不受限制的情况下继续进行所有疾病前表现的患者被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "ee5f95d0-3824-4ce4-bf58-1ecd3ce4e7ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "初级试验测量了患有疾病进展(PD)或死亡的参与者的数量,以评估其干预的表现。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "初级试验或次级试验中没有发生心脏缓冲。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "ccb703ea-df18-451b-8db8-ed0e510a4c0f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "与二级试验不同,初级试验不指定其干预的具体剂量或频率。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "56cd4492-3884-4b2a-a000-7c859d86f6f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "在初级试验的两个群体中,共有两名患者在身体组织中氧气水平低。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "08b79e0d-5e97-45fb-ac83-0096b56f714b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "初级试验的两群体中不到 1% 是由 Pancytopenia 或 Coagulopathy 引起的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5,
            11,
            15,
            16
        ]
    },
    "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "初级试验的安慰剂组的平均保留率超过10%高于多尼佩齐尔氢氯化物POQD组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "6d549a9b-47bf-4369-962b-2759cfd7051e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "初级试验和次级试验都调查了伊特拉康纳佐尔500mg QD的药理学。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "596f20cf-299d-40a3-881a-cdd49bcb21f6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "HER2初级乳腺肿瘤的参与者,通过现场荧光混合证实,有资格参加二级试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            7,
            8
        ]
    },
    "78ae19aa-6e26-4f9a-b381-cd77d92e4ecb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "在初级试验中,至少有一名患者患有胃食管逆流性疾病。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "1d4f9f95-6f97-4054-9dd8-fe78aa5fc685": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "萨姆最近接受了肝脏移植,不符合初级试验的条件,但符合次级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "d4b2d877-34af-4944-84f7-046e22c2854e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "初级试验中的所有受试者都必须接受轻微手术。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d3ca3729-2795-4cd5-9968-666781d17fac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "初级试验的1和2组记录了不同数量的患有心脏衰竭的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Statement": "初级试验中观察到Tibia或Fibula骨折的0例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "b98c7a50-ed79-41ff-9733-fff143f630be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "初级试验的1号联盟记录了与二级试验的1号联盟记录的中性热病例数量相同。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "47aa5686-75af-4ed8-b4ff-715b458ce40a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "实验室生物标志物分析用于二级试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "e89fdc93-d624-4ba7-aa64-574a278e982b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "初级试验研究一种新的化疗治疗方法,而次级试验则测试一种类型的心理治疗方法。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1739541a-2d3f-4a13-b956-769a1cbed4d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "初级试验中的1名患者被诊断为清晰细胞肾细胞癌。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "初级试验中的一名患者因植入设备存在而患有疮。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "206fc00c-2c34-42bc-8fca-44be696e03c9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "初级试验的两群体接受相同的干预措施; 注射(IV)在145mg/m··········作为单独治疗每21天一次,各群体之间的差异是患者被诊断的癌症类型,1群体是NSCLC,而2群体是mBC和每个群体的周期数,1群体为1群体和4群体为2群体。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "初级试验中Trastuzumab + Sunitinib组的患者中期(95%信任间隔)无进展生存率(PFS)超过一年高于Docetaxel组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "83cef795-d4a8-486c-8ac1-34a9acee9672": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "左侧乳腺癌和1至2之间的ECOG患者被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            8,
            14,
            17
        ]
    },
    "b3cee7a6-cec1-4676-974d-7cfb3ccd9919": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "初级试验记录了一名患有关的并发症的患者,而在二级试验中没有观察到。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "007de11b-4265-4695-b18e-e0d6909a347a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "HER2阳性肿瘤的患者被排除在初级试验中,但可能被纳入次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ce621235-b584-439b-bb11-ab2fa04c3195": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "二级试验和初级试验的每个参与者都会接受实验室生物标志物分析,并填写一个问卷。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "f358f023-2393-44eb-9535-3f0e1851318d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "二级试验和初级试验在研究中都使用辐射技术。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0e963b25-0d2b-4fc6-89c6-1eb068bc092e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "在初级试验中,每位患者都接受了tipifarnib PO,以及帕克利塔克尔、多克索鲁比辛氢氯化物和 acyclophosphamide IV。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "390b08d3-e147-47f9-82d7-0643b8d5c8ae": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "在初级试验中,最小和最大PFS之间的无进展生存差距不到8周。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "2570cb04-4edd-48c9-b634-9f2e086469de": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "在初级试验和次级试验之间,Bevacizumab仅用于次级试验的2组患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "f6a7e279-b923-45e3-8ad5-e81e17c0a682": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "初级试验中的60名患者能够完成至少85%的计划剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "3d82851c-f302-4988-bd78-232583e04e96": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "以前接受化疗的患者有资格参加初级试验,但被排除在次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "5c9f5916-37d3-4f6f-977b-be70204cf57c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "所有初级试验参与者在整个研究期间都有相同数量的卡路里饮食。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0c5f2498-4c10-4e51-8915-d86b37b08156": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "在初级试验中,参与者根据癌症诊断进行干预,而在次级试验中,干预被随机分配。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            5,
            6,
            7
        ]
    },
    "c54dc963-671a-4384-8b1f-d8058a832131": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "初级试验中没有患有鼻鼻子反应或左腹功能障碍的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "在初级试验中,共有32名患者患有腹泻。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "91adb350-ab20-41a6-944d-c13b55cf33f2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "初级试验的一组报告2/680名患者经历与眼睛相关的不良事件,而两组报告没有。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "78949f1f-6738-4220-a233-e7831902e6f3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "无论是初级试验还是次级试验都没有测量BYL719与T-DM1结合的剂量限制性毒性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "135311d8-c579-4568-913e-937be00dde7e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "在二级试验和初级试验中,测试群体的总体反应比对照组更好。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0984431d-4997-41dc-9ba4-07134568c3fa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "初级试验的1组不接受任何Eribulin Mesylate 与预防性 Filgrastim,而二级试验的两组都接受了一些。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d9dc4a6d-a913-46ac-b0aa-d50823ff2305": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "甲状腺数超过100000/mm····························································································································································································",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18,
            22,
            23,
            24
        ]
    },
    "9d9ab190-cdcf-4320-b69a-12f2dad9dba9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "二级试验和初级试验使用不可比拟的评估指标,并且有显著不同的时间框架。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "89fdf182-7474-4e70-baf7-03c8920c4ff3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "安慰剂治疗用于二级试验的群体2,但在初级试验中只有一个试验组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "9f2fd0cc-af87-433d-9d2f-6235591d6cb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "由独立辐射评估监测委员会评估的乳房中具有临床客观反应(cOR)的参与者的百分比在2组中最高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "90364098-7e9a-47be-ab2e-f66958cfb09d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "初级试验和次级试验的干预措施每天进行,持续数月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "021c3f62-8067-49e3-9d4b-c7641feb2548": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": "对于初级试验和次级试验的干预措施,使用了相同的特拉斯图苏马布剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6893c9b4-d3a3-47a8-ada9-8aef67de2375": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "患有不可治愈和不可复发的乳腺癌的患者有资格参加初级试验,除非它是转移性的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "b88cde11-ae29-48e8-832b-4b9cb2596c30": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "海伦2年前患了第三阶段卵巢癌,目前仍在康复,她被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            14
        ]
    },
    "ebe7078c-fd8b-439a-b1f5-7bd482071ead": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "初级试验研究改变肿瘤直径,而次级试验调查心力衰竭率的变化。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d0b9c11c-50f2-4803-a96c-fff3ca90cf36": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "初级试验的两组接受相同的干预措施; 注射(IV)在145mg/m·······作为单体治疗一次每21天(1周期),群体之间的差异是患者被诊断的癌症类型,群体1是NSCLC,而群体2是mBC。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "b620e1c5-69c4-4c30-9006-faa346200b60": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "主要试验是研究认知行为疗法,一种类型的心理治疗,而次要试验研究是对比Trastuzumab,一种类型的化疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0900325b-6ecd-46f1-b3f1-a2ce1605d151": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "初级试验的群体1和群体2之间没有结果或群体大小的差异,Gy的增加没有显著的影响。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "6f10e1f3-1197-464e-b574-d697fb49331d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "患有HER2+乳腺癌的患者有资格参加初级试验和次级试验,但只有患有1至2阶段乳腺癌的患者有资格参加初级试验,而有3至4阶段的患者有资格参加二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "cbf91beb-829b-488f-8e80-3b08b891a181": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "二级试验和初级试验都要求他们的患者每天接受各自的干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "985df98b-b397-4dbc-8fad-43ada30927d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "需要积极支持护理的患者可以参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "0d4fdeef-89b2-463b-8252-66fa51d9ce8c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "二次试验干预是每天两次应用于手掌和脚,初次试验的参与者不会在手或脚的皮肤上服用任何药物,而是在胸部或胸部墙上服用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "在以米诺西克林氢氯化物治疗的初级试验中,有脂肪酸合成(FASN)表达的患者中,有 27.6% 没有病理完整反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "494c1f01-5a2d-409e-b614-5871f408fbe6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "在初级试验中,A组的患者比B组在治疗后3个月内肿瘤面积增加>25%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "17881072-2517-483f-9c03-1edad21a58cf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "总体而言,二级试验只记录了比初级试验更多的皮尔克西亚病例3例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "癌细胞转移到少于3个淋巴结的患者,至少有一个大于2毫米,不能进入初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "da6ce3a9-b653-47b2-9271-f831e4de3f19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "初级试验的群体2中的患者少于群体1的患者,在肺周围有异常的液体量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7,
            8,
            15
        ]
    },
    "66979ae5-a709-4adf-9067-287f0f92b9e2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "来自初级试验的2群体参与者的数量较多,与1群体相比,经历了发烧。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "0af6799b-655f-4b8b-a192-ce8dcbb2fcff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "只有黑人女性有资格参加初级试验,只要他们没有未经控制或症状的大脑转移。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            10,
            11,
            12
        ]
    },
    "3a3e2387-c4c7-48e6-b3ca-1257de7019c2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "患有明显的乳房损伤和轴心淋巴结的患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            12
        ]
    },
    "46ac8a9f-77ab-40cf-9421-64aad4ae6976": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "初级试验中的1组参与者和次级试验的所有参与者都服用了1毫克阿纳斯特罗佐尔POQD。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "d2b7253b-0654-4bb1-a9a4-b203714d64f9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "初级试验和次级试验使用相同的时间框架来衡量各自干预的DLT。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "9a896e4a-ae6b-468c-a7c0-32c1514c0b48": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "在初级试验中接受干预的患者中,有不到5%的患者出现了不良事件,而二级试验的1组患者中有近10%的患者出现了不良事件,而二级试验的2组患者中有超过30%的患者出现了不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            8,
            9
        ]
    },
    "41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "二次试验的干预是应用于手掌和地板每天两次,初级试验的参与者不局部服用任何药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0931065d-35e4-4f82-8ef6-ac6db900127a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "乳腺癌已经扩散到皮肤和胸壁的患者有资格参加二级试验,但不是初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "70912726-ba1b-47ef-9005-9584c8caf559": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "根据盖尔模型,在未来5年内患乳腺癌的风险低的女性,没有与遗传性乳腺癌相符的家族史,有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            8
        ]
    },
    "6743f85c-8318-49cc-acba-94aeb1f57130": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "初级试验的 1 组的 PFS 比 2 组更长,但最长 PFS 的患者在 2 组中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "ddffa26d-2581-477a-955c-ebf0c2ab0f97": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "加速部分乳房辐射以某种形式用于二级试验的两组,但根本不用于初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "f1a45b47-498d-45c8-b6d9-6c8f035da30b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Statement": "初级试验中有1名患者患有 Sepsis。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "a5272c37-0e32-42db-a44a-d17df7bd70ff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "在初级试验中没有观察到与疼痛有关的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "4c67a7b4-36fa-4c20-a15a-122609550973": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "阿黛尔是一名85岁的女性,患有 IV 阶段的 histologically 确认的 ER+ 乳腺癌,ECOG 值为 0,她有预期寿命低于 6 个月和血栓事件的历史。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            6
        ]
    },
    "120c6aa7-fcaa-4eaa-b520-6382968a6724": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "初级试验测试了两个不同的牙齿成像模式,即乳房和伽马成像。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "初级试验结果表明,Zoledronic Acid Upfront比Zoledronic Acid Delayed-start更好的治疗,以防止脊椎(L1-L4)骨质矿物密度(BMD)的任何变化。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "ac997ae1-7e48-48e2-af9e-f7e289622250": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "初级试验和次级试验对不同干预措施的不同结果措施进行调查。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "初级试验的两组患者间的平均总生存率(OS)差异不到一个月,最长OS的患者在1组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "441c0760-ca4a-4f1d-864e-a77395fd1f18": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "初级试验中的拉帕蒂尼布组与Odanacatib 5 mg组相比,尿液中I型胶原蛋白的N-telopeptide的基准比例变化较小。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "fbe60029-8944-4e12-b4b2-3413037a10cc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Statement": "初级试验的1组患者中,有57%的患者在手术中有病理完整反应率。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "fe1782aa-a871-4608-a7cb-8f83b7f76d8a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine 在初级试验中不使用,并且仅在二级试验的群体2中使用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a153ecbf-11ac-4c40-a3af-9dbb0e12c49b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02364388",
        "Secondary_id": "NCT01425268",
        "Statement": "在初级试验和次级试验中使用的治疗方法没有重叠。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "bcd48c1e-bfeb-4f1e-993f-cbbe4fadbf6e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "脑内转移的患者可能有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10
        ]
    },
    "4dc22366-3ff3-41c8-aa4c-7342d7b7085d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "大多数初级试验受试者有进展性疾病或未确定的中枢神经系统的客观反应率。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "196c2132-c735-4b79-bf03-3a830fcaf0fc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "初级试验记录了其患者的几个与中枢神经系统相关的不良事件,而次级试验没有。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "72619b0a-57c2-465c-8428-72019b59f8ae": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "在初级试验中,所有 Enteritis、 Vertigo 和心脏衰竭的病例都发生在 2 组中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "b8663fa7-585a-4cd9-afd2-89e8e1a58b82": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "马克在上个月抱怨他有两次比赛心脏,因此他被排除在初审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            14
        ]
    },
    "7c92d075-ba9d-45b5-9834-83b09d2753bc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "初级试验和次级试验都通过IV给他们的患者提供治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "如果汉娜一直服用酮治疗运动员的腿6周,直到今天,她将有资格参加下周二的初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18,
            33
        ]
    },
    "9a346aac-46c2-4a50-8f3a-309b3b7bc295": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "无论是初级试验还是次级试验都没有使用低剂量氧化物、生物检测或莫梅塔森在他们的干预中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "949d79e0-95db-47a2-802a-6280c0255923": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "在初级试验和次级试验的两组患者之间,只有一个患者在血液中缺乏粒细胞。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "6e080a1e-a03e-4547-a7c4-c9d5a80de977": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "参与初级试验和次级试验的患者出现严重的眼部疾病。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "63218fb2-3f5b-4738-bea8-11fbbc560949": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "患有严重吸收障碍的患者不适用于初级试验,除非他们能够接受静脉(IV)营养。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            24,
            31,
            30
        ]
    },
    "d7fa4f81-e108-491f-9b08-c147a33863e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "接受初级试验的干预1的患者,将服用药物口服和静脉注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "f24afb09-ea65-457f-9f9b-0db3cc3101ac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "十二名初级试验参与者被归类为乳房和节点的病理完整反应(pCR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "3cd79df2-e6dd-41dd-b819-4d993b5f7aed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "在参与初级试验的患者中没有观察到白血病、癫痫或 Arrhythmia 病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "d2d6f646-5881-42a2-b965-0c6f79e89463": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "初级试验的候选人必须在研究入学前1个月进行骨密度扫描,如果结果超过2个标准偏差低于正常,研究医生仍然可以决定让他们参与。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8
        ]
    },
    "428d5165-560b-4783-8c4b-5fd3a3289cab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "初级试验中没有任何一群患者有超过1年的PFS。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "6e7df2e4-11b3-4183-aefc-760f85809515": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "初级试验和次级试验都给他们的患者施用Zometa通过IV,虽然在不同的剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "45e6b4b6-ca31-4318-936e-5b27cbca47a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "初级试验中的一个患者在3个月内总MRI功能肿瘤量(FTV)下降了2.87厘米。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "22a6d10e-55c5-4a8c-8010-3e8252bcb279": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "最近接受外部射线辐射治疗的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "7fd1ae1e-bfdb-4c37-aaea-ed97663758e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "初级试验治疗持续时间比次级试验治疗更短,但更频繁地进行。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "50d119f6-a657-4619-918e-7617ac57f052": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "初级试验的联合体1报告了一个AML病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "e436827b-10db-4179-bf8f-07786ee6145b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Statement": "没有种族准入初审的标准,但有性别准入的标准。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "fcc6708a-b0fc-4215-a45f-02b1e0e2d30a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Statement": "肝炎患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            19
        ]
    },
    "d63706f1-4fb8-488d-8f86-c1a19df341d4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "HER2表达不足的肿瘤患者被排除在初级试验中,但可能被纳入次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ab357056-67a7-4227-966d-8c96eb1640fd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "初级试验的候选人预计能够保持呼吸半分钟。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "0359eef3-6339-485e-95bc-0cb6fa7bcd12": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "具有雌激素受体的乳腺癌患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "57ef3c6c-b4e1-4302-b423-aa9faca21200": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "初级试验和次级试验不使用相同的服用途径进行干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "29d5779b-c228-4b82-9ca8-075beadae879": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "在初级试验中观察到的发烧性中微波尼亚的病例比发烧性中微波尼亚的病例多,但发烧性中微波尼亚的病例比发烧性中微波尼亚的病例少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            3,
            4
        ]
    },
    "4e124d90-68d7-40bd-a8b1-27cb49d64c64": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "初级试验患者在1至28天内服用Trametinib,Akt Inhibitor GSK2141795 PO QD,最多8周期。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "在初级试验中,两种干预方法的服用途径是局部皮肤霜。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f4c7dae5-012f-4f05-b5ba-da072fe1359c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "初级试验中的一个患者被观察到患有内膜炎。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "927bbb75-37da-4b75-9483-252d31a0fd98": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "与二级试验不同,初级试验不提供周期持续时间或干预部分的任何剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "80a5cdbc-0721-41b6-af1a-28e3f46557ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "初级试验中的1名患者有与心脏相关的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "af710d36-8062-4412-8d11-1c57a14b5e5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "初级试验的发病率是次级试验的三倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "c91c7dc1-17b7-4475-9aec-38999a18a306": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "在初级试验中,有几名患者患了肺炎。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "5357ce66-7f7b-4ffd-926c-f6116f5a2e20": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "初级试验和次级试验在他们的患者中观察到不同的不良事件数量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "3c7ecca8-5397-41f5-b72b-84217bf3acd2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "患有慢性阻塞性肺病的妇女不需要系统性固醇,有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ]
    },
    "2c53e14a-719c-4994-9090-73f9bddb60ba": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "初级试验记录了比次级试验更多的癫痫发作,尽管在其总群中有不到十分之一的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "总的来说,初级试验中有更多参与者没有肿瘤响应,而不是部分响应,只有3名患者有完全响应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "bfb617c8-51ae-4ab2-be05-6346daad5437": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "二级试验和初级试验干预都要求受试者遵循卡路里限制饮食或无葡萄糖饮食,同时完成食品日记。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "dcc5c3b0-848b-4ef4-afe6-e9c9933e33af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "不正常的LVEF,怀孕或哺乳自动排除患者参加初级试验,除非他们接受草药治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17,
            22,
            28,
            29
        ]
    },
    "18fcd396-cb03-4e80-bb2d-ee03c12ba32a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "在二级试验和初级试验中,在二级试验的群体1中,只有一个怀孕案例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "694c5820-ebb6-4271-8685-a0b51c637f7f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "在Exemestane + Celecoxib小组和初级试验单独Exemestane小组中具有临床效益的受试者的比例没有显著差异。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b87abb47-13b6-4dbe-9cfd-e63075b676aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "在评估0中,初级试验的参与者对所有目标和非目标损伤的确认消失。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "eb025223-1b4a-4df7-a85e-2eeeb62a6bf5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "接受超过5年的安斯特罗佐尔治疗的患者,完成不到1年前,有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3
        ]
    },
    "23df2cc2-6aae-4251-a8a7-e2f5a65f176a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "在初级试验中发生的任何不良事件都与GI无关。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "1bd51c93-d7a8-4da4-825d-ada625033c34": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "萨曼莎最近接受了肝脏移植,正在服用合成口服避孕药,她不符合初级试验的条件,但符合次级试验的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            10
        ],
        "Secondary_evidence_index": [
            3,
            4
        ]
    },
    "58c58b68-fc9a-438c-8a85-9233dde714c9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "初级试验的三消极乳腺癌群体的ORR比HR+/HER2群体要低得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "843778c6-a320-49a1-93a0-5dc6239b822a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "在初级试验中最常见的副作用是感染和胃炎。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "a5486f80-69e5-4a5a-8435-f82f39cddf85": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "在初级试验的群体2中,胃肠道出血的病例比在群体1中更多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "c2c60b25-f255-48ba-bcb7-2bcd2de4315d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "初级试验中有四种类型的不良事件,没有记录发生。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "a8167a90-8ccf-4024-a4cc-8c1b047fd548": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "初审和次审不使用相同的管理途径进行干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "初级试验的参与者每月两次口服600毫克Pemetrexed治疗,直到完全反应或疾病进展。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "277f5d17-36cc-44c5-9b94-7e052f2bdb2c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "与二级试验不同,初级试验只提供干预部分的周期和药物剂量的持续时间。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "fcb195de-2143-44d8-8c46-136104554e2d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "原始试验的两群体中只有不到1%的患者对Pancytopenia产生了影响,但1群体中只有5%以上的患者患有凝血病。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5,
            11,
            15
        ]
    },
    "70337af9-3d4a-44bc-bbfa-0d97ea88553c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "患者必须至少有3次前期治疗,以获得初级试验的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "9cf89221-5801-4709-a098-de763b6e702e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "一名女性手术患者将被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6
        ]
    },
    "f89883ea-dd60-4d5f-9354-13fbca2aeec8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "莎拉正在经历脑肿瘤的癫痫发作,这不会阻止她参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5
        ]
    },
    "a289f67c-ff56-44a9-b3da-152fb0d20271": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "在二级试验和初级试验期间仅记录了1次呼吸不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "10ed1242-c6ab-4ad0-b93c-4738857f543a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "患有ICD的患者可能有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7
        ]
    },
    "683b9885-4027-4108-b37e-61255611538a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "亞洲,白人英國和白人愛爾蘭婦女有資格參加初級試驗,只要他們沒有不受控制或有症狀的大腦轉移。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            10,
            11,
            12
        ]
    },
    "a47e048a-56aa-49e0-9903-563f53797b6e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "初级试验的联合体1以比联合体2更高的频率和剂量接收Bevacizumab。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "690de5e2-3d7f-407e-8eb9-783adf58841b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "任何年龄的女性都可以参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "f5477a02-dde7-44c8-80b5-2cdb9fa66f23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "在初级试验或次级试验中发生了两种以上的麻疹病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "dc184dcb-a22d-4cac-bee1-6c182692e522": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "患者必须有超过1年的预期寿命才能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "4dfbdeba-cae0-48b2-a38d-07338512904e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03076190",
        "Secondary_id": "NCT03196635",
        "Statement": "分子乳房成像不适用于初级试验或次级试验干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "62489179-bb30-4b96-a904-ea907dd05e23": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Secondary_id": "NCT01009918",
        "Statement": "初级和次级试验中的每个患者在2年内至少经历了1次治疗新兴不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "45891239-bb78-4f83-8306-8edceb8247fe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "所有初级试验的患者必须在入学前进行双边乳房筛查。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9ec1e3f0-64a2-4629-aee8-cdb516fd27f3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "初级试验的1组不接受任何Eribulin Mesylate或Vorinostat,而二级试验的两组都接受了一些两者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "91f23b55-38b6-41c4-af30-baa15e989aa7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "患者必须有Eceptorsestrogen受体(ER) - progesterone受体(PR) - 和人类表皮生长因子受体2(HER2) - 非转移性乳腺癌,以及没有 dysphagia。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            8,
            12
        ]
    },
    "7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "初级试验的结果表明,通过口服服1500毫克(mg)的参与者在5年内达到DFS的可能性比安慰剂患者高出两倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "a2d489d5-3677-43ef-b03a-33d571c0c3b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "第三类肥胖患者不能被纳入初级试验,但可以被纳入次级试验,只要他们没有不受控制的高血压。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "943ff737-4edd-4dbd-a3c9-213e3e0234d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "初级试验和次级试验都报告了患者群体中的混乱情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            15
        ]
    },
    "be50c45f-ec51-40c8-904f-ffc200d39d9d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "只有能够理解英语的患者才有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            11
        ]
    },
    "f53c8212-6da8-470f-a392-1bb037ed90e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04030104",
        "Secondary_id": "NCT02525718",
        "Statement": "二级试验和初级试验的干预1既不包括治疗,也不包括安慰剂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "7b7e6e8b-aa62-4fcd-af1e-c243995243d1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "在初级试验中,DLT患者的数量是初级试验的2组的2倍,而不是1组的2。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "74a53536-bb9d-4c64-9280-679d7b660cdd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Statement": "初级试验不调查其干预对患者TPCR的影响。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "6b35c306-a699-44f2-8606-a58d58fc18f3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "初级试验的1组有6个不良事件类别,至少记录了3例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "62f50fe5-a83d-4f07-9dc7-8f495254d398": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "乳房乳房辐射以某种形式用于二级试验的两组,但在初级试验中并不使用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "edcae553-8a0a-45d2-a0fa-4db68608ef03": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "初级试验要求参与者具有最长尺寸的初级肿瘤 > 5cm。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "a1b3667f-bfa5-426a-975a-20ed350c12c0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "初级试验中的患者每月服用5剂Azacitidine(Vidaza)和每月服用3剂Nab-paclitaxel(Abraxane)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "903617fa-7c40-45ac-a03c-498f51879408": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "初级试验的两组患者间的平均、最大和最低总生存率(OS)差异不到一个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9436e18a-a055-41c3-980f-bf451b4da7ee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "初级试验中有四种类型的不良事件,其中记录一次发生。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "f57403d9-7278-481e-bcb9-066bf31b6158": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Secondary_id": "NCT00932373",
        "Statement": "初级试验中有1名患者患有分裂症,二级试验中有几名患者受到影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "ec601f6b-6ce3-4df7-b7b3-fbde1a241e93": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "初级试验和次级试验的患者没有经历任何相同的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "0f0e5a8e-3972-46c2-84dd-7436e82a9787": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "在初级试验中,治疗的持续时间是二级试验中的一半,但频率是两倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "420e4977-ce75-4fab-99e0-3e7db837d521": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "最长的疾病进展时间 初级试验在Docetaxel Plus Capecitabine组中超过21天。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "d07b4a30-e74f-468a-8420-7ade791d372d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "初级试验结果表明,与安慰剂相比,CoQ10降低了乳腺癌患者的PFS约8%",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "412b2743-8f76-494a-af97-f7bf9541a890": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "在初级试验和次级试验中的患者中至少观察到一种呼吸道疾病。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            11
        ]
    },
    "fd43feb6-4a55-4de6-b21d-25ff723b0959": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Secondary_id": "NCT00193037",
        "Statement": "患者可能被迫参加二级试验和初级试验,即使是违反他们的同意,只要这是他们的最佳利益。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8
        ],
        "Secondary_evidence_index": [
            0,
            9
        ]
    },
    "e1fa68ac-42b4-4223-a362-a89c43562e06": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "在初级试验中,最常见的不良事件是发烧性中断症(14.29%),而在次级试验中,排泄率下降(4.95%)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6f5570c0-4114-47ee-9611-b2e4be91cf9a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "初级试验中有2名患者患有DVT,二级试验中有0名患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "初级试验的干预2导致肿瘤直径比干预1的百分比变化较低。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "6495c223-f7d9-459f-8c57-66a2caac5ee4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "所有参与者在初级试验中都有中央神经系统(CNS)进展自由存活期(PFS) >=16周。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "eb61fee2-30fc-42f9-80bd-4d73d6af592c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01216319",
        "Secondary_id": "NCT03346161",
        "Statement": "二级试验和初级试验正在评估患有乳房切除手术的患者的乳房重建相关的干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "79c698bf-a756-4a73-8075-38c3c5eb7a04": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "两个小组的初级试验的负面(平均)百分比变化从基线的激素调节尿液N-望远(uNTx/Cr)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f7be0a6e-6c63-473e-af00-df009f3d7d46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "乳房植入物和分散微钙化剂不会使患者免受初级试验的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "6f686de9-f110-4be0-9cd8-1ceb0ce6f073": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "初级试验的2个小组受试者获得3.25mg的阴道DHEA胶QD比1个小组受试者多,在二级试验中的两个小组中,只有小组没有疼痛的每日Duloxetine 30mg。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "2c602b4d-c8a5-4606-8e3a-a87ee7bbc480": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "患者必须通过Hcg阳性测试确认怀孕,如果他们要参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "ffa913b7-9875-458e-8a28-476f9e788bb0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "在初级试验中,在GTx-024 9 mg和GTx-024 18 mg组中具有客观反应的参与者的百分比差异不到5%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "初级试验记录了7种不同类型的感染。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "d8e47fe7-be41-4f74-881b-a80cd3a1e95f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03456427",
        "Secondary_id": "NCT02685566",
        "Statement": "没有关于初级试验和次级试验的干预部分的服用时间或频率的细节。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e77e15a3-d851-4174-80c3-7b5156e7f987": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "初级试验和次级试验在其干预中不使用相同的药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "c003dd08-af3b-44cc-b31c-6fbdadfa1d83": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "在初级试验中,超过85%的患者在3年后报告了无复发的生存。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "8ddf49c7-316e-4c7c-b2dd-423182a37612": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "在二级审判和初级审判中,在二级审判的第一组中,只有一个突然和意外死亡案例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "d9e41be5-1e37-4dff-b51a-166576f351d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "在初级试验中的所有不良事件类型中,至少记录了一个病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ee2287bd-af76-4232-9575-d371fe3257dc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "初审中的每一次不良事件都发生一次。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e5495b51-5f42-4e97-80ec-c215652bd3ab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "具有 ImmunoHistoChemistry 测试结果 3+ 的患者被排除在初级和次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            15,
            18
        ],
        "Secondary_evidence_index": [
            0,
            15
        ]
    },
    "9b6bd158-a66d-42b6-8fe6-843ff05e0c8d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "儿童和文盲的成年人可以参加初审,除非他们能读和写意大利语。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ]
    },
    "9ae51f9c-8544-4764-b731-e4efe9ae0ba6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "初级试验 1 组中的 1/7 患者患有剂量限制性毒性。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "5b1915da-1819-4504-81bd-3f44a83b5e95": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "初级试验的凝聚体2记录了白血病病例的3倍于凝聚体1。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            13,
            17
        ]
    },
    "edb1e4c0-7669-4b8c-878b-ea8ca060c350": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "初级试验中只有2例不良事件发生在1组患者中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "915939cf-7813-43e7-b503-e14a7eb4e568": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "在初级试验中,只有一个群体接受了600 mg/m2的拉斯图苏马布。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "126c1169-b375-4f89-95b2-52e971d19565": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "初级试验的1组没有记录死亡和没有传染性 enterocolitis的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "11235250-3627-427e-aae9-099507484456": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "在初级试验中的三个群体中,共有两名患者在他们的身体组织中氧气水平低。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "8a9f2247-7c51-44be-910b-5091d9abb2ea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "初级试验和次级试验都给他们的患者群体施用了帕克利塔克尔和吉姆西塔宾,但只有次级试验使用了分子排放扫描。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7e283897-4d9e-4353-8331-00f8db16cc7e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "初级试验中的患者群体分别接受不同的口服药物,无论是Tamoxifen还是Exemestane。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "54b15068-023b-4e60-bb82-2a22512fda62": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "患有系统性疮的男性患者被排除在初级试验中,但仍可能有资格参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            24,
            32
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35
        ]
    },
    "78764961-52be-4235-a2b7-e581497d0099": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "初级试验中的两组接受了相同的药物治疗,但剂量不同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "e09fe98c-ec5c-49cf-9f49-92ba8824e82e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03708393",
        "Secondary_id": "NCT03456427",
        "Statement": "初级试验和次级试验的干预需要患者积极参与应用治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a83d98c9-e3da-4449-878b-5fa2f3bee8cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "初级试验不是测试新的物理治疗或放射治疗干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "41db854e-1565-4eda-8236-550556043b47": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "为了有资格参加初级试验,患者必须具有侵入性癌症,由核心生物检验确认,以及人体冠状腺素尿液测试。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            8
        ]
    },
    "f559cacb-30e7-47cf-9ac6-5929c1a508f7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "在二级试验或初级试验中没有MRSA感染。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "79362f6d-ef2c-4b93-8719-be361d0b5acc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "女性患者最近处方Rapamycin不符合初级试验的条件,但可能有资格参加次级试验,除非他们有第1阶段至第2阶段的管道癌,并能说英语。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "54918996-1b4d-48bd-a0ca-13d8e259767b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "第三类肥胖患者不能被纳入初级试验,但可以被纳入次级试验,即使他们有不受控制的高血压。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "二级试验和初级试验的患者没有共享相同的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "52c8361f-75dc-45f1-a35c-79180a22b931": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "在初级试验中没有记录出血管细胞压缩的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "初级试验的对照组患者的平均总存活期不到一年,但B组的几名患者存活时间超过一年。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            11,
            12,
            13,
            14,
            15,
            9,
            17
        ]
    },
    "db8ffa86-bf52-47bb-89f7-42e7ae47b84d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "在初级试验中,Afatinib单独治疗的客观反应(OR)参与者的百分比低于Afatinib和Paclitaxel或Vinorelbine组合治疗组的18%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "5a01d00f-8601-4c17-b814-be87e63b0d8a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "初级试验的群体不根据患者的特征分离。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7577f05f-04e9-44de-9e00-b7411ff4010f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "目前处方流感剂的患者不被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            18
        ]
    },
    "3b0440e6-cf85-4236-8a1d-2e3572143946": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "初级试验中的患者只经历了一种类型的食管不良事件和几种类型的心脏不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "6f342205-ef33-482a-b74a-74644537538b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "患者必须年满18岁,女性,具有一个或多个目标损伤和超过2个化疗团参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            5
        ]
    },
    "5b63fffb-0a75-414f-8744-5fea78395f28": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "初级试验中Afatinib 20mg + Herceptin组的100名参与者患有剂量限制性毒性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "9e655973-7d1d-4528-8394-a9cbcf0b978f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Secondary_id": "NCT00943670",
        "Statement": "历史证明HER2渗透性乳腺癌的成年患者,他们曾经历过前一次乳腺切除或同一侧乳腺减轻,均被排除在二次试验和初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "ea62355f-aab9-4796-8658-746c0b669ca7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "在初级试验中没有安慰剂或控制组,在次级试验中,Suramin作为安慰剂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "55eaae8d-611c-4dbb-b162-de664902e059": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "在初级试验中,在1群体中肠道阻塞的病例比在2群体中更多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8,
            14,
            22
        ]
    },
    "c3438bb2-4a49-4f14-ae50-a46fb48d0208": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "二级试验中的循环磷酸胺剂量和初级试验中的安慰剂量尚未确定。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "8f505cec-6ad4-4142-a861-1771e3ae5cdd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "初级试验的参与者每 28 天周期总共 13 天,每天一次应用皮肤损伤的局部 imiquimod。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "8f4f9793-041d-448b-9da8-b0c787a875bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "适当的血液、肝脏和肾功能不必要参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "d13e5689-2a9e-4295-b3f8-e4a18fe42bf1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01735175",
        "Secondary_id": "NCT01216319",
        "Statement": "二级试验是试验外科干预,与初级试验不同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "61d56c2a-089f-4fa3-9e97-3a9007576077": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "初级试验在研究期间没有接受任何 IV 介入,口服或手术。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5b90b8de-97b9-4ed7-b5a4-e3724fd38c41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "如果汉娜已经服用酮治疗运动员的腿6周,直到今天,她将不会有资格参加下个月的初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18,
            33
        ]
    },
    "bad4d3e7-a05a-44fd-937a-c94a23655c03": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "初级试验中的2组患者接受纳普罗克森与第二组试验中的2组患者接受Pilocarpine相同的频率和剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "在二级试验的群体1和初级试验的群体2中,有多个多器官失败病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "0c435231-a09c-4424-924a-13840c6b7068": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "在初审中,有一个黄病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            12
        ]
    },
    "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "二级试验中的患者不允许先前暴露于exemestane,但初级试验仍可接受患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "a29e6a86-65f3-4565-93e2-81f49fa837e4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "与二级试验不同,初级试验没有记录任何贫血, dyspepsia,恶心或抑郁症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "计划在开始前10天内重建关节,对于进入初级试验的患者来说是可接受的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "34bb7f09-3b2b-464f-96df-c8d80b1206fc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Secondary_id": "NCT01805089",
        "Statement": "所有癌症阶段均接受初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e9824c27-bb70-4707-9599-ff20281f873e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "初级试验的1组患者中只有不到20%的患者出现了静脉动脉。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "43fcba9b-4edd-433d-86a7-370cbbf56853": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "从随机化到由于任何原因导致的疾病进展或死亡的第一个记录迹象的所有初级试验参与者的平均时间低于二级试验的患者的平均时间。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "从随机化到因任何原因死亡的中间时间在初级试验的1号群体中较2号群体较高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "27e0b995-b3d1-46a6-900a-d6e513504ff3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "在初级试验中,三分之四的患者没有出现任何不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "36a5357f-0c5f-4c64-a56a-a84aab165a16": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "初级试验和次级试验干预涉及各种扫描,如CT,PET和剂量测量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c876167f-fe1e-4c3b-9183-dd3c1069ed0b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "初级试验的2组患者接受了包装红细胞输血。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            18
        ]
    },
    "d6989b67-ae99-4c2a-a67d-c2285cc57058": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "最长的疾病进展时间 初级试验在Docetaxel Plus Capecitabine组中超过11个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "初级试验中的两组在中间PFS中优于次级试验的1组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "886d3280-bc44-4a58-a5ba-66b018210332": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "从研究治疗开始到初次客观肿瘤进展或癌症死亡的记录为初级试验中的任何患者的最低时间仅超过了一年。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "03dcb6d9-efae-40ec-87ee-68ef89424498": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "在初级试验中,心理健康恶化的病例比二级试验的病例多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "b881b717-1c8a-41b8-9554-6ed9e8ee7c77": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "初级试验共记录了7名患有各种感染的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "20530faf-addb-47bf-896d-b9666e149223": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "在总体上,初级试验的1组记录了比2组的20%更多的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            14,
            15
        ]
    },
    "52557c9f-f771-4f31-bb71-01f87f9f5821": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "具有 ER 阳性、PR 阳性或 HER2 阳性 4 阶段肿瘤的患者可能有资格参加二级试验或初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42
        ]
    },
    "11472413-533f-45f9-9aac-c46bca318aab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "初级试验的 1 组包括超过 200 名患者接受 Sunitinib 和 Paclitaxel 治疗 18 个月或直到死亡,该组的PFS 中位数仅低于 7 个月半。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "3b8f5ef2-b0bb-42e8-a165-45a2d35780e0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "患者不需要具有 Her2neu 阳性肿瘤或可测量的指标损伤才能纳入初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "6446f085-c6b0-43ce-82ed-16d6952b549e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Secondary_id": "NCT00916578",
        "Statement": "只有初级试验2组的患者接受了压缩,但二级试验中的所有患者都接受了压缩。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7348c2e8-9eb5-4ed6-9a5d-bcb02a5c3a0a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "初级试验的参与者接受了50mg/m2的拉斯图苏马布、塔莫克西芬或埃克斯梅斯坦。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "db90c9d8-b289-48e2-a7df-f41620b3feab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "初级试验和次级试验都报告了患者发生疮的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            12
        ]
    },
    "f2533676-1e72-444e-8aef-1fa826ceb804": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "初级试验中没有发现农细胞病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "c15309b3-eb08-4d46-94ef-e4a504a111db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03708393",
        "Secondary_id": "NCT03456427",
        "Statement": "初级试验中的干预是由医生、X射线摄影师或声学家进行的,而二级试验中的一个干预需要患者积极参与。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4885cd77-628c-4b8f-8345-6bce2165938c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Secondary_id": "NCT00246090",
        "Statement": "符合初级试验和次级试验资格的患者必须居住在美国。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "8809cc5e-36d5-4f7e-b06d-b1915a421f71": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "只有一个不良事件,乳房肿瘤,在初级试验的1组患者中观察到。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "60 岁以上的妇女患有 histologically 确认的乳腺癌和先进的阿尔茨海默病,不符合二级试验和初级试验,除非他们有一个ECOG>2。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            21
        ]
    },
    "ca27db58-14c4-4889-95b1-69be9c10a07a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "在初级试验中发现低血小板数的患者比在次级试验中多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "5147b171-b5dc-46d6-a153-1a6d9a062ef1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Statement": "所有癌症阶段均接受初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a5ed3500-1ea1-40b6-b1cb-3d5ae776f713": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "初审没有记录任何不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "3c482d5e-bfad-4a46-9e98-ba9967f2d900": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "BCC患者被排除在初级试验和次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            12
        ],
        "Secondary_evidence_index": [
            6,
            10
        ]
    },
    "48ccd744-abf1-4e98-bc86-8ecd625e6279": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "乳腺转移性HER-2负性腺癌患者可能有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            5
        ]
    },
    "dce5d9c8-7da6-4732-b969-c492c876cdca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Statement": "任何年龄的女性都可以参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "1882de62-2df2-4b73-a3d2-81811f85f661": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "二分之二的初级试验患者在用化疗或维持疗法治疗3年后被诊断出脂肪肝病。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "161c852e-a42c-47c2-ab6a-2b7bd6a4b934": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "希望参加初级试验的患者必须停止任何抗肿瘤激素治疗,并必须有3个月以上的预期寿命。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            8
        ]
    },
    "eb152d1b-a0d6-428c-8d1d-eb5d862a8147": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "初级试验的1组中,至少有1名患者患有罕见的凝血障碍 Hemophilia。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "0701ac32-45b3-4199-aa20-a71080ce9bf6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "在初审或初审中没有 Vertigo 病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "866876f5-68de-44bd-b58a-e4b590aa4b39": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "初级试验的参与者必须在干预过程中至少进行一次MRI,在二级试验中,患者必须使用Fitbit。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "b4304362-1cb4-4606-9de4-03935ad509f1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "在初级试验的群组2中有55名与最佳部分反应(PR)或完整反应(CR)肿瘤反应的参与者比在群组1中更多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9cddd86a-4340-4918-b000-7e6e593a3f7f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "18 至 25 歲之間有穩定的喉症的婦女不能參與二次試驗或初級試驗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66,
            67,
            68,
            69,
            70,
            71,
            72
        ]
    },
    "c3f01101-2259-4677-add1-1b1f48a0202b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "在初级试验中的群组2中受不良事件影响的患者总数超过1000。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "33b827a0-ada5-4204-abb8-d5239ea16f0b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "在初级试验中,Exemestane组和Anastrozole组的最大记录TTP之间的差异不到3天。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "40f1d3ce-2ff8-4177-9b11-0bf10b7f6591": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "该初级试验研究了Fulvestrant,阿纳斯特罗佐尔对雌激素受体H分数的影响。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1
        ]
    },
    "22bff413-a1bd-419b-b19b-2157dedc9948": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "二级试验的组 1 的 ORR 比初级试验的 NKTR-102 14 天小组和 NKTR-102 21 天小组都高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "b64d6e41-7ec7-4e62-beda-c28559a6cee7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Statement": "只有初级试验的2组患者接受了Trunk压缩。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2ea80a50-0db3-4ff2-8ca0-71eb048649f7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "初级试验中有3名患者患有感冒。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "20545360-b2a1-4be9-997a-97040866b239": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "艾滋病患者有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            14,
            18
        ],
        "Secondary_evidence_index": [
            12,
            26
        ]
    },
    "3b1bdc19-62cd-4ff1-9e30-424e124342f3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "二级试验和初级试验都测量他们的患者群体的PFS,并使用相同的时间框架。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a44cd0d1-92b3-4add-badf-b8dd5a324138": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "初级试验记录了一名患有心脏衰竭的患者,二级试验没有记录任何患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "291bb67e-f02f-49d4-b967-29cc9f5098c4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide、Cabozantinib和Trastuzumab在二级试验中使用,但在初级试验中没有使用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "55704a1f-eab2-44ea-a6de-8df508a28066": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "患有4级癌症的患者有资格参加二级试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            2
        ]
    },
    "6e1955b8-e6fa-42b2-a498-7ada9e733304": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "阿斯巴达氨基转移酶超过正常水平的3倍以上的患者均被排除在二级和初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            18
        ],
        "Secondary_evidence_index": [
            23
        ]
    },
    "52337e14-7f51-40c1-b965-fb6aba8ae4e7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "用比索普罗洛尔或拉贝塔洛尔治疗CHF的患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            20,
            33
        ]
    },
    "8a6397e9-84cd-4a2e-ac6a-b56ee355d862": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "从乳腺肿瘤传播到其中枢神经系统的癌症患者可以参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4
        ]
    },
    "8b5f946c-71d9-42cd-aa9a-1d3a4845c460": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "初级试验根据其激素状态指定其患者的具体干预措施,Cohort A是TNBC患者,Cohort B是ER/PR +HER2-BC患者,相反,次级试验随机分配干预措施。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "8f0aff7f-0d9e-498b-bcb6-05e6d309724c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "二级试验以初级试验的两倍的速度服用安慰剂,但不到一半的剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b7936bbc-f0c0-444c-a199-2db323c30396": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Secondary_id": "NCT00305448",
        "Statement": "在初级试验中,用Fulvestrant 250 mg治疗的患者的客观反应率比用Fulvestrant 250 mg +加载剂量治疗的患者高33%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "6d6625ec-26b7-4157-a38c-87c770201323": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01373671",
        "Secondary_id": "NCT00686127",
        "Statement": "Lidoderm产品用于二次试验的干预手臂1,而西门子产品用于初级试验的手臂1。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e8b8c2b7-612d-4bab-b8a6-3dbc756cc210": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "患者必须呈现IHC 3+或FISH增强结果,以参加初级试验,这意味着他们的癌症已被 histologically确认为三重阳性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "7e0259a3-073b-45f5-8e08-2cfaceecef0b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "初级试验测试MRI扫描作为指导生物检测的技术。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c94ad26b-1f5e-4446-a4fe-bb949c5dc561": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "患者必须具有BUN < 20 mg/dL,血小板数: < 90,000/mm3,白细胞数 5,000/mm3 至 8,000/mm3 才能符合初级或次级试验的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "4e31e4f8-a6da-49fc-8bfe-1309674ec2ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "初级试验中有30%的参与者在治疗42天后增加了CEC水平。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "5c00f992-5066-42f2-88d7-566b8b9104b5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "在初级试验中的1组参与者中,急性毒性率增加,而在2组参与者中,没有急性毒性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "4c0ffc50-5cb2-4574-b954-335d142edbe4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "用西塔洛普拉姆作为抑郁症的持续治疗的患者不符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            32,
            49
        ]
    },
    "4e3379b9-f971-4ab6-8846-c395f1162bf2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "皮肤感染在二级试验的1组患者中比初级试验的1组患者更常见。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            8
        ]
    },
    "9872394c-18b7-4f88-849e-0e2831e6ebf0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "初级试验的参与者目前不能接受 rheumatoid arthritis 治疗,在过去的 3 年中经历过不受控制的脑筋痛,接受激素替代疗法,或有任何先前的侵入性乳腺癌。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            6,
            8,
            10,
            11
        ]
    },
    "adf3bb50-ec36-467a-987a-f33c10380c60": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "具有2个ECOG的日本参与者有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2ef37a06-a1ed-47eb-b8f4-2f97f46293d1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "初级试验中的一名患者遭受了脑梗塞。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "03cb39e4-1d21-47e5-9b09-ebe508eb2a17": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "主要试验的59名患者获得了最佳总体反应,分为至少6个月的完整或部分(确认)肿瘤反应或稳定疾病。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "dca6ba74-441e-482f-b667-6c45800ed8c1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "接受初级试验的干预1的患者必须接受21天的治疗周期,总共6次,除非死亡发生。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "aeecc244-13a9-4944-858e-27ef49585e90": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "具有无法治愈和无法治愈的本地先进乳腺癌的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "741ca5eb-4737-4a35-a9fd-4235d6552b4f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "初级试验是研究认知行为疗法,一种类型的心理治疗,而次级试验研究Neratinib,一种类型的化疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b8e0458c-b834-42b5-b5fd-8791f89b0853": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "初级试验中的 Gemcitabine 群体中,Kaplan-Meier 预测的无进展生存时间比 Carboplatin 群体短了 2 个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "1a112ed3-8318-493b-8973-10de01794892": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "在初级试验和次级试验中的患者中,只有一个患有疮。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "6044590d-0f89-4a6e-8be7-54ca0c0327d9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "初级试验没有以催眠疗法为基础的干预,而次级试验没有放射疗法干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8d3378f7-caaf-4654-b12a-382a0e911eb1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "血小板数50 x 109/l的患者不符合初级试验的条件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "f701473d-e034-4a06-9829-d20cc483162c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "初级试验和次级试验的结果不相同,因为群体大小的差异太大。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3889cecd-aa2d-4f58-857e-11d7209f9cf4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "在初级试验中,1组患者在治疗后3个月内有较高的无进展生存率比2组患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "19d0c9de-02ad-4a8e-937b-e9d0f0cc8051": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "没有一项初级试验的参与者有1年以上的无进展生存率。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "cb023dbc-3e99-4c32-a857-7f8d49ef5a96": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "二级试验报告了更多 Haematemesis 病例,但初级试验在其两群群体中有更大的总体 DIASTOLIC DYSFUNCTION 病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "1d0ce237-70eb-45b4-9c77-f0b70d410387": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "18岁以上的女性患有肝脏病的患者不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6,
            8,
            16
        ]
    },
    "93290529-38b1-444b-9ac8-fa32b98821c5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "希望参加二级试验的患者必须在特定地点,这在初级试验中是不必要的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "dad5ecc6-afcf-496c-8193-778a100c0318": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "患有脊椎脊椎上超过20度的Cobb角度或前一次脊椎脊椎手术的疮患者被排除在初级试验中,因为这些是对脊椎双能量X射线吸收测量(DXA)的禁忌。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            39,
            40,
            41
        ]
    },
    "d0efe29c-1d76-4129-9cf5-2955564d1370": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "LVEF大于或等于60%的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "63ec91be-7e12-431e-84b0-ca401bfb157b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "初级试验记录的总不良事件比二级试验增加了2.38%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "fd5af11f-7270-49d5-924a-755ff399c463": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "初级试验的1组包括250名患者在18个月或直到死亡期间接受Sunitinib和Paclitaxel治疗,该组的平均PFS为不到7个月半。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            7,
            8,
            9
        ]
    },
    "f07e932e-1d79-4e1f-9ac2-ed9e2db1c276": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "在初级试验的B群中,血清25(OH)D大于或等于30 ng/ml的妇女没有接受每周的胆固醇补充剂。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6a5ee728-7db9-4ec0-b98c-0500e9a6187e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "初级试验中的一个患者具有异常低的AST,ALT和ANC水平。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "a495df61-260d-479c-8d5f-d586f295c672": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "二级试验和初级试验的2组是控制组,接受了安慰剂片POBID。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "917afeec-5152-4424-89e3-7f3ffad6378f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "重量小于45公斤的初级试验小组1的参与者比45公斤以上的参与者获得了4百万单位/平方米的IL-2,但所有参与者将每周服用IL-23次,服用6剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "19f84eca-6bb1-4d32-a9b0-b2dd7c3f22e6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "患者必须有健康的肾脏、肝脏和骨髓才能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8,
            9,
            10
        ]
    },
    "f5aa1aa3-7be3-4518-8cc5-df2394e70e96": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "未确定雌激素受体状态的患者可以接受初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            5,
            7
        ]
    },
    "45338f7c-5aaa-40fb-8503-7c943e1f3a29": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "通过肌肉注射服用Fulvestrant 500mg的初级试验参与者比接受额外800mgVenetoclax口服的参与者具有更高的临床益处百分比。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0964be32-f9e7-49ec-ad22-b030d483702a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "与二级试验不同,初级试验不会口服任何药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "73cfc4ea-afc0-465b-a403-c1bd771ded33": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "用西塔洛普拉姆作为抑郁症的持续治疗的患者不符合初级试验的资格,因为心理疾病不允许。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53
        ]
    },
    "75b67d63-9727-418d-afd5-c0fb867417b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "患有溃性结肠炎的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            15
        ]
    },
    "94cd9451-35a4-4035-a7de-2d385f771607": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "初级试验2组中的42名患者中有一半失明。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "18310f83-54ca-4530-92f1-7c41419ab69e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "初级试验的1号群体中,比2号群体中有更多的患者出现了发烧性中性衰竭。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "4fa6b99e-0e70-465d-8b24-b728979b3689": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "初级试验的两群群体中有相同数量的贫血。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            12,
            14
        ]
    },
    "e0fac0a4-a5ab-4089-8986-f601586506af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "遗憾的是,患有膜转移的妇女被排除在初级试验中,因为这将阻止他们为研究入学提供知情同意。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18,
            19
        ]
    },
    "85210693-996a-4ab9-92f4-62060571da21": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "最多每分钟心跳50次的西班牙女性有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f0fbdbf4-af12-4cde-a5f1-a56cc60658f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "初级试验的1和2组记录了同样数量的中性衰竭患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "6a37e999-4b7e-4654-b9ac-7776a0720040": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "二级试验中有1名患者出现饮食障碍,初级试验中没有出现这种情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "a625ff4b-9c91-4ab8-a78b-df833d15759a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "初级试验和次级试验都报告了他们所有的患者群体中的混淆案例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            15
        ]
    },
    "b25e7c40-a1db-4ae7-9613-0f65ddb4c040": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "在初级试验中,至少有一名患者患有危及生命的骨折。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "25f1f3b8-15ed-4339-bf56-1cf1e0c2909f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "初级试验的1组没有记录死亡和没有贫血病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "c0ddffa9-4a88-4ee1-8525-a77e887c3d85": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "在初级试验中,Eribulin Mesylate 组的完全响应(CR)或部分响应(PR)患者比对照组的比例更高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "64ea58e5-e28f-42bc-818e-31bbf347080c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "持久感官丧失,干扰日常活动的患者被排除在初级试验中,但仍然有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            22,
            30
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53
        ]
    },
    "7a0f4365-9775-4f1d-a1c7-4630b41b43ea": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "初级试验仅为群体2定义了干预剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "64dcb690-ef14-4cf2-85e5-670eb0645d7f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "18岁以上的女性,其最后一个月经是2周前的,有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "cacd1b1b-510e-421b-9adb-c5715f281794": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "初级试验2组的患者在治疗期间至少出现1次不良事件(AE),而不是1组的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c3e5a015-e8b5-4281-828c-deb1f7fc7e3a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "初级试验中不良事件的最大发生次数为3。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "7926bfa3-cf49-4589-8143-0a0826336b67": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "所有初级试验1组的患者都有偏好药物管理方法。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "初级试验没有明确说明其任何患者群体的Triptorelin剂量,另一方面,次级试验提供了用于LBH589的剂量,卡佩西塔宾和拉帕提尼布的细节。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "二级试验的组合1的患者数量超过了初级试验的组合1的患者数量的50倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "36957dd8-fe28-4b70-b651-8f6ea7d1d0e9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "初级试验的1组和次级试验的1组具有相同的总数不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "1aee22c7-96f2-4ea6-909a-48741f87ba07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "在初级试验的患者群1和2中没有观察到抑郁症、腹泻、恶心或发烧性中毒症。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "d677707e-9ca9-4801-8fcd-7960a9f4f30a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "paclitaxel是IV提供的初级试验中唯一的药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "5335a9c9-bae1-42e9-9428-eb0eded62d7f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "初级试验中没有受试者被要求服用任何药丸,而二级试验的两群人必须服用每周一片药丸。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "e6c0f7af-b549-4aad-8f3c-15f367a04a50": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "初级试验中的Abraxane + Tigatuzumab组有10%以上的患者完全响应(CR)消失的所有目标损伤;部分响应(PR)至少减少30%的目标损伤的最长直径的总和比Abraxane单独组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "1fc3aeac-3bc0-4a47-8222-ea267a822804": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "初级试验中没有发烧骨髓缩病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "9e664bcb-38cc-4ca6-9738-28d96248b7f2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "初级试验的参与者必须每天服用6片Lapatinib Monotherapy(1500克)PO。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "1b8403ac-7eb3-41cb-8b7e-a89af3492805": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "在初级试验中,所有 Enteritis、 Vertigo 和 Anaemia 病例发生在 2 组中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "ad853675-40ed-4a65-a401-d09ac3153570": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "T2 N1 M0乳腺癌的参与者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8
        ]
    },
    "b43bee02-cc3f-4dc8-b13f-8a93de5dc422": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "初级试验的 1 个小组比 2 个小组具有更长的平均、最大和最小 pfs。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "62258901-8207-413d-913f-a04682635add": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "初级试验结果表明,Zoledronic Acid Upfront比Zoledronic Acid Delayed-start更好的治疗,用于增加脊椎(L1-L4)骨质矿物密度(BMD)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "d23aee47-e80f-42fe-b095-9cd81f9e0ed3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "两个初级试验小组报告了相同的结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d23eb56e-c232-4754-94aa-903bc174cb35": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "初级试验的Trastuzumab手臂比拉帕提尼布手臂有9%更好的结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "1c0dcd29-4a04-4b78-abbf-b047d4c29597": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "乳房植入物的患者总是被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6
        ]
    },
    "b1a17048-dfe8-4173-ae80-6ec273244848": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "超过20%的初级试验1组患者经历了不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "33652443-0bb4-493e-adfe-f5032b96b13d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "初级试验 接受Neratinib Plus Capecitabine的患者的PFS时间比研究的38个月更长。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "74dba58a-8f5d-478b-a886-0e9758847fe3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "临床上焦虑的患者不能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            9
        ]
    },
    "5344044c-127d-4a39-80dc-277538b5ad33": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "在初级试验中,TCH + P组中不到60名参与者达到基于肿瘤样本的综合病理反应(tpCR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ed43519d-9954-4e0f-9d42-39a3ed81e4a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "超血糖是初级试验1组中最常见的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "8d2fde27-a5e8-40ee-a35d-3d4697198a4e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "初级试验中没有发病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "fc0da76b-e5b5-44e3-abaf-6231fff493c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "初级试验的安慰剂组表现比试验组更差。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "1a32e1c1-31b1-40e5-bbb6-84041ef796fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "初级试验的1和2组中,有3名患者患有心脏衰竭。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9a31db67-e28a-4114-a308-e899f9c22813": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "初级试验中的一个患者患有食道的炎症。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "f948a2d1-2e22-47c8-9345-0eb68569bd3f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "艾米莉患有不可操作的乳腺癌,她有资格参加二级试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "e3265040-8316-4f62-969c-27af396ba18c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "以前接受了贝瓦西苏马布治疗的患者不符合初级试验的资格,除非他们在试验入学前2周也接受了卡博拉丁。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            22,
            24
        ]
    },
    "6c25e195-47cd-48af-bb51-5b5c44772baa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Statement": "患有甲状腺炎的候选人将自动排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7
        ]
    },
    "382747d3-69df-41be-a771-4218407ce5d3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "初级试验结果表明,Zoledronic Acid 4 mg Upfront会导致骨质矿物密度的 +ve 变化,而Zoledronic Acid 4 mg Delay 会导致骨质矿物密度的损失(在某些患者的人口统计中)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d05ec90a-f267-44be-aaa6-3be960a0d50c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "大多数初级试验受试者至少经历了24周的完整反应(CR)、部分反应(PR)或稳定疾病(SD)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "37301690-9b68-48de-b280-6307e632043e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "二级试验和初级试验记录的唯一类型的不良事件是腹泻和各种疼痛。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "b61e798c-d38f-4c72-91bb-4d3e28b6184c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "任何年龄的女性都可以参加初级试验,但只有成年人可以参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3ca27248-0728-4b10-b940-6e2603acef30": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "患者必须有渗透性乳腺癌才能参加二级试验或初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "c2da6504-96a1-4669-b609-16731a5330d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha是一名32岁的韩国女性,患有不可操作的乳腺癌,她既不能参加二级试验,也不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            6,
            10
        ]
    },
    "646959e4-25d0-4eb1-b7b0-2d7b1e02e132": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "在初级试验中,不到5%的患者经历了不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0e6eebe9-46c2-4fa5-b9ed-e0997044960b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "初级或次级试验中的任何患者都不需要接受放射治疗或手术。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a781374c-99e1-47ee-a266-bff9267c2ed1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "初级试验中阿法提尼布30mg + Herceptin组的100%的参与者患有剂量限制性毒性。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "9aea5a84-bced-4441-b8b8-154c307f5a03": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "初级试验中的安慰剂组比MM-121群体的PFS中位数要低得多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "deb77d34-76a5-4e6e-bc9d-176cc30eca07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "初级试验2组的一名患者在摩托车事故中死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "bfe97430-fcec-4c4a-9621-51f6ec05d8d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "初级试验的 1 组患者比 2 组患者出现致命的渐进性疾病。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "568beebd-b350-4ba1-b8fc-c43f4d6ed517": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "初级试验研究了CTX/IMQ/RT和IMQ+RT对系统肿瘤响应率的影响,治疗开始后9周。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "6bcc18b7-b063-49a1-8ab7-773636c02f1d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "从研究治疗开始到初次客观肿瘤进展或癌症死亡的记录为初级试验中的任何患者的最低日数为191天。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "dfa2ecee-96cf-4551-875e-aedd8aac5df9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "在主要试验的两个手臂中,在化疗的第 1 周期中,4 级中性衰竭的平均持续时间差异不到 24 小时。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "81c85a29-d449-4f79-a3b3-682ba5f288ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "在初级试验中,小组 2 患有 Leukopenia 的患者比小组 1 多,而在二级试验中,小组 1 患有 Leukopenia 的患者比小组 2 患有 Leukopenia 的患者比例最高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            14,
            19
        ],
        "Secondary_evidence_index": [
            0,
            3,
            12,
            15
        ]
    },
    "9c48c5d6-83fd-42cc-aacc-2e888099bcdb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "初级试验的参与者每天比Letrozole更多的Imatinib梅西拉特。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "79a3bb0d-315f-4c39-8786-2aa98e2e3f6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "男性不符合初审资格。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "cea17554-6736-4b52-b76c-b3c5dc9ecb77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "所有初级试验的参与者必须最近接受 echocardiography 或 MUGA 扫描。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "b250a17c-9d4d-405d-ba64-40f7eda16707": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "初级试验结果表明,根据NCI不良事件通用术语标准评估的第二阶段帕克利塔克尔的推荐剂量为90 mg/m2。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "698849c5-78fa-4c15-a1dc-f44eb9c970c2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "在初级试验中,至少有一名患者患有运动障碍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            14
        ]
    },
    "4b4e6ac7-107c-46f4-adbb-c77c01f51935": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "初级试验的1组中最常见的不良事件是低血糖水平。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "6b73dee4-0291-455e-90c2-786f0c2371d4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "初级试验的参与者目前无法接受 rheumatoid arthritis 治疗,在过去的 3 年中经历过不受控制的脑筋痛,或有任何先前的侵入性乳腺癌。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            8,
            10,
            11
        ]
    },
    "2a1d9064-fde9-4645-95ab-7ddaea4ad322": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "初级试验 3 中的 2 组与 1 组相比,具有完整反应的患者多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "847de3fe-b584-4d43-b82d-93263ce88830": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": "初级试验中的患者每天每日注射300毫克帕佐帕尼布,持续进行,直到疾病进展或不可接受的毒性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3c798991-6366-43e2-94ca-0523629930c2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Secondary_id": "NCT01004744",
        "Statement": "在过去6个月内对抗癌症治疗的安特拉西克林药物的先前使用是禁止在初级试验中的患者,但不是在次级试验中的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "64fe54a2-8897-4324-af88-f627c1c208ed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "初级试验的2组记录了多起 Thrombocytopenia 事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            13
        ]
    },
    "4eac6a2d-64cd-4289-a545-211eb835f0e9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "可行性参与者的百分比在初级试验的队列1中比在队列2中高出70%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3ee1c60e-46ce-4f25-af52-31d5c6d8eba1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "二级试验和初级试验使用最佳的整体响应(OR)作为他们的评估指标,但它们使用了显著不同的时间框架。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "da1e1019-adb5-47bf-8093-e03352ca9e51": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "患者每天不能进行超过半小时的体力锻炼,如果他们要参加初级试验,但这不是二级试验的要求。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "e7fb6490-1ec7-48ff-95b1-715d79faec92": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "患者必须英语才能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "d5ea3443-103f-4d29-9be3-522210b84152": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "初级试验和次级试验仅记录2个相同的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            8,
            10,
            5
        ],
        "Secondary_evidence_index": [
            0,
            9,
            3,
            6,
            11
        ]
    },
    "d54cae08-3ac9-4460-bf6d-7338b45d8cd7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Statement": "患者必须年满18岁,预期寿命超过6个月才能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            11,
            13
        ]
    },
    "608c5521-c9a6-47de-9ebf-791ce317a02d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "初级试验1组中的所有患者都经历了不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "14a8e9e9-0a46-4537-bc07-53c786bcbe97": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "患有HER2负MBC的患者有资格参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "2d97bfa0-336f-4976-95e5-1262327a730b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "初级试验记录的总不良事件比二级试验多2次",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "e68dddc8-ea04-49b2-ae91-ff7b4fcb1240": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "在初级试验中,具有最高百分比无事件生存率的患者群体是IIIB阶段的患者,最糟糕的是IV阶段的疾病患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "8c83330f-f2f3-48e1-9905-dc2ba1970c54": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "初级试验组2的参与者接受与组1的参与者相同的综合脱阴物理疗法,并将胶带应用到麻疹区域。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "4613834d-c178-475c-b9fd-c9c66d5681eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "初级试验的2号群体接受的Q-122剂量高于二级试验群体接受的AZD9496变体。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b4555685-6e25-4797-8616-bcab5b06a135": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "初级试验研究了Fulvestrant、Docetaxel对雌激素受体H分数的影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1
        ]
    },
    "c1b90c18-45f4-4e28-b50a-a00b0eadc523": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "乳腺肿瘤宽度为0.1厘米或更小的患者有资格参加二级试验,但不能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "33ef3abf-97c0-4d15-909d-258fb47ac54a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "只有HER2阳性乳腺癌患者才有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "a381e340-18b1-4baa-91ce-0c420bcb411c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "二级试验和初级试验结果表明,参与者的PFS与年龄,癌症等级和种族部分相关。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "初级试验不是测试基于药物的干预,而是测试一种名为手动淋巴排水的医疗设备。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8e246d8f-e063-4f2e-a382-5d201a946b87": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "在初级试验中,没有一个患者在积极治疗Trastuzumab和RAD001期间患有心脏衰竭。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "8154bd8c-90a2-4b2f-8090-fcc89aeae30c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Statement": "任何种族的患者都可以参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "537781f9-3693-479e-af22-824cdd827b9c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "初级试验表明,不同Pembrolizumab剂量对报告剂量限制毒性(DLT)的受试者数量没有影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "5feefe8b-ddca-4eb8-af68-d1e211963d1f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "2名患者,在初级试验的1组被记录为具有过度活跃的甲状腺。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "2a5d8ca7-1608-4607-b996-490fc447b593": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "所有初级试验受试者都需要每天服用干预药片PO。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "178c50cc-49ee-4083-bc8e-b5832037498a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "初级试验中的4名患者经历了3级或以上不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "92ace4fa-4426-4f34-af52-ee62913e60aa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "在初级试验的群体1中,左心室系统功能障碍的患者比在次级试验中多出10%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7,
            12,
            19
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "7dbde84d-f1c9-4197-9d44-500fd337bebd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "最多12名以Meso BioMatrix Acellular Peritoneum Matrix植入的患者患有乳房相关不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "824da29f-b2ff-440e-8b78-7a8291cbd6d2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "在初级试验中,共有89名患者患有超心心脏病。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "初级试验中的1名患者被记录为具有过度活跃的甲状腺。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "052ee533-7daa-4cbf-a64c-bc9a50444173": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "初级试验没有监测血球素C疾病在其不良事件的发生。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1d7dbb44-049d-4887-8bd6-6aefc77aa1e9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "在初级试验中,共观察到7名患者患有白血病、心肺衰竭或腹泻。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            6,
            8
        ]
    },
    "9b622b9b-3ad3-4cff-acb3-4127d0304de0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "职业暴露于离子辐射不会使病人被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "825ba6fd-8c08-49d2-941b-3338ef01e7fd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "非洲裔美国患者有资格参加初级试验和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "0421750d-66c6-47be-bde7-0c41ee43a28b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "患有严重吸收障碍的患者不符合初级试验的资格,即使他们能够接受静脉(IV)营养。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            24,
            31,
            30
        ]
    },
    "95345dbe-446f-4999-8f3e-a429b77ea554": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "适当的肾脏,肝脏和血液工作是需要进入初级试验的,这包括以下标准; 血球素 11.5 g / dL,以及ALT,AST,碱性磷酸酶和总比利卢宾 < 2.5xULN,和血清激素应该小于1.7xULN。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "b05fde86-4004-427f-8baf-2ea4a0a535c7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "在初级试验中,所有人都接受了两次手术,首先在2周后,然后在一个月后再次进行。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "21e24c6c-d282-48fb-8d68-3e723458794e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "以下任何条件的患者将被排除在初级试验中;第3级感染,不稳定的喉咙痛或第4级出血在最后一个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            87,
            94,
            95,
            108,
            117,
            118,
            119,
            120
        ]
    },
    "d1e579e2-b057-43da-8a2f-64dad964b789": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "初级试验的参与者每 28 天周期总共 14 天,每日 1 次应用皮肤损伤的局部 imiquimod。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "在二级试验中记录了与心脏有关的不良事件,但不是初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9,
            10
        ]
    },
    "d130c981-f602-4f17-b1cb-11a7ad632b92": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "初级试验超过6种不同类型的心脏相关不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            13,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "c1f9982f-c4c9-48dc-887a-7ae05f508c21": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "初级试验 参与者每天服用 niraparib 200 毫克(mg) PO 28 天的周期,为 2 周期",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e966302f-9378-4681-b2c6-9d8b5b5f709f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Statement": "初级试验中的大多数患者经历了不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "75130da8-77be-45d1-bc32-dfc97c1a1dae": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "二级审判比初级审判要长得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "c71cbcd6-3786-4b90-8991-b3c6e159ae77": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "初级试验使用与二级试验使用卡佩西塔宾和拉帕提尼布相同的Triptorelin剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ed48936e-4933-437b-a7ba-e65b4c1fd276": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Hypofractionated Simultaneous Integrated Boost Radiotherapy 用于二级试验,但不用于初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b01e966e-6624-4740-b477-a8bbbd8eec50": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "与二级试验不同,初级试验没有记录任何皮肤淋巴结炎、骨髓抑制或过敏冲击的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "92acd36d-ea44-4b98-acbc-e51382233089": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "腹泻是初级试验1组中最常见的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "01280892-ca31-4e46-831b-a076426f65e5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "在过去6个月内接受T细胞转移治疗的患者,并完全从相关的毒性中恢复,将被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            8
        ]
    },
    "959bd67a-1b2a-48da-ae44-211cbab4b665": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "初级试验中的Docetaxel + Sunitinib组患者中期(95%信任间隔)无进展生存率(PFS)超过一个月高于Docetaxel组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "92923765-76d4-4a27-a240-101690d9fea4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "初级试验的患者比 Methotrexate 和 6-Mercaptopurine 更频繁地和更高剂量服用循环磷胺。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "437cb2c2-63e8-4d9b-a501-4b6a35db8d2b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "与二级试验不同,初级试验不会口服或静脉注射任何药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5a5695e8-9b84-42ad-9f34-6dd043153943": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "适当的肾脏,肝脏和血液工作是需要进入初级试验和次级试验的,这包括以下标准; 血红蛋白 11.5 g / dL,以及ALT,AST,碱磷酸盐和总 bilirubin < 2.5xULN,和血清激素应该小于1.7xULN。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "33634c51-0fb9-4de1-966d-14784bca93f8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "至少每分钟心跳60次的西班牙女性有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "8e46dc77-fa36-4231-a124-0ff6392891a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "二级试验和初级试验是控制组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d11b0673-42a9-46c0-887f-d5a9b038264f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "初级试验的手臂1在没有疾病进展或不可接受的毒性的情况下,在一周长的周期中接受剂量密集的化疗最多12次。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e08c196a-e3f0-420b-a252-7e2818949038": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "所有妇女(不论其生殖状况如何)都必须使用适当的避孕方法才能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            16,
            17,
            18
        ]
    },
    "83511f04-e07c-438d-bf1e-f680fa49b384": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "初级试验的1号联合体记录了比次级试验的1号联合体更多的中性热病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "在初级试验中记录了一个生殖器不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "72bb3c6e-66b0-4380-9da2-5a5867d715fd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "与初级试验的群体1相比,在群体2中观察到的每一个不良事件的病例都多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "1b433096-f36a-4205-b16e-f9a370be3d05": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "初级试验的18多名参与者患有辐射性皮肤炎。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "076ead15-ce03-4c33-9050-1f6eb13764a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01490892",
        "Secondary_id": "NCT02364388",
        "Statement": "初级试验中的干预需要注射和两种不同的成像模式,而次级试验在干预部分中几乎没有细节。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "在初级试验中有更多的肺症病例,而不是二级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "3e1037fd-cc1e-4229-892f-95d0987d9a68": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "在初级试验中观察到的 1-methyl-d-tryptophan (indoximod) 的最大容忍剂量(MTD)为 800 mg。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "f25adbc7-c0a0-44ed-af93-02f4bced7208": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "初级试验的2组接受了与次级试验的2组接受 oral itraconazole相同的Pilocarpine剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "99951bae-37c8-4299-8ec1-4577a97d0b81": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "初级试验记录了 pleural effusion 和脊椎压缩骨折的病例,二级试验中都没有观察到这些病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "b66b62c4-902d-4e19-929e-2086b349bd93": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Statement": "在初级试验中,对抗癌症治疗的安特拉西克林药物的先前使用是禁止的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5
        ]
    },
    "c789e79c-a254-4bb1-9d15-73d1726da8a6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "没有二级试验或初级试验的年龄限制. 患者只需要被诊断为中间性肺炎或肺纤维症才能符合条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "2b182323-9357-486a-87aa-09ddc6230bf1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "初级试验中仅发生了1次以上的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "9681ec15-7545-455e-ac8c-1052fc199b11": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "在初级试验中,Herceptin组的患者达到病理完整反应的数目比CT-P6组更高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "8ca512c3-72d8-4179-a63e-51d83d76445f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "二级试验和初级试验都在纪念斯洛恩凯特林癌症中心进行。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "171d0a20-8943-4994-a48a-7dff124e62ee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "初级试验的群体1每天服用60毫克金戈比洛巴两次。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "25cc9a6e-656d-44ee-a301-93f5879407a0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "初级试验的干预1要求参与者每两天服用总量150毫克alpelisib。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d9b4d4aa-0094-405e-83a3-cf2978cfda38": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "在接受Lapatinib 1500 mg治疗的初级试验受试者的56.9%在第12周没有进展性疾病。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "caa55802-329d-4a1f-a9a7-b99afc44fd67": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "初级试验中的患者群体分别接受相同的不同口服药物剂量,无论是Tamoxifen还是Exemestane。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "二级试验和初级试验的1组患者接受了相同的口服安慰剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "在二次试验中,与其他患者相比,HER-2 neu阳性乳腺癌患者接受额外的维持疗法,而所有初级试验参与者接受相同的治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "baea8eb9-a6e7-4473-9b4b-28a4fdb531ad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "初级试验的两组都以不同的剂量服用相同的药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "01f89936-1621-4dd5-93b7-8b0c64b397fd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "患有严重的喉综合征但冠状动脉正常的患者将无法参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            33,
            35
        ]
    },
    "ee7fe82e-de91-45c7-bd12-bff5d6c887a3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "初级试验的参与者必须每天服用6片Lapatinib Monotherapy(250mg)PO。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "888a8d39-3ad6-401e-acf2-cf5e01a73bf2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "初级试验的不良事件率比二级试验高得多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "13466cbb-9f78-46ff-a983-09e2e9ad5a2c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "初级试验中的1名患者除了咳嗽或喉咙疼外,还出现了发烧。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            12
        ]
    },
    "0beaef44-a39a-462c-a084-d3f824857673": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "初级试验结果表明,通过口服服1500毫克(mg)的参与者比安慰剂患者更有可能在5年内达到DFS,但两组之间DFS率差异不到30%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "8e45da73-f016-4ca0-b106-a3fabc960b36": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "在初级试验中,患者比梅托特雷克萨特更频繁地和更高剂量服用 6-Mercaptopurine。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "37dc56a4-4756-4ab0-8055-7637bf579740": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "初级试验和次级试验都是单臂临床试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "65e370b7-7726-477e-8730-8cea734d1609": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "在初级试验中,患者以大约 3 ml/min 的速度接受 3 ml Perflutren Lipid Microspheres 注射,而在次级试验中,受试者被植入永久性Meso BioMatrix Acellular Peritoneum Matrix。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "affdd551-15e2-4a47-8c20-209cc01570ec": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "初级试验中的一名患者经历了疮事件,这种情况与高程度的发病率和死亡率有关,然而,最常见的不良事件是腹泻。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "2152f503-4fa4-4f32-b766-a05a4c69742f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "无论是初级试验还是NCT0306117都没有使用化疗,不良事件管理课程或放射疗法进行干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "a7903e59-9620-457a-8d83-eb6eb5dd8a2b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "初级试验的每个群体中至少有1名参与者表现出肝功能不良的迹象。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "dc7e7fbe-eed9-4307-b584-30ecaeb77c95": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "在更年期前范围以外的E2患者不符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "a34c6194-b6d9-49c3-8ddb-72de10c8a18c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "无论是初级试验的群体都需要在每一次安特拉西克林循环之前进行低强度锻炼。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "da00532d-57a8-4fe2-a2de-acc525161fd9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "初级试验1组中至少有1名患者患有凝固障碍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "f90364e9-caee-4075-b444-2db1bf846d3a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "以前接受化疗的患者被排除在二级试验和初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "deb78676-8f04-44c4-a5f6-389740d8a268": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "在初级试验中,对多克萨泰尔的先前暴露是强制性的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a06d1ca5-c890-4157-b1d2-0b70fd0092bd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "在初级试验的1组中记录了4种不同的心脏不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "5bc0d21d-a040-4d30-b0c7-8793cba6aba8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "初级试验的对照组患者的平均总存活期不到一年。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            11,
            12,
            13,
            14,
            15,
            9,
            17
        ]
    },
    "9bcbadcc-ae56-4254-ac8b-ab5d35e80eba": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "在初级试验和次级试验中,但每天服用安慰剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "5a1358af-f51b-49f8-b1c0-99a0b108b0a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "在初级试验中,比白血病观察到的发烧性中毒症的病例多,但比白血病的病例少。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            3,
            4
        ]
    },
    "ed0e1b04-aea7-4da0-922f-2be69c768c09": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "具有可植入 cardioverter 消防器的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7
        ]
    },
    "73d323e7-1a38-49d4-97f4-a15f1664fb3e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "初级试验中的一个患者在3个月内总MRI功能肿瘤量(FTV)增加了0.98厘米,比平均水平减少了近1厘米。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "02dea6a3-d94f-4650-bf4f-be8fdb0a382f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "一名患者最近做过手术,他们被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            11
        ]
    },
    "4c8a124b-f015-42e2-8ad3-6168f21fe705": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "初级试验中患者QTcF间隔的平均持续时间从基准的变化在第三周期的第一天,在T-DM1静脉注射(IV)之前是最高的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "fb43432d-6c1b-4ff7-aea8-72bc2519a12d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "初级试验的1组中没有人患有 hyperbilirrubinemia。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "d6df95f5-472f-4b14-9cd4-5d5ef238175a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Statement": "初级竞争性治疗、患者特征和疾病特征的准入标准为初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64
        ]
    },
    "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "由于年龄,一名患有疮的55岁后更年期患者将被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "只有更年期后女性才能进入初级试验,只要他们没有之前的激素替代疗法。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "二氧化碳作为干预的一部分在一项初级试验中的单一研究组中使用,二级试验中的二级试验中的两组使用盐盐。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f820384b-0bf5-4f2e-96fd-2c8b13a4646c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "初级试验和次级试验在他们的化疗团中至少有一种药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3
        ]
    },
    "f7410166-82a7-4d15-8a04-47287ef6884c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "只有两种类型的不良事件发生在初级试验1组的1%以上的患者中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "80726ab0-e8e4-4c42-860b-fdedad407517": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Statement": "那些不愿意签署并给予书面知情同意参加初级试验的患者仍将被纳入。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "f2e1c4f6-2f62-4a5e-b033-d798ba781d1d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02725801",
        "Secondary_id": "NCT04030104",
        "Statement": "无论是初级试验还是次级试验都没有安慰剂组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d42054cd-deb6-4436-941c-9e3a06c713cc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "在初级试验中,不到10%的患者或复发或死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0507fbf8-3557-4ace-b015-5e106b96f6a9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "初级试验和次级试验使用用剂量限制毒性确定的最大容忍剂量作为其结果测量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "49ecc5a6-89be-48b6-85c5-c809c83f5baf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "以下任何条件的患者将被排除在初级试验中;1级感染,不稳定的喉咙痛或4级出血在最后一个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            87,
            94,
            95,
            108,
            117,
            118,
            119,
            120
        ]
    },
    "68792f63-d7b5-4570-bf8e-95e4cb8094e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "初级试验的 2 组接收比次级试验的 2 组接收 oral itraconazole 的 Pilocarpine 剂量较低。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2ddd64c7-98ef-4b06-9f01-e59d3731e8ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "二级试验中肠道穿孔、胸痛、死亡、疮和肺炎的病例比初级试验多",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "a1a5767f-07e7-4a33-a26f-586cf71a208d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "我们无法比较二级试验和初级试验的干预部分提供的剂量和频率。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9c80fb61-66dc-4b3d-82b9-4fb62db89422": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "在过去3个月内患有心脏病发作或深血管结血症的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            18
        ]
    },
    "6755a378-08bf-4e9b-a6de-166733d0307b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "在初级试验中使用的干预措施之间的唯一区别是患者的位置。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b7f3e657-638b-4463-9639-4fb0da2be042": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "在二级试验和初级试验中,与其他患者相比,HER-2 neu阳性乳腺癌患者接受额外的维持疗法。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "5498a85b-a086-4d5d-b677-9ae44646a382": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "初级试验或初级试验中没有出现 Vertigo、腹部延伸或中性衰竭的病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "在开始前10天内服用抗生素对进入初级试验的患者是可接受的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "f25d63c8-9033-4db6-9c15-2151d82e2a6d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "在初级试验的两只手臂之间,小组1在完全肿瘤反应的患者数量方面大大超过小组2。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "患有 histologically 确认的乳腺癌的患者将被接受初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "4fd10abc-81d1-44f4-825a-26e2eaeae979": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "基于神经肿瘤脑转移反应评估(RANO-BM)响应标准的初级试验组合1中有23名参与者(CR)或(PR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a12a46de-9d3e-4c6a-becb-d43653040bf0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "初级试验使用SB-715992的3周循环,研究持续21周。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "66ee10ac-1bfe-44d6-9b91-8a2bb1983606": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "二级试验的患者群比初级试验多5个。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "714c540c-1fa1-47c7-ac13-1e8f056d1e31": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "总共3名初级试验1组的患者经历了与疹相关的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3948b30d-934d-485c-b324-b3571e2957a3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "在初级试验和次级试验中最常见的不良事件是中性衰竭,在所有群体中共发生3例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "45cf29ce-25f5-4719-8468-69d94893c9e7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "初级试验记录了4起危及生命的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "7502090d-1bcb-4be9-9358-81afb9440a17": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "用于防止出血的金属血管剪辑的患者,如头骨动脉,有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            19
        ]
    },
    "89f84928-82a9-413e-ab25-400657002c55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "初级试验和次级试验不排除同时接受系统性抗肿瘤治疗的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "79dbf7bf-e08d-4eae-a804-0daeb83d6f01": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "初级试验的1组中最常见的不良事件是淋巴嫩。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "初级试验中的Exemestane组比Abiraterone Acetate + Prednisone组有更好的平均无进展生存率,但最大PFS的患者属于Abiraterone Acetate + Prednisone组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "23040754-d1ad-4660-aacf-3298aefa5dae": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "在初级试验或次级试验中没有抑郁症患者,但在次级试验的2组中有1起自杀未遂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "e3be834c-c311-4132-8529-d354b9e620b9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "在初级试验中记录的唯一不良事件是单一的肺部泄露病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "8115b5e3-e178-433b-b114-09d97daaa8d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "在过去2至6个月内患有心脏病发作、透皮透光性冠状动脉动脉手术或深血管结血症的患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            18
        ]
    },
    "bbcfc019-2d60-413f-88f9-04cacec55e30": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "在初级试验中记录了几个心脏不良事件,但在次级试验中没有一个。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "e7899445-9b80-4429-b4c3-d47bd36a2347": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "HER2阳性乳腺或结肠癌患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "2a50cc2a-281b-4bc6-9f18-6bd9686c682d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "接受超过5年的安斯特罗佐尔治疗,完成2年之前的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3
        ]
    },
    "26419cec-e256-46a7-9026-94dbe026c63d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "初级试验中的安慰剂组比MM-121群体的PFS中位数要低得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "8ef93fe0-0a12-4a7e-93aa-c40af7154a57": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "二级试验是对其干预的DLT进行测试,而初级试验是对SentiMag和SiennaXP的剂量限制毒性进行评估。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "f5d50d87-b419-4537-87ec-7c9d23b765db": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "初级试验结果表明,Zoledronic Acid 4 mg Upfront会导致骨质矿物密度的 +ve 变化,而Zoledronic Acid 4 mg Delay 会导致骨质矿物密度的较小但仍然积极的变化(在某些患者的人口统计中)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f52ab54b-7a78-4449-9dfe-5fc67323e5c2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Statement": "初级试验的Cohort 2只接受了安慰剂,没有其他药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8,
            9,
            3,
            4,
            12
        ]
    },
    "c0277198-6eef-4cf3-9527-dea5d01a4000": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "在初级试验中,在所有群体中有3例以上的发烧性中性衰退、白血病和中性衰退。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "fea87f74-c8ef-4efd-944a-053f5e5a752f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "为了参加初级试验,参与者必须有20/20视力和 histologically确认的,可测量的,侵入性乳腺癌。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "43560d8e-0767-40ce-b2fb-1b8dda231bdf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "心脏衰竭的病例比在1组中记录的心脏泄露的病例多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "2417fea2-7c8e-4f03-a918-c3cfcbe97425": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "在初级试验的1组患者中,发现了同样数量的中性衰退、发烧中性衰退和泛细胞衰退。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            3,
            4
        ]
    },
    "55391bc6-41a8-4686-82d6-6814166d32b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "患者必须有 LVEF < 50% 才能符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "初级试验的 1 个小组对尿液调节的尿液 N 望远(uNTx/Ur)的基准值有负的(中等)百分比变化。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "15553950-e26b-4fbb-a576-8455e6bb7b23": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "对于初级试验的干预部分没有详细说明干预的类型,剂量或持续时间,与二级试验不同。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "58838d25-bf87-44e7-a604-23468d67a1e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02606708",
        "Secondary_id": "NCT02504424",
        "Statement": "只有初级试验的患者获得了40.5 Gy的加速强度调制放射治疗,二级试验的患者根本没有接受放射治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "02426c34-ebf9-4bd4-9d55-86fad89baf20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "总的来说,在初级试验中,只有20%的参与者没有达到完全的病理反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9e28c807-8d88-4eea-87ee-48a42bd002ab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "初级试验和次级试验仅记录了4个相同的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            8,
            10,
            5
        ],
        "Secondary_evidence_index": [
            0,
            9,
            3,
            6,
            11
        ]
    },
    "80ac126e-c756-4031-9541-e50d51c18b38": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "患有白血病、肝炎或多细胞肾病的患者不能纳入初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            8,
            9
        ]
    },
    "1a1d7d1d-ec49-46db-b6bc-dfd94575e46c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "初级试验中的患者每周接受比Fulvestrant少于Enzalutamide的mg。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "68a9f2f0-cf11-4cd4-847c-53b8befd6002": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "以前的轴心手术,轴心辐射,乳腺癌和乳腺辐射不允许进入初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9bcd40cf-8221-4383-8891-76a4bcc5c766": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "cytologically 确认的,非转移性,早期阶段侵入性乳腺癌患者与 Allred 得分为 1 被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "341156fc-9cbd-492f-8e9e-8fbf98191625": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "对于初级试验的参与者来说,达到6小时、24小时或12小时的最大血浆浓度的时间是不可能的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "44ae021e-241b-4dbf-b88f-0b9d41eab555": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "在初级试验中没有观察到食管 spasm 的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "523a44a3-6b90-4be7-ab46-6b6addd7b5b9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "在初级试验的2组中,比在1组中,TROMBOCYTOPENIA的病例增加了5例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            13,
            20
        ]
    },
    "258a51ca-e1f0-4d9a-88a6-8749f4822034": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "初级试验的参与者根据其癌症激素状态接受不同的干预措施,因此,例如,三负患者与HER2+患者分离,而二级试验的所有患者都采取了相同的干预措施。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "83bacd68-871a-4777-ba23-1f9a3df9227d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "在初级试验中使用的无复发生存率和临床益处率作为次级试验的结果衡量,不是同义词,并且代表了完全不同的患者特征。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "初级试验中的一个患者有确认的肿瘤部分反应,而二级试验中的三十名患者有部分肿瘤反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "1a451f2e-0818-4a86-8808-0e4cce700aef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "总共在初级试验中有32例发烧性中性衰竭病例,仅有一例贫血病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            4,
            12,
            14,
            16
        ]
    },
    "52333afb-0e7a-4823-ae9b-746e0ce57c8c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "参与初级试验和次级试验的患者经历了各种心脏问题。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "4216b27f-4d3e-4029-9637-2e6dade15b73": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "初级试验中只有一个病人群。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "14a32a42-424b-4b97-bae9-05f4bb2b415b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "初级试验的凝聚体1比二级试验的凝聚体2的总不良事件减少0.0015%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            15,
            16
        ]
    },
    "4d83c630-d767-40cf-9aec-c871c6fc7f38": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "患有I级、II级、III级或IV级乳腺癌的患者可能适合进行初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            2,
            11
        ]
    },
    "4fd230f2-caf1-44d6-81f2-4f51dda6da3a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "任何卡诺夫斯基指数低于80的患者都可以参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "7a3d1ca7-8776-4ace-bbc0-107635b93583": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "初级试验的超快速代谢剂组在4个月内平均增加了Endoxifen浓度超过6 ng/mL。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "e95902f1-bf4f-4bb5-8f48-4fa5ba6425d0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "只有男性和更年期后女性有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "1196db61-0846-4185-afc9-dc4b2fccd059": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "在研究入学前一年接受乳房保存手术的患者将被排除在初级试验和次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5
        ],
        "Secondary_evidence_index": [
            5,
            12
        ]
    },
    "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "所有初级试验和次级试验的参与者在同一时间内接受相同的每日剂量口服Letrozole。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "7e629f62-2981-4462-a4c1-f0cc9c24777a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "初级试验的组合1比组合2的组合有25%更多的患有胆囊炎的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "c660faec-58d8-4ba9-8e18-1775b1135819": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "初级试验的 1 组接受 Bevacizumab 的频率比 2 组更高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "初级试验的2号联盟报告了一起AML病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "3ee5742b-6bc3-400f-92eb-641384a75201": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "在初级试验中,患者不接受任何额外的药物用于研究,而在次级试验中,他们接受口服药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "f6af788f-ee96-4308-8dec-12d0c46e957a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "对狭窄空间不合理恐惧的患者不符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            19
        ]
    },
    "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Secondary_id": "NCT01401959",
        "Statement": "初级试验的参与者获得2年无疾病生存的概率高于二级试验的两组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e0b7a120-8735-413d-9a47-8508b2feffb3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "不到20名初级试验参与者获得了部分反应(PR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1393c5d9-d2be-433b-9abf-9449b46588c4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "经历了乳房扩张手术的妇女,并从那时起移除了植入物,被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "abfa5699-2863-4319-9386-4b359f2062f2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "初级试验的2组是安慰剂组,二级试验没有安慰剂组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4038f7c3-87e2-47d6-811b-fd2b21679577": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "初级试验的参与者必须愿意接受基于安特拉西克林的化疗,或者之前接受过循环磷酸胺或癫鲁比辛。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "5097f4cd-9118-473d-a2a0-72f0cd12c7a5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "莎拉正在经历脑肿瘤的癫痫发作,这排除了她参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "68e6a088-ab80-4a89-90d4-39308bccb1c2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "所有初级试验受试者都必须每天采取干预PO。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a4c49b44-91b3-4a3c-bfbf-b3758cc398f1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "初级试验和次级试验在他们用于干预的药物中没有重叠,但他们都有安慰剂组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "08917306-11b0-44ad-8f45-9a67d7f6073e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "阳性FISH结果的患者有资格参加二级试验,但不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "9702cb6a-bdb1-415f-bb99-3b740728a4ea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "初级或次级试验中没有安慰剂或控制组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7afa2d1f-7922-4b09-b52a-43bd9a4788a9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "来自初级试验的两个群体的参与者与二级试验的参与者相比,CNS客观响应率显著低。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "dfd5acc2-6824-4b63-93ad-34e6a0a4c621": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "乔患有酒精成瘾已有15年,导致肝脏病,因此他可能会被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "97e9967e-6525-4082-bd11-8c30e14d23fd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "患有同步严重未经控制的疾病的患者可能有资格参加初级试验,但总是被排除在次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            4
        ]
    },
    "d11dd4ae-28be-4ad2-a452-4374c48f08d1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "初级试验结果表明,每周期1日以3小时的静脉注射(IV)施用40 mg/m2+卡佩西塔宾,与单独卡佩西塔宾相比,可能增加OS。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3b6229a9-00a1-4d26-9285-6d9f6a25fd77": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "初级试验的1组患者的Erysipelas患者比腹泻患者的两倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            11
        ]
    },
    "9eab20ad-ffc6-473f-8087-c6c3f06f356f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "初级试验和次级试验使用不同的指标来评估潜在候选人的绩效状态。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            2
        ]
    },
    "92680a4c-a1e0-47d2-9b7f-cacb20cd1fde": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "初级试验结果表明,根据NCI不良事件通用术语标准评估的二期伏里诺斯坦的推荐剂量为300毫克。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "b3dd4e23-f78c-4bf9-9268-d1018c966980": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "患者必须有触摸可感知的癌症才能符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "553d7721-289e-4ab1-a9b9-7b2c939f47c1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "初级试验1组患者的最大无进展生存期为1年。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "01c6f82e-710d-4fa4-aa62-2d26e72f4533": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "在初级试验中没有发生任何不良事件,该试验发生了超过71次。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "没有解释的发烧超过39°C的患者被排除在初级试验中,但可能被纳入次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            25,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "862c0bfe-10a6-453c-9ada-929dd00141a0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "二级试验和初级试验采用非可比的结果措施。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "一个在过去一个月内做过手术的患者不符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            7
        ]
    },
    "5501dae3-0d3c-4812-96c2-35ca863e24a5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "在初级试验的第1天,科霍尔特1接受多克索鲁比辛水氯化物IV,口服cyclophosphamide, dexamethasone IV或口服和ondansetron IV。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "ece8e7df-790d-4e26-9c34-40cf66d2abf5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "所有初级试验和次级试验的参与者都接受相同的每日剂量Degarelix注射到肌肉中,在相同的持续时间。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "550a36e2-43bb-40af-b0c8-49498fbe2c8c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "初级试验调查了一种新的放射疗法治疗,而次级试验测试了一种类型的心理治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "95869347-6c3d-4de8-a325-a9a652f11edf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "与二级试验不同,初级试验没有记录任何 Sinus bradycardia、骨髓抑制或抑郁症的病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "8df8e2c0-a0ca-4ea2-ba83-494f250c4bef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "初级试验中有 3/112 名患者 (2.68%) 患有糖尿病无症",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "1d4a385f-1c72-4c61-8d49-9ada0e3b716a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "初级试验的两组都应用相同的局部干预,大约每四到六个小时,每天为期一周的研究。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "b15aa13a-fbd9-4b2e-9dd2-b16628084d07": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "最大容忍剂量 (MTD) 和推荐阶段 2 剂量 (RP2D) 用于 Alisertib 与 Paclitaxel 结合,以初级试验组 2 的结果为支持,是 40 mg/m^2 口服,每天两次 (BID) 天 1-3, 8-10 和 15-17",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c9214d06-2733-4c78-99e5-a42015908eae": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "接受标准护理的初级试验的肾癌患者基于核心放射学实验室评估的平均PFS为2.5个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "a318fc31-4f28-4356-b09a-59741bb7c97a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02660788",
        "Secondary_id": "NCT01490892",
        "Statement": "初级试验是研究与51至73岁的女性沟通的不同方式,而次级试验不是。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "70ec4bc8-f8fa-4901-aa7a-2388b53960c6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "在Taxotere/Docetaxel治疗的初级试验中的患者中,最常见的Chevalier级别为3A和3C。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ]
    },
    "00dc0e37-1d0b-4f53-a037-86bf9799dae6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "具有子宫功能的女性患者不能参加二级或初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "a1a421cc-01c9-4afb-8f09-6b10b0ff5094": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "患者必须在13岁至76岁之间参加初级或次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            16,
            17,
            18
        ]
    },
    "9316ef0d-55b0-4547-88ae-887e0132a263": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "接受标准护理的初级试验的患者基于核心放射学实验室评估的平均PFS为2.7个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "5d815fac-c66c-43fe-9ac8-a352b6e47a5b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "初级试验和次级试验在其干预中都使用测试和控制组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "7b9fdeaa-5cb7-4453-b174-07b44bb58234": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "初级试验中的更多患者患有阴道收缩的功能障碍,而不是阴道放松。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            17,
            18
        ]
    },
    "c330f152-c64e-47ab-8568-5129a1a2099e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "初级试验2组的60多名患者中没有出现任何不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31
        ]
    },
    "e3b88c8c-241d-4ead-8573-534a46210707": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "初级试验中的大多数患者没有出现左心室功能障碍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "e621f354-dea0-4d0f-a252-5480028c1712": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "初级试验中至少有1名患者患有放射治疗诱导的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "ee209156-74dc-475e-87af-ae51160982ef": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "初级试验中,30%的参与者在3周的Cediranib Maleate治疗后,CEC水平增加。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "edf813c0-2271-49ca-a040-a355bf71d8b4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "在化疗的第1周期中,第4级中性衰竭的平均持续时间差异仅仅超过36小时,主要试验的两个手臂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "352475ea-1b17-4d1a-a5e3-71f1b87cffd8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "任何具有 histologically 确认的阶段 4 腺癌 HER2/neu 免疫系化学 3+,ECOG 性能状态 <2 和负 HCG 怀孕测试的患者均可参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            14
        ]
    },
    "c7c745d6-03ee-4740-9ef4-641fb6546e46": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "在初级试验中,每个不良事件发生8次以上。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c5c8ab0b-8062-4467-8ecd-bb15f35f54c0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "在初级试验中,与二级试验相比,出现不良事件的患者总比率较低。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "初级试验的三消极乳腺癌群体的ORR比接受Eribulin 1.4 mg/m2的群体要低得多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "8f1959e4-b93a-4112-9726-27a4034f0e07": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "患者必须有一个双维,可测量的指标损伤被纳入初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "e1782960-8d44-4acc-aaae-bfa4f8e38de0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "患者必须有低于3的ECOG分数才能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "61bd93b2-b38f-496d-acd9-f8b188d28a39": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "黑人男性和ECOG <=2, ANC >1.5 x 10^9/L,比利鲁宾 > 2.0 mg/dl,PLT >100 x 10^9/L和没有先前的血液凝结的历史有资格参加初级试验,但被排除在次级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10,
            12,
            15,
            25
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "741c95c7-825c-4321-8d12-9037bb701ab8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "初级试验是测试基于网络的教育工具,而次级试验是测试使用辅助酮对后更年期妇女的影响。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "6ce047b6-c18f-4f63-90ec-8643f5145efe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "初级试验的两组中至少有11名患者实现了完全响应(CR)或部分响应(PR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "d647aad0-47f7-4b77-a265-e77dcf5e0983": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "初级试验的干预要求参与者在佩戴 Fitbit 时锻炼 12 周,而二级试验则要求每天进行全年体力锻炼。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "74fed085-3389-49c6-bdd2-a95c97071f2d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "初级试验中的所有小组与次级试验中的小组1相比,与pCR的参与者比例较低。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "986ffe33-8e8b-4cbf-8408-eb9489fb2314": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "有几种类型的手术和治疗方法,如附录片和放射治疗,这些方法禁止那些希望参加初级试验的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "aeac5b1c-26f9-44bc-b1c4-3bd0d498914e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "二级试验中肠道穿孔、胸痛、死亡、高血糖和肺炎的病例比初级试验多",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "3f98cd71-ec28-4fd1-9ca0-2184eef3390a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "患有HER2 +、PR和ER - 肿瘤的患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10
        ]
    },
    "11138479-1666-4973-84c2-c6779b5444f5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "在初级试验中,只有1个群体接受干预,而在次级试验中,两群体接受相同的干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "35c62055-2832-4119-9080-5603beea1934": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "在初级试验或次级试验中没有发生肺炎病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "59ff0501-f6af-4739-bd07-71e12e8cd8a7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "未确定的人类表皮生长因子受体2表达的患者不能接受初级或次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "ab52c559-5712-44ff-becd-1c491e107472": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "男性不能参加初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4619b957-3368-47b9-b949-01ec91208f96": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "二级试验记录了比初级试验更多的心脏相关不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "5bb09d7b-622f-4bdd-8dfd-809ea014a278": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "二级试验的1组患者的副作用比初级试验的1组患者更高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "07327b61-973b-48bb-b42b-dfde1efcfb7d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "最短PFS的患者在二级试验中,最长的PFS记录在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "3307a083-0c8a-47b8-94cb-0bf4095b9c3b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "临床阶段II(T2N2)侵入性乳腺癌的患者不符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            4,
            10
        ]
    },
    "bda2752e-082e-4d06-926a-04ade3f61c26": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "初级试验中的11名患者患有肝脏病,二级试验中的0名。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d4d73d33-4f71-46b2-b0c1-eac6741fd8f3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Statement": "只有1名以口服拉帕提尼布和口服塔莫西芬治疗的初级试验患者获得了完全和部分肿瘤反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "f418c027-439a-4b19-bfb0-e1c1241886d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "在初级试验中,抑郁症的病例比脱水多4例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            6
        ]
    },
    "4805e49a-b99e-46d8-b937-13ac2501c4a4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "持有阳性守望节点生物检的患者必须进行手术去除淋巴结,否则他们将不符合初级试验的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "9a3cb836-66a8-4c68-980c-97e5841f331f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "最大容忍剂量 (MTD) 和推荐阶段 2 剂量 (RP2D) 用于 Alisertib 与 Paclitaxel 结合,主要试验结果支持,是 40 mg 口服,每天两次 (BID) 在日期 1-3, 8-10 和 15-17",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "45d4f78f-04d4-434c-9679-fd92291e97b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "一名患有 Sarcoidosis 的 55 岁后更年期患者将被排除在初级试验中,因为这将防止延长后续。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "5338f894-aecb-4678-bb67-fe058653e12b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "初级试验中不到四分之一的参与者患有辐射性皮肤炎。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "2cebae78-f4a3-4e09-ac54-cd2388670274": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "接受初级试验的干预1的患者,将得到局部和静脉注射的药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "d8a98ace-009c-47e4-a812-3bc0df91ed2b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "初级试验和次级试验没有比较的结果,因为他们记录的指标完全不同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c8cfd67e-5fac-4bff-9296-6e42dcb09f80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "初级试验的参与者被分配一个干预,取决于他们的激素受体状态。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "57cf3760-1692-439f-bbe2-82a6bc8862ce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "初级试验的2个小组受试者获得3.25mg的阴道DHEA胶QD比1个小组受试者多,在二级试验中的两个小组中,只有1个小组每天服用Duloxetine 30mg。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "7db1447c-b4e8-49c6-a125-8161bcd98560": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "伤口在五到八周内愈合的患者不符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18
        ]
    },
    "626a05e9-2caf-4e73-a132-5432a5b2c7d9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Secondary_id": "NCT00143390",
        "Statement": "超过20%的患者在初级试验和次级试验中经历了心脏病发作或 arrhythmia,其中大多数来自次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "在初级试验中有0例夜间失明,在次级试验中有1例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "b1cd4818-9623-45e5-a2b3-4c80016e3c82": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "在更年期前范围以外的E2患者不符合初级试验的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5
        ]
    },
    "3050bca2-a8bc-412e-b679-5be1055e3749": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "二级试验的1号群体在整个试验期间不接受相同的Daratumumab剂量,而初级试验的1号群体在整个试验中接受相同的Daratumumab剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a49666fd-f278-4dcf-b6bf-287ace3969aa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "在初级试验中没有记录到中枢神经元转移的病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "f6c014af-63db-4578-9b2d-74ea95901842": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "初级试验和次级试验使用相同的时间框架和相同的测量单位测量各自干预的DLT。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c8ef1457-63a9-4eac-a98b-edb805afd35b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02660788",
        "Secondary_id": "NCT01490892",
        "Statement": "初级试验是研究与51至73岁的女性沟通的不同方式,而次级试验是评估定期锻炼和饮食的影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "515d0710-429b-4c28-b881-8a6531ee973e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "18 至 25 歲之間患有骨病或骨病的婦女不能參與二次試驗或初級試驗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            4,
            5,
            6
        ]
    },
    "b4d261a4-9b42-4158-9b21-159859b59e2a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "无论是初级试验的群体都没有通过口服或IV获得任何药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "1c043d17-15a9-496c-a69b-9ec95a7ab8df": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "男性不符合初级试验的条件,因为他们不产生雌激素。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "79c69498-7dd5-41fa-8946-36d452a5b9ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "通过精神测量诊断COPD的患者不符合初级试验的资格。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "93fc76a9-5f3d-490b-8802-21d0fa806728": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "初级试验的凝聚体2报告的结果比凝聚体1更差。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9f5e55af-8a94-4531-ab00-f16199795b64": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "无论是初级试验的群体都没有通过口服、IV或辐射接受任何药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "ee85e355-3d0a-4e40-8a8d-6a0b71c77148": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "多中心乳腺癌患者可接受初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "c4a2ca0b-c4a7-4366-92c7-145dadd38af3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "导致无法忍受的瘫痪的周边神经病患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            13
        ]
    },
    "c6ca8c6a-7eae-4671-9eff-c44a1222fadb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "患有 rheumatoid 关节炎的妇女不需要系统性固醇治疗,有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ]
    },
    "e591b3bb-0628-46e7-9d60-28989fd6a3d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "初级试验中的一名患者被观察到呕吐血液。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "75da6329-e8a1-4808-bb0f-78fd3a2dde9c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "最佳总体响应(BOR)在初级试验的群体1中高于群体2的群体10%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "dab9d582-eaf3-443f-bdb9-073aec304ee6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "二级试验记录了比初级试验更多的心脏相关不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "8b9bb672-1de3-4220-956c-9e86ed78063d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "在初级试验中记录了1例血液分析病例,而在次级试验中没有。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3194a043-d156-49d6-97bb-81867ed188f0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "初级试验中的患者在IV中服用Zometa的剂量低于二级试验中服用PI3K抑制剂BYL719的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "8c3ab1eb-c473-4399-b18c-512ef16e4a47": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "为了有资格参加初级试验,患者必须具有侵入性癌症,由核心生物检验确认,以及人体冠状腺素尿液测试。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            8
        ]
    },
    "aeac1009-91c3-40ad-8583-5b548e1f4b3b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "初级试验和次级试验在他们的研究中只有测试小组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "3058d104-172e-41be-b641-9f0f9cb172be": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "至少有一名初级试验参与者在没有记录疾病进展的情况下存活了超过200天。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "bc845a3d-1f69-41a3-bf84-36a62e8127a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "总体上,初级试验的群体1记录了与群体2的不良事件数量的10倍以上。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            14,
            15
        ]
    },
    "69ced998-f3c9-460a-a272-b2c95421b89d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "怀孕6个月以上的女性患者不能参加二级或初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            8,
            18
        ]
    },
    "45fb84a3-674c-40f5-ac8c-26a3c7844e7b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "接受初级试验的干预1的患者获得了比安斯特罗佐尔的4倍的西姆瓦斯塔丁。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c349cad6-8b63-4e5e-9b87-4fc08bb6fc30": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "初级试验的1群体接受的Neratinb剂量不到2群体的60%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "初级试验的群体2中的患者多于群体1的群体1的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            8,
            15
        ]
    },
    "b3effb24-6ec0-4fa3-9c91-74a45bcc4602": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "初级试验是测试放射治疗干预,而次级试验是测试一种新的手持医疗器械,患者必须自己使用它来排泄他们的淋巴血管。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9026c2ff-2dd8-4aa9-b2fb-f6bef856189d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "初级试验中的患者每3周接受至少150mg IMGN853 IV。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "341c0861-b9a3-491d-8d49-aa61a8501a4f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "在初级试验和次级试验中,任何不良事件的发病率最高为39例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "16d6e554-a1df-42f9-b051-947d70595cbb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "初级试验中唯一的白血病例发生在1组中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "8f0159ce-1044-4f31-94b7-e394cf91d4e1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "任何有第 4 阶段或不可挽回的,本地复发的乳腺癌的女性都有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ccc5e420-dda4-4fb9-8d68-82551d69017f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "初级试验和次级试验中的患者都患有肺疮。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "89f8ba8c-e626-4bd4-9994-3d0264018932": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Statement": "患有末期肝脏病的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            12
        ]
    },
    "0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "在初级试验中,试验组的患者的健康结果比对照组更好。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "57e6f0e1-6157-43bc-8bdf-c3649ed49133": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "超过一半的初级试验参与者被认为是被审查的;二级试验使用了相同的结果测量,但没有被审查的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "300dbe96-0be8-4ca0-aa3b-41bc059bac7f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02725801",
        "Secondary_id": "NCT04030104",
        "Statement": "无论是初级试验还是次级试验都没有控制组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f40c8d92-2921-45fd-8389-15048b08e229": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "中性化是初级试验中最常见的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "31387af4-aad1-4f3c-bd81-641340ad4096": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "初级试验和次级试验使用完全不同的药物和技术进行干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "eabe9a78-965e-4984-82c2-25598b6b35da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "初级试验的中间 TTP 是不到 27 个月的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "006f6b4e-6245-4f09-9786-327bbed3d766": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "可行性参与者的百分比在初级试验的群体1比群体2高出10%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "88b13330-b937-4bbc-80ea-4bf8ccc17bd1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "初级试验中的三分之四的参与者患有剂量限制性毒性。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ]
    },
    "e90e2368-808d-454d-8080-30427235b89d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Secondary_id": "NCT01688609",
        "Statement": "没有进入初审的种族标准,但有第二审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ],
        "Secondary_evidence_index": [
            17
        ]
    },
    "d375ef3f-8b35-40eb-b9c0-3fc9592d9bec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "患有1型和2型糖尿病的患者不适合进行初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            9
        ]
    },
    "2f2301cd-b8fa-47cc-94cc-e31150ce8f9e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "初级试验和次级试验只有试验组,所以所有患者都接受新的(FDA批准)干预措施。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "eea73ae4-0985-4f74-957d-e2aad7ab453c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha是一名32岁的韩国女性,患有不可操作的乳腺癌,她太老了,不能参加二级和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "6550c068-14e6-4e93-8f98-756338c91e35": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Statement": "在初级试验中,用Fulvestrant 250 mg治疗的患者的客观反应率高于用Fulvestrant 250 mg +加载剂量治疗的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0f5b81f0-b422-4000-8e0e-9f09c612ebc3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "初级或次级试验中的任何患者都不需要接受放射治疗或支持组课程。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f6bba549-3d18-4a53-8685-96b4e321b1a7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "初级试验在其患者中记录了几个与免疫系统相关的不良事件,而次级试验没有。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "1fe36432-40f8-4c53-ac2b-0f8e50e5743f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "二级试验和初级试验中的几种治疗是口服的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "3576f3e7-a1b9-4a75-934a-1ad2165b69dd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "在初级试验中,贫血和呕吐的病例比二级试验多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "de71f285-4382-465f-9e7e-d163662f6d9c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "初级试验在其两组中仅有66名患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "406247fb-003a-47b7-8fe4-b6b963b98f08": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "初级试验没有记录任何与疼痛相关的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "47553222-0aff-4394-bcfc-9f19c0863835": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "二级试验没有明确的终止日期,而初级试验持续了2周。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "e4756896-55c2-46e1-be19-14697ad3b39f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "初级试验中的一个患者的血液钙水平远高于正常水平。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "594c9a79-d601-46b4-ae30-0b48a1117693": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "二级试验和初级试验的二级试验和二级试验之间的群体大小差异使得无法进行有意义的比较。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "99e8ee0e-d72d-4e19-9424-20e5891bb2b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "适当进行临床结论,比较二次试验的群体2和二次试验的群体2,尽管群体大小存在差异。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "f1b0653f-b5ce-4558-b325-56244940c0cd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "心脏不良事件在初级试验的1组中是失眠症的两倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            8
        ]
    },
    "24b24d36-2500-4841-99a3-13cba905d77d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "初级试验至少有8种不同类型的心脏相关不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            13,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "0797ff90-f847-4442-92fd-017c539bb38f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "初级试验中的1名患者患有阻断他们的流血管的血栓。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "6b595151-7e51-4062-b587-3207ea251677": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "初级试验测试辐射扫描作为指导医疗程序的一种技术。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e802b1f6-62fb-4759-b261-c69dbdc1d7ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "初级试验的两群群体都收到高剂量的Q-122比二级试验的任何一群体都收到AZD9496变体。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0a24a07e-2cb4-4591-aea4-a370f462cc49": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "初级试验治疗持续时间比次级试验治疗更短。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "97d0bbf0-c2c5-409b-820b-6e14a6326b06": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "具有 histologically 确认的雌激素受体消极、 progesterone 受体消极和人类表皮生长因子 2 阳性乳腺癌的患者,没有已知的大脑转移和没有心脏功能障碍的历史,可能有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            22,
            15,
            33
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "bbb5ebc0-83c8-46cb-89b4-e1c67e042350": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "海伦早在7年前就患了第三阶段的卵巢癌,但已经免疫了5年,她被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            14
        ]
    },
    "620106e8-2a7f-4078-80b6-d5f1840c66e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "初级试验结果表明,第二阶段试验(RPTD)的推荐剂量水平(第一阶段)为3mg/kscixutumumab。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ]
    },
    "94a7b007-0332-4d01-979e-9677e5da4316": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "在初级试验中,FEC-75 然后帕克利塔塞尔/特拉斯图苏马布组比 Paclitaxel/Trastuzumab 然后特拉斯图苏马布/FEC-75 组有更多的入侵性肿瘤留在乳房。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2849d0ce-fed2-4c49-bec1-777c440caaeb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "初级试验中的更多患者患有腹腔收缩功能障碍,而不是腹腔系统。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            17,
            18
        ]
    },
    "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "在初级试验中记录的12种类型的不良事件中,只有2种发生过多次。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "01a57096-0278-4c70-be43-acd57010cd6f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "在初级试验中的1组血压明显升高的患者比在次级试验中的1组血压明显升高的患者多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "49213077-0a5b-4368-a48a-282d2ca9d77a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "在初级试验中,患者在整个试验期间接受了比Fulvestrant多于Enzalutamide的mg。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "426d3ecd-73e3-4226-83c6-cfcb9212ed62": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "所有初级试验受试者均有进展性疾病、完全CNS客观响应率或部分响应率。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "7c12676c-7973-4e9d-b1fc-3b14d241d0c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "在初级试验中,用Dasatinib和Letrozole治疗的20名患者有超过2年的无疾病间隔(DFI)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "3419e901-5880-488d-912c-023e8d1b51c7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "初级试验记录了一名患有心脏衰竭的患者,二级试验记录了更多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "cd645637-0a31-4f54-bc75-4a52349cf100": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "初级试验中的患者每周每5天每天服用50mg/m2,75mg/m2和80mg/m2",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "adfc79ba-2996-47ce-9986-7d287931df89": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "总共3名患者在初级试验中经历了与疹相关的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "414ae027-b420-4f01-afd5-164cd8146a30": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "初级试验的16名参与者被认为是被审查的;二级试验使用了相同的结果测量,但没有被审查的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "45b2b9ec-ba58-4323-810a-4baed9c84a0e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "初级试验的参与者将不会收到任何Lapatinib后WBRT。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "72ffdfbf-aa72-4d44-814a-1d6ab8883898": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Statement": "患者必须已经参加特定临床试验才能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "db613a72-e300-41a7-987f-788c306d94a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "在参加初级试验的患者中,没有观察到白血病或 Arrhythmia的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "2667d301-2efb-4d92-bc12-ccfc869e4835": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "初级试验的群体1和群体2之间的区别在于在群体2中为患者插入额外的负压排水。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            5,
            10,
            5
        ]
    },
    "60bff573-0251-4f05-b2b7-dec74c7363cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "总体而言,在初级试验的两组中,至少有2名疲惫的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "f6f8a0d3-6288-44cf-9b34-27444110dd10": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT01008150",
        "Statement": "主要乳腺癌的 histologically 确认的广泛的导体组成部分将导致从初级试验中排除,但不是从次级试验中排除。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43
        ]
    },
    "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "初级试验和次级试验的患者将注射Herceptin®(trastuzumab)或帕克利塔克塞尔。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "878dcfeb-c3db-4077-9a3e-8098efa80a99": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "患者不能因为种族或种族原因被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "fc5dbfec-ba79-4c5d-9e38-3c97d0397570": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Secondary_id": "NCT00493636",
        "Statement": "任何患者都可以参加初级试验或次级试验,只要他们愿意提供知情同意并能够使用互联网。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38
        ]
    },
    "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "在初级试验或次级试验中没有发生麻疹病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "64411610-090b-42d2-a176-d2b13ffef591": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "与初级试验不同,二级试验没有控制组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "82bd50ac-9407-413b-9eb8-653cef49706c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02364388",
        "Secondary_id": "NCT01425268",
        "Statement": "温暖的盐溶液用于初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "470611af-16b2-4094-ae2a-c9c6155e2672": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "对于初级试验的干预部分没有详细说明干预的类型或持续时间,与二级试验不同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "f3a03aec-194d-4538-9be3-cea8281d995c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "初级试验记录不到3个不同的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "14a5e557-b223-4649-9867-0ff0e9001f5e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Secondary_id": "NCT02352779",
        "Statement": "初审和次审不解释他们在干预部分中的干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "c8df3461-4063-4fb0-ae48-f57062eb0a68": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "初级试验 参与者每天服用 niraparib 200 毫克(mg) PO 每 28 天的周期,持续 3 周期,随后所有参与者接受新辅助化疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "1cd7cf90-bf66-480b-9227-2f7d2eccd647": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "初级试验使用局部干预,而次级试验仅使用静脉注射治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "15f9d033-ebf7-44b3-94e2-3b8ee90b862b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "在初级试验中的2个群体中,具有最佳部分反应(PR)或完整反应(CR)肿瘤反应的参与者的百分比有20%以上的差异。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "初级试验的1组患者中没有出现急性冠状综合征。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "51cf1333-78b1-410a-82fe-aabfaa00a840": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "患有63的球状过滤率的患者,严重的对比过敏和BI-RADS类别c的乳腺组织将成为初级试验的选择。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            4,
            5,
            6
        ]
    },
    "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "在评估0中,初级试验的参与者对所有目标和非目标损伤的确认消失。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "aef2367d-78a5-4dc7-a6f7-d96415082362": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "在二次试验的群体2中有1例心肺衰竭,但在初级试验的群体1中没有。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            13,
            14,
            15,
            3,
            4,
            5,
            19,
            20,
            21,
            22,
            10,
            11,
            25
        ]
    },
    "29ae75a2-d8d2-4427-bba3-ab2c411d5718": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "在初级试验中没有观察到食管 spasm 、 Diastolic 功能障碍或 thrombosis 的病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "985c4cb3-2684-4a67-a479-998602044a0d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "与初级试验的群体1相比,除了突然死亡之外,在群体2中观察到的每一个不良事件的病例都更多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "在初级试验中接受干预的患者中,不良事件发生在5%以下,而在二级试验中,副作用事件发生在近10%的患者中,副作用事件发生在二级试验中,副作用事件发生在三分之一以下。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            8,
            9
        ]
    },
    "d695120e-db68-481d-9023-881e48654e29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "患有骨外转移的患者仍然被允许进入初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5319ac1a-07ae-4531-bf93-5fce83016c87": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "初级试验的1组患者接受Exemestane的频率高于2组患者接受Cytoxan的频率。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "087aba29-40c6-4453-a44b-e63c3867e5b4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "一名75岁的女性患者,其ECOG值为3并预期寿命超过1年,可以参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            11,
            12,
            13
        ]
    },
    "c66f3e9e-f232-4035-b705-2785946d1542": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "患有痴呆症的72岁患者将被排除在二级和初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            7
        ],
        "Secondary_evidence_index": [
            56,
            73
        ]
    },
    "c679f426-b235-4ae9-ad6c-4f1a46a494d2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Secondary_id": "NCT00485953",
        "Statement": "所有初级试验和次级试验的群体都通过皮下服用接受治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "122b1aef-4506-464d-9852-47caa508b047": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "初级试验的1号和2号小组有相同数量的贫血和中性衰竭患者,但1号小组的白血病例比2号小组多8例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            4,
            5,
            14,
            17,
            18,
            19
        ]
    },
    "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "初级试验中的所有小组与次级试验的小组1相比,与pCR的参与者数量较少。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9f7dc38b-1945-4035-a0ff-e08ead55145b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "在研究入学前2周内完成了治疗当前乳腺癌的特拉斯图苏马布团的患者有资格参加初级试验,但被排除在次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8,
            10
        ],
        "Secondary_evidence_index": [
            8,
            9
        ]
    },
    "b259774e-410a-49aa-b5d4-31b8d9505fc3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "继承BReast CAncer基因1或2的未受损变异的人有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            13
        ]
    },
    "e09a11e4-afc8-4351-a5bc-d847424c79ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "初级试验中的一些患者被记录为患有与心脏相关的不良事件,而二级试验中的许多患者经历了几种不同的呼吸相关问题。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "d22f01f0-b2be-45b9-8996-11727750b91e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "初级试验的参与者比二级试验的患者获得了更多的阿纳斯特罗佐尔、富夫斯特兰特和埃克斯梅斯坦。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "893d5684-03f8-4acd-86e4-6d38eea3ce16": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "初级试验的群体2比群体1的群体2中有80%以上的胚胎病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "4b46164d-a4c2-4738-be36-588ab231ceb1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "初级试验中有 0 名患有 dysphagia 或 Fever 的患者和次级试验的群体。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "d9236874-7f3d-4402-9699-2889db9f5c61": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "初级试验的2号凝聚体记录了比1号凝聚体10%更多的白血病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            13,
            17
        ]
    },
    "e33825f1-45df-41f5-ba07-e9059636a146": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "DLT的发生率,用于二级试验的结果测量和临床益处率,用于初级试验不是同义词,并代表了完全不同的患者特征。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5b0295e1-a322-40af-9acf-9cc1d55d3e64": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "二级试验和初级试验使用类似的结果测量,评估患者在治疗后存活多久。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3658f2f7-a497-4abb-badb-c877036456f2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "患者必须年满18岁,女性,有三个或多个目标损伤和1个以上的化疗团参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            5
        ]
    },
    "37bc71d5-d9c0-4174-8da5-725d2d53a91b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "接受D+C和Taxane Na‘ào√òve的初级试验的群体,产生了比其他群体差不多更好的结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "初级试验的干预要求参与者在佩戴 Fitbit 时锻炼 12 周,对二级试验没有明确要求的身体活动。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "8bcc9fa3-0317-471a-a5b5-b115b5b72dea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "初级试验的两组患者中介的胰岛素变化比基准低于 -15%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "52610141-321d-4e3d-8660-ebc14b9f1696": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "初级试验的结果表明,每周期1日以3小时的静脉注射(IV)的40mg/m2 + 卡佩西塔宾,与单独卡佩西塔宾相比,患者的OS为三倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "90203158-6477-4486-b8d9-09dcaca63617": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "二级试验的1群体中有1例心肺衰竭,但初级试验的1群体中没有1例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "03334f23-49ab-47e5-b420-a6753ce6e832": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "初级试验或次级试验中没有发生心脏结核病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "a847cfc1-9556-4a55-9698-69c22696148f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "初级试验中有2例 angina 病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "fcbb7e0f-d106-44bd-a252-9b57adc6f071": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Statement": "在初级试验中没有观察到心理健康问题。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "f82d94fe-c633-4bae-b28d-074196a08577": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "通过肌肉注射服用Fulvestrant 500mg的初级试验参与者比接受额外160mg的参与者获得更高的临床益处。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "e5379a89-f880-44c1-bee0-a0d8ad2abfce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "初级试验的干预期为5年,次级试验的持续时间在干预部分中未说明。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            5,
            10,
            5
        ]
    },
    "d811aaec-b3bd-4376-a9d6-d14eacae875a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "未经前方轴心手术、前方轴心辐射、乳腺癌和乳腺辐射均未被允许进入初级试验,如果符合所有其他入院标准,未经前方高剂量化疗的患者仍可入院。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "99312d82-614c-4422-b6e6-104fe5a7fa54": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": "只有在9个低血管淋巴结中出现转移的患者才有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "b02c99f3-70bd-4404-8d80-c57c6dfef7b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "初级试验的患者总数与二级试验的患者总数相同。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "3cbf2726-ddb0-460c-9dd2-082b8dda495d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "在初级试验中,1组患者中不到一半的患者经历了不良事件,但超过45%的2组患者经历了不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "e7741151-2b2c-4e78-a4df-fe998c580714": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "在初级试验中,只有1个群体接受干预,而在次级试验中,两个群体接受干预,但2个群体接受了1个群体的两倍以上的剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8cff36b0-a022-4469-8d14-7120be891cb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "不到十分之一的初级试验受试者至少经历了24周的完整反应(CR)、部分反应(PR)或稳定疾病(SD)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "4ce24508-3d12-499f-ab7f-4b437ea51366": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Secondary_id": "NCT00876395",
        "Statement": "最低体重为50公斤,必须参加初级试验或次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "2514da19-b30a-44bb-8853-4545e97295da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "初级试验中的40mg/m2Ixabepilone组报告的结果比Cetuximab 250 mg/m2 + Ixabepilone 40 mg/m2组更差。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "cb9f8a52-b88e-4b04-bb28-a0eabead1439": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "初级试验的1组有6个不良事件类别,记录了至少一个病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "c921d3a1-bd6e-41c9-b0e9-23babf7ead7c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "患有阶段2B、病理确认的雌激素受体阳性乳腺癌的患者可参加初级和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "358a1d3c-9ccc-48fc-badc-1644e326c8cb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "二级试验和初级试验记录的唯一类型的不良事件是腹泻和腹痛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "60a86c87-7387-4eae-b5dd-6245f8bf541e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "拒绝使用避孕药的WOCBP被排除在初级试验中,但如果他们是英国居民,可能会有资格参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "bd3055c6-09aa-47f0-89ed-67ad3798a580": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "初级试验的候选人必须在入学前1个月进行骨密度扫描,如果结果超过2个标准偏差低于正常,则必须排除。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8
        ]
    },
    "21d7d726-8557-459f-a307-fae3e08f45d8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Secondary_id": "NCT00328783",
        "Statement": "患有甲状腺炎的候选人将自动排除在初级试验和次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9a8157a9-82fc-4d7e-9254-295123459430": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Statement": "主要试验中的大多数患者的EGFR表达值为0,0患者的EGFR值为3或更高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "ff37494d-2c61-4c06-86c1-d6bcfbe9e360": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "在二级试验和初级试验的所有小组中,只有一个记录的心脏病和心脏病的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "eb00b609-f17b-4595-87bd-d0843ec9e39a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "二级试验给其患者提供150毫克/天更多的氧化物,而不是初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            14,
            15
        ]
    },
    "8bc9ea31-b731-4799-a1cc-a5ba63da00c1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "患者不需要性活跃才能接受初级试验干预,但这是次级试验的要求,其中干预必须在性活动期间应用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0864493d-9f64-49d1-a585-21be71704c59": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "在初级试验中,在服用 100 mg 与 125 mg 口服 PD-0332991 的剂量限制性毒性参与者的数量/百分比中没有记录的差异,这意味着初级试验中的 0% 患者患有 4 级或以上血管细胞压。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c49428a7-cc55-474e-a773-88ff2019de1b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "初级试验的两个小组都服用了相同的药物剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "78136809-c8de-4c40-9a7e-1d61d879ba27": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "初级试验和次级试验以不同的频率进行干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b430ea52-fa55-4280-9e23-8a7392afca58": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "阳性守望节点生物检的患者必须进行手术,从肘部(下臂或肘部)去除淋巴结,否则他们将无法参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "adfeff22-7bdd-4868-ab6e-90dd43d9621d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "在Exemestane + Celecoxib小组和初级试验单独Exemestane小组中具有临床效益的受试者的比例没有差异。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "51b8964b-86b8-4e93-9fb1-cb4b6f7f3451": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "在初级试验中观察到的不良事件之间仅有重叠,而次级试验是两次试验中发生的几起分裂症的病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "276f5523-f45b-45b0-ad30-b737f2c1b1d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "初级试验记录了他们的患者的几次皮肤感染。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "884ba067-d3fe-4837-ad2a-a802b671b53c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "具有3到5之间的ECOG分数的患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "6619c75a-4073-47e9-8586-5070be1b3d39": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "参加初级试验的参与者必须是夫妇,乳腺癌幸存者和护理人员,双方都必须流利地说英语或西班牙语。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d81fafa4-1196-407b-a8c2-27d7b5da2f4f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "已 histologically 确认,新诊断的 0 阶段乳腺癌的患者不能参加初级或次级试验,除非他们显示 LVEF 低于 50%",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6d8b4720-e600-47d7-b6c5-3b8627f2358f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "在初级试验的2组中没有出现不良事件,这些不良事件发生在超过5%的患者中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "1b84007d-0002-4ab6-8e05-609e7de58684": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "二级试验和初级试验在研究中不使用局部药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "适当的血液,肾脏和肝脏功能是必要的,以参加二级试验和初级试验,然而,严重认知功能损失的患者仍然有资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "dc7c4409-32e5-4211-83fe-0a97b6176ca0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "在初级试验的1号群体中,发烧性中毒比在2号群体中更常见了5倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            12,
            16
        ]
    },
    "73e7447b-a940-4126-a1d9-fffd7c56c900": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "在初级试验中,Eribulin Mesylate组中的几名患者存活不到一年。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c160ae6e-4dfe-47a4-ac9a-7497babbc2a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "患有周边神经病症但没有神经病症症状的患者被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            13
        ]
    },
    "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "持久感官丧失,干扰日常活动的患者被排除在初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            22,
            30
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53
        ]
    },
    "a7106a35-36da-423a-a6b3-3da62fc0eea8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "在初级试验中,对患者进行先前暴露是强制性的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f4f50a05-9d63-4006-9680-b7ef68dbb5fe": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "在初级试验和次级试验中组合2但每天服用安慰剂量PO。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "f34760f4-965e-4bbb-b88f-8b63a7045808": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "具有HER2阳性肿瘤的患者不能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "f4a33395-7e6b-46b9-b222-af3bbfff1591": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "在初级试验中,不到2%的患者经历了不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "e7d00591-381f-45e2-abdb-2ae1e568b193": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "在初级试验中,超过3名患者患有与低白细胞数相关的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "59da1fb5-2636-4ca8-8970-6cb45dedbed3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "患者的食欲在初级或次级试验中没有受到影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "f144c34b-9428-4836-bf01-5f7030eb579c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04030104",
        "Secondary_id": "NCT02525718",
        "Statement": "二级试验和初级试验的干预1是对照组的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e7e87023-2227-4594-931a-0a3d89ec686e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "重型吸烟者(每天吸烟超过5支烟)和接受甲烷或布普雷诺芬维持疗法的患者可参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ca4a190a-9007-4f8f-a199-b8fe4064e55b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "在初级试验中发生的几个不良事件与心脏无关。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "4f790768-7fa4-4729-bcd6-cf7bcb44fa3c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "初级试验参与者接受认知行为疗法治疗,这在二级试验中根本不使用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "cb133915-dc40-4f93-a6a7-076e4d7f07a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02685566",
        "Secondary_id": "NCT03076190",
        "Statement": "初级试验和次级试验有相同数量的研究组,但正在测试不同的干预措施。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1f0825b6-8e32-44ff-96b7-ab082e24b493": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "拒绝使用避孕药的WOCBP被排除在初级试验中,但可能有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "db96c4d6-ffcd-401a-8af3-807f665f16f7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "诊断为骨质疏松症的患者有资格参加初级试验,但被排除在次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "b74dc1bc-76c3-4ce6-9735-634e7a507ff5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "LVEF 等于 53.5% 的患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "f078c722-b879-40f2-ac72-c733001b93dd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "二级审判和初级审判只能接受18岁以上的受害者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            15,
            16,
            17
        ]
    },
    "c33d78e5-13be-4cde-b36e-7cc097f180a2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "初级试验和次级试验使用相同的结果测量,相同的药物和相同的群体大小。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "58dbc33b-d32c-4e91-a940-ca1148bbdae4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "初级试验是测试化疗治疗,而次级试验是测试植入物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "二级试验中的几种治疗方法是口服的,初级试验中的任何一种治疗方法都不是通过这个途径进行的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "2c462296-35f5-482a-9ece-3b4ed4c2f53a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis是在初级试验中记录的唯一不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "16358be6-3895-48f7-8006-4effeb3f74b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "初级试验的参与者必须愿意接受基于循环磷酸胺的化疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "6d4ecb16-6586-4ea8-a1dc-f825e951e060": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "HER2初级肝肿瘤的参与者,通过现场荧光混合证实,有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            7,
            8
        ]
    },
    "5bb009f0-bc19-4a85-85b8-bd7bf0675f3f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "与二级试验不同,初级试验没有记录任何贫血, dyspepsia,恶心或呕吐的情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "2731552d-195a-4f43-b6b5-02a3fbda81d9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "二级试验和初级试验没有相似的结果测量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8fee5ce4-3e46-4731-842e-a5b1df451c7d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "不到40%的初级试验参与者获得了完全响应(CR)或部分响应(PR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "def4199f-a22d-4939-b15d-66fd073fb280": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "初级试验的2组是控制组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "初级试验中的1名患者被诊断为清晰细胞肾细胞癌。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "d97c3981-50f9-4221-aec6-60661b831c8e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "56岁的患者偶尔出现记忆损失将被排除在二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            7
        ],
        "Secondary_evidence_index": [
            56,
            73
        ]
    },
    "86c1430c-553b-4388-a034-b82f78afdc0d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "与 aromatase 抑制剂相关的肌肉骨骼症状的患者,如 1 级或以上肌肉骨骼疼痛或 0 级感官神经病症,有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5,
            6
        ]
    },
    "b7cef0e1-7bd8-4c0e-a044-b11708cf927c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "两个初级试验小组都接受医生的选择,从4标准的护理转移性乳腺癌化疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0b55d5b7-5e71-497f-96ad-9dc2f872c4aa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "在初级试验中,共观察到2 / 93患者患有白血病、心肺衰竭或腹泻。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            6,
            8
        ]
    },
    "225f95a5-7c22-4cb7-a463-1c57d5b69d7a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "在二级试验或初级试验中,对患者不明确禁止以前暴露于exemestane。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "5464e8a7-159c-4e00-8710-45a44ceaeda3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "二级试验的1号群体在整个试验期间不接受相同的Daratumumab剂量,而初级试验的1号群体在整个试验中接受相同的干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "98965d07-e2db-41bf-ac3e-a5c130513275": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "在初级试验和次级试验中的患者中,只有1.56%患有疮。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "784cc905-937f-43fd-96a6-34ea8dce9e8d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Secondary_id": "NCT00878709",
        "Statement": "末期肝脏病患者被排除在初级试验和次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "2e3f2fde-569e-46ef-958d-710599fec9a1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "初级试验研究干预对目标损伤的影响和次级试验测量骨质矿物密度变化,因此这两项研究的结果不能直接比较。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d1080199-2591-44bd-bdad-0dea3830e657": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "初级试验的参与者每2周注射600mg/m2的Pemetrexed,直到完全反应或疾病进展。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c37c21f5-19a0-4fcc-af92-89690fb64091": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "在初级试验中的群体之间的差异是,一旦群体获得了750mg低剂量的欧米茄-3脂肪酸和其他500mg,而在次级试验中的差异是患者的特征。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "bea7f10e-09d6-42c3-9e89-dfd1112a33d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Secondary_id": "NCT00688909",
        "Statement": "初级或次级试验中的0名患者死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "3d41d86b-f53f-4bf9-a4dd-eae2412c485e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "只有初级试验的群体2接受了莱特罗佐尔,但两群群体都接受了内分泌治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "0159bfb3-231e-4711-b3ee-2798c66f5f6a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "初级试验和次级试验都记录了患者群体内直肠出血的案例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "9e7628cd-931e-4b1f-b4c1-f03f0449ac27": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "初级试验记录了两种不同类型的疼痛在其不良事件,在头骨和脚部区域,二级试验没有记录任何类型的疼痛在其参与者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "f1108cbc-db27-431d-9154-1a267278bda4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "心肌病和白血病的病例仅在初级试验的1组中观察到。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "8eb69e3e-ac08-4e85-98be-211aecd4525d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Statement": "任何患者都可以参加初级试验,只要他们愿意提供知情同意并能够使用互联网。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "baf7e338-91fd-47d0-b766-a4e039efc5d7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "初级试验中的任何一群患者都没有经历DLT。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9401b12d-3888-4a41-93a1-b2075930098b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "在过去两周内接受过外部辐射治疗和重大手术的患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            12,
            21
        ]
    },
    "c7aa030a-6b76-4bd7-a934-f02a4638a1ac": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "60岁以上的妇女患者,患有 histologically 确认的乳腺癌和先进的阿尔茨海默病,不符合二级试验和初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            21
        ]
    },
    "94f9a957-33bb-4409-8878-ba734d6b0d5c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "使用Meso BioMatrix Acellular Peritoneum Matrix植入的几名患者在重建的两个乳房中遭受了乳房相关不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "04fd88c2-cf92-468d-bbc4-567cae19948d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "初级试验记录的恶心患者比次级试验少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "在二次试验的群体1和初级试验的群体1中没有出现多器官失败的情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "8074c35f-b74c-4250-94f1-9ad22fa315d7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "患有骨质疏松症的患者有资格参加初级试验,但被排除在二级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "afc4a45b-6592-4ca8-b174-033fb6a0624a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "申请人必须有不到12周的预期寿命才能参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "2e1d4811-ae58-4b81-b53a-dbcb8c980a08": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "伊丽莎白有HER2阳性乳腺癌,她有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d4f738c5-c99a-4d8d-b335-5821ce97fbd5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "完全残疾的患者,完全被限制在床上或椅子上,无法进行任何自我护理,有资格参加初级试验,但被排除在次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "f27b25bd-c28e-4aac-8ad6-951fd7381ce4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "在初级试验中,超过1名患者遭受了不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5311216c-94e0-4d04-acd2-b95b932ddc02": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "初级试验至少记录了1名感染的患者,而二级试验中没有观察到任何患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "01dfa37b-ce65-4e90-addc-395241c92f5f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "初级试验中的患者经历了各种食管和心脏不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "43588c50-7dc4-4d46-a53d-e94576e8ab55": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "孕育能力的男性和女性都必须使用适当的避孕方法,以获得初级试验的资格。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            16,
            17,
            18
        ]
    },
    "f419f810-ca53-4168-86fd-d1d9a9154d3a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "患有甲状腺炎的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "630a8241-b776-4799-a7ca-b1fddf17686c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "在Taxotere/Docetaxel治疗的初级试验中的患者中,最不常见的Chevalier评级为1,3D和3C。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ]
    },
    "8f3fddf2-97ab-4456-bff7-8f83b27e3849": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "具有 ImmunoHistoChemistry 测试结果 3+ 的患者被排除在初级试验中,但被纳入次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            15,
            18
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "11617367-193f-4f6b-bc3e-e58ea76d1052": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "二级试验中的循环磷酸胺剂量为每4周一次150mg,初级试验中的安慰剂量为12mgQD。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "882f22f6-36d9-4c2f-8f49-52469d570977": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "初级试验和次级试验不排除非瘤皮肤癌患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "8f5423c9-17b5-4f66-aa9f-1fc9763958b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "初级试验中的任何患者都没有 Thrombocytopenia、心脏衰竭、Pancytopenia、急性冠状综合征或心脏病发作。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8,
            5,
            7,
            9,
            10,
            11
        ]
    },
    "0c45a782-1a3d-4e9b-a258-136ab080dbb6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "在初级试验中记录的任何不良事件都没有发生少于两次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "4e42302d-2cd9-4a91-9338-8e3b0ffb9292": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "乳腺转移性HER-2阳性腺癌的患者可能永远不会有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            5
        ]
    },
    "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "在初级试验中,60%的受试者能够完成至少85%的计划剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "da2ea2e9-3109-433e-9033-9ae322c30c4b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "在过去两年内经历过乳房扩张手术的女性被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            8
        ]
    },
    "c77c8e02-7abb-4b63-8917-01babe5cd372": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "与小组 2 相比,初级试验的 1 个小组中有 5 个更多的贫血病例和 1 个更多的散发性血管内凝固病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            12,
            13,
            14,
            15
        ]
    },
    "f2b14720-6ff2-4ff7-a5bc-3841b93f647e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "初审没有解释其在干预部分的干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "03e9368b-18a7-4643-a38b-a7b002403bf1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "完全残疾的20岁以下的患者,完全被限制在床上或椅子上,无法进行任何自我护理,有资格参加初级试验,但被排除在次级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "c5dbd52d-01d4-4919-bfe9-2b7885490d6a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "由独立辐射评估监测委员会评估的乳房中具有临床客观反应(cOR)的参与者的百分比在2组中最高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "83115abd-1c07-4ee7-8ba5-b4575be2d50f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "放射性确认骨质转移症的患者均被排除在二次试验和初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            14
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "784872db-8ccf-4ddc-a432-6ee00fd0b0cc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "二级试验为其患者提供氧化物,而初级试验测试教育干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            14,
            15
        ]
    },
    "adae7d81-bc8e-48e4-b966-27c2633eb72d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "在初级试验中,TCH + P组的100多名参与者获得了基于肿瘤样本的综合病理反应(tpCR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "4ee4061e-a532-459e-8d03-3055bd92419c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "在整个初级试验期间,帕里提克比Fulvestrant更频繁地服用Tipifarnib。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4cbb7f8f-ea60-453d-b4ab-e967944426d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "在初级试验中记录的16种类型的不良事件中,只有2种发生过多次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "47f11df7-6c82-4c50-9249-5085313a5064": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "在成像上最大直径为5毫米的细胞学确诊乳腺癌的患者将被接受初级试验,但不会接受次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3114ff0f-184c-48ba-b33d-631505cffeef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "初级试验报告了共计3例Askites,Astenia和Gastritis在1群中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            8,
            9
        ]
    },
    "edf31a43-a774-4f2a-8a02-89b84de941bb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "在接受高剂量欧米普拉佐尔治疗的初级试验中,有脂肪酸合成表达(FASN)的患者中,有27%没有病理完整反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "在初级试验和次级试验患者群之间至少有15名患有 dysphagia 或发烧的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "初级试验使用每日Lapatinib的固定剂量为1000mg,而卡佩西塔宾剂量与患者体重变化。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "5a076708-c8d4-4341-9c1d-3ee762f57be5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03456427",
        "Secondary_id": "NCT02685566",
        "Statement": "没有关于在初级试验和次级试验的干预部分中使用的成像类型的细节。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "98a946b0-2be1-474c-b373-043f329ba261": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "无论是初级试验还是次级试验都没有测量 Ispinesib 服用后具有总反应率(ORR)的参与者的百分比。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b82e6861-3908-43e9-8e54-cf60c7d96a4e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "患有 ER 阳性肿瘤的患者有资格参加初级试验,但不能参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "b8e5baf7-ddc5-407f-84d3-4c93224477cd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "初级试验中超过一半的患者经历了不良事件,二级试验中没有一个患者没有出现不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "79c34b71-a90f-4ddb-9aee-5f61f71f0846": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "初级试验不是测试新的物理治疗或化疗干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "患有63的膜过滤率和BI-RADS类别c的乳腺组织的患者将被选为初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            4
        ]
    },
    "02d5fe7a-60e2-422f-98c0-92461b8fa13f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "初级试验和次级试验具有局部干预,应应用于乳房或脸部。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "869e413e-01c5-4a9e-8a4a-b6079f7ae300": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "艾米莉患有非转移性乳腺癌,可以参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c0b528ef-ae9f-4c01-8915-b47856f07c95": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "初级试验接受3级神经病患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17,
            19
        ]
    },
    "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "在初级试验的第48周,大多数患者患有稳定性疾病,没有人完全或部分反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "da15fae6-7fa1-4fe0-b61c-e043df3e9e74": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "所有初级试验的患者必须在入学前进行双边乳房MRI。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            7
        ]
    },
    "8ce665b5-20fb-44a3-b3c9-25493e8dd7ff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "具有HER2负性、PR和ER阳性肿瘤的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10
        ]
    },
    "01236718-14da-450c-8051-0207d31743a5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "从随机化到因任何原因导致的死亡的平均时间在初级试验的1组患者中比在2组患者中长一个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3419af1a-7923-419d-a673-2de96d41eabb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "潜在的参与者将被考虑,无论他们的乳腺癌的激素敏感性,除非他们是过度表达ERBB2。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7
        ]
    },
    "2048912d-9e9f-4cbc-89cc-19020f20a976": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "在研究入学前的一年中进行全面双边乳房切除的患者将被排除在初级试验和次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5
        ],
        "Secondary_evidence_index": [
            5,
            12
        ]
    },
    "f5907902-d4d1-4d73-a196-7fbe0dcb44ad": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "初级试验和次级试验都有控制组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "93a8e018-ac25-48b2-81d2-fd5b01be8f37": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "与初级试验的患者相比,二级试验中的患者的感染人数较多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d72c45e5-6654-4afe-91a0-1f47b0c13dc0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "安娜是一名57岁的女性,ECOG为0,被诊断为乳房的HER2阳性侵入性腺癌,具有双侧节点pN2.她有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            15,
            16,
            17,
            18,
            19,
            10
        ]
    },
    "e68b5690-11fd-4567-8dcc-dec91d1e4bb8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "在初级试验中记录的唯一不良事件是脊椎骨折的一个例子。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "e1417a26-2f40-4dd6-b598-e66e57312595": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "初级试验的1组小组中有不到5%的患者有眼泪障碍,二级试验中有0%的患者被记录为有眼泪障碍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "6ee89773-958b-4eb9-bc67-18fa98a70c2d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Statement": "初级试验只记录了一种类型的急性不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "4d776c28-8ed1-4f3f-9837-0821029d3775": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "初级试验的1组患者中没有一个患有血小板缺陷,而2组患者中没有一个患有抑郁症。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "50e54a67-9cfb-4259-b810-2e9bc0b09b4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "初级试验和次级试验要求患者接受至少两周的乳腺炎治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9f23f617-b8ec-4665-ad0b-9a9bc8b19691": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "在初级试验和次级试验中最常见的不良事件是中性衰竭,在所有群体中共发生3例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "b76c9c21-64f7-487b-bf08-e232a9da0174": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01490892",
        "Secondary_id": "NCT02364388",
        "Statement": "初级试验的干预需要注射和两种不同的成像模式,而次级试验首先需要咨询,然后进行强化放射治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "66aaca41-f5f9-4ed4-b165-9510b7c64456": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "只有认定为女性的患者才有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            6,
            7
        ],
        "Secondary_evidence_index": [
            18,
            38
        ]
    },
    "611317e3-83f9-4e8d-9a9d-3dcda62fb6cb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "初级试验中的一名患者患有口腔真菌感染。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "d6b09c0f-979c-4151-87f9-830b964e275d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis是初级试验中最常见的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "92da8d30-a7e9-4fb4-95e4-484b53279ad7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "初级试验和次级试验监测其患者群体的DFS,但次级试验报告DFS患者的百分比 >=5年,而初级试验报告DFS患者的百分比 >=2年。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "762c3b23-547a-40cb-86c9-767294f4a142": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "由于她的年龄,一个56岁的病人进行切除手术不符合初级试验的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            3
        ]
    },
    "95a509d6-2990-49ac-b36c-aedf842f17ee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "在初级试验的患者群1和2中,没有观察到抑郁症、腹泻、肿胀或发烧性中毒症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "初级试验中的一个患者经历了4级不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "19c2c2d7-4c33-4842-9ed4-02cfae663ce2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "初级试验中有1例夜盲,二级试验中有0例夜盲。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "1fdaafdc-766b-488e-9cc4-cbcad74ade97": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "在初级试验和次级试验中,唯一口服的药物是多克索鲁比辛和维利帕里布。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2e591059-5a3b-4a69-84c5-59d9604394a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "所有性别均有资格参加初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "94a54cdf-4c1c-4994-929a-ced7a33f2b43": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "在初级试验中,不到1%的患者患有抑郁症。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "b217583e-2dbb-4951-8f73-cac08e365a7a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "患有节奏剂或的患者可能被允许根据他们的医生的裁量参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6
        ]
    },
    "42086f11-1fb1-4041-8d1e-e150d4cc09ea": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Statement": "最低体重50公斤必须参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            14
        ]
    },
    "0d75c493-58ce-4a45-8823-a9a1126751b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "主要试验是测试化疗和放射治疗的组合。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d0d4e184-0764-4c28-9af7-4535c7ed1aad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "初级试验的2号凝聚体产生了比1号凝聚体的差不多更好的结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "e45886af-1edd-4987-a280-2609a86fd3dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "20岁以上的女性在过去4周内接受化疗,有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5
        ]
    },
    "c207ff16-b7d0-49e4-9177-0597044f3008": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "一些接受凯拉丁的初级试验受试者每天在大约3至6周内局部服用两次,其他参与者可能通过皮内注射服用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "35234f08-cf01-478f-b739-600b5a6ea3d9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Statement": "初级试验中的16/179名患者经历了心脏事件,大多数来自2组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "87adb323-6f56-4e1a-a04d-8437ac571eab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "乳管癌患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "94410f2c-9c1c-4130-b479-738e343ba9f7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "在初级试验和次级试验中使用的干预措施之间至少有一条通道。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b811e872-90ef-4649-9c8d-f5488f316ccc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "纯管癌在现场(DCIS)的患者有资格参加二级试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            12
        ],
        "Secondary_evidence_index": [
            0,
            9
        ]
    },
    "f66f4c30-2d39-4e29-876a-487bca9a8ccf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "初级试验和次级试验在其干预中不使用任何化疗或放射疗法",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "初级试验1组中的7名患者患有剂量限制性毒性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "011991a5-724d-4b95-b9ab-9e1371d77368": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "初级试验1组中的所有患者都经历了白血病和发烧性中性衰竭。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "8421197a-3a35-4738-b1c8-83cce0ac4115": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "二级试验记录了比初级试验更多的心脏不良事件总发生。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "d09091f1-3fc5-498b-8c59-4678590c8464": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "虽然在二级试验中患有 Enterocolitis 患者的比例比在初级试验的 1 群中要高得多,但由于群体大小的显著差异,无法进行强有力的比较。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "203a2e22-cae9-4bfe-b82d-6dc665a66ce6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "用 bisoprolol 或 labetalol 治疗疮的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            20,
            33
        ]
    },
    "f4909215-5b14-42d9-bda4-4d112cf2a108": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "初级试验1组中的三分之一以上的患者经历了不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "9c27202c-7090-4be5-840e-351992aeb81c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "初级试验和次级试验在研究期间报告了相同数量的脱水患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            11
        ]
    },
    "fc7d8ffd-9896-4806-a095-d435cde83c88": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "在初级试验中的群体2中受不良事件影响的患者总数大于二级试验的群体大小。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "23116aca-0064-4426-b147-7af688a82443": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Secondary_id": "NCT02287675",
        "Statement": "患有溃性结肠炎的男性被排除在初级试验中,但有资格参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Secondary_id": "NCT01217385",
        "Statement": "进入初级试验和次级试验的唯一标准是,患者必须是女性,21岁以上和英国人。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "98850daf-738c-4005-b476-8c5479ad3b79": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "马克有HER2阳性乳腺癌,他有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fd8ddc92-4625-4392-b7ef-0ea218e2eb1c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "初级试验是每天试验一次胶囊的组合与放射疗法。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a4ed4cc0-9444-4a5d-863c-578fd42b8794": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Cohort B的干预被描述为阿法提尼布50毫克,口服,每周两次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a4dcb9b6-7b6f-4467-a159-d6e770f6762f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "护理患者不符合初级试验或次级试验的资格,因为研究干预可能对护理婴儿造成伤害。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            19
        ]
    },
    "be1c82e6-200d-4bef-b723-c78655fa40e5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "初审未说明其干预的管理途径。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "790047b1-43e3-486e-b41c-eaa89026eae7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "在初级试验中,11%的患者有严重的副作用,没有患者有严重的药物不良反应,超过一半的患者有意外的副作用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "fc8ed290-e2b3-4eea-a837-d369dcd9b5da": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "初级试验1组中的3名患者中没有出现任何不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "207b0895-91de-4238-8d50-e2b8b7420fb0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "总体而言,二级试验中不良事件比初级试验多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            14,
            15
        ]
    },
    "1340769c-b55c-480c-a4c4-130034e128ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "患者必须至少先前接受1次拉斯图苏马布治疗才能符合初级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "a4d6e27f-737b-4597-86e1-79b3f064cbee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "初级试验的候选人预计能够在水下保持呼吸30秒。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "二级试验的1号群体的群体大小超过了初级试验的1号群体的3倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "030eded8-6513-4028-b1fe-fefd6dd388ad": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "血小板数为50,0000 x 109/l的患者不符合初级试验的条件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "412d3ee2-bbfb-4e24-b159-684ae144e742": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "患有最小症状但左侧主要冠状动脉严重阻塞的患者将无法参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            33,
            35
        ]
    },
    "d1d77877-9c85-41c8-9eca-6fd75b254a15": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "雷切尔19岁,皮肤溃和对三克洛桑过敏反应,她由于年龄不能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            4,
            8,
            9
        ]
    },
    "c32d1b74-07ab-4afb-9db6-878e20727661": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Statement": "历史上证明有单焦HER2渗透性乳腺癌的成年患者,未曾经历过前列腺切除或相同的侧乳腺减少,并且没有对手术的禁忌,被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "ba0c0dc6-826b-426f-8738-eec23e47f6b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "沙龙在2个月前进行了臀部更换,她不能参加初审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            6
        ]
    },
    "77982c81-d147-48d9-909c-18b9a98224e9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "仅在二级试验和初级试验期间记录了1种类型的感染。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "初级试验和次级试验的结果表明,Abraxane + Tigatuzumab比Caelyx,Docetaxe和Trastuzumab产生更好的ORR。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2e03f6f1-0d4f-4ebf-8781-20918d70d78f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "一名56岁的病人接受了切除手术,不符合初级试验的条件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            3
        ]
    },
    "57e74ef2-f170-47bd-a908-2a7b3cec150d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "没有QT延长的患者被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            29
        ]
    },
    "b5957a75-140f-445b-99dc-199b8182b8ed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "乳管癌症的更年期前患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            3
        ]
    },
    "142cc983-b0cc-4f9f-b3ef-4eb57e2a317b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "初级试验的两个群体之间的区别在于1群体接受了更高的IMGN853剂量,而2群体更频繁地接受了更低的剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f57350c2-ac90-47ea-92b4-d903509bf07a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "初级试验的两个手臂的患者经历了4级中性衰竭相同的时间,没有记录任何差异。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "77c61307-567d-4ac2-a7f7-85feffd30473": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "患者不需要有已知的激素受体状态才能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "35dd977f-53d8-4400-b5cb-34caaa938e78": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "初级试验的超快速代谢剂组在4个月内平均增加了Endoxifen浓度超过6mg/m2。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "54554da5-e67f-4da5-819b-a85b7bc5d52c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "初级试验中的不到三分之一的参与者在12周的研究治疗后达到无进展生存率。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "592edd64-7841-4c19-ba75-583066308137": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "在第 1 天至第 7 天,初级试验的 1 个小组接受 Doxorubicin hydrochloride IV、口服cyclophosphamide、 dexamethasone IV 或口服和 ondansetron IV。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a1d207c8-2d57-4c49-89fa-60ceacf65829": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "临床抑郁症患者不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9
        ]
    },
    "4a8f0562-355b-4a68-8790-c283d93ce766": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "初级试验和次级试验在研究期间报告了相同的脱水患者百分比。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            11
        ]
    },
    "04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "二级试验的凝聚体1记录了比初级试验的凝聚体1更多的腹泻和消化不良病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8
        ]
    },
    "3cd353ed-af0d-4356-8f45-efc1e91a2a0d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "外科病人,能够完全自我照顾,但无法进行任何工作活动,被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "b8473ae8-11c9-4578-aab8-ee96e6287715": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "候选人必须有超过3个月的预期寿命,以参加初级试验,对二级试验没有最短预期寿命的定义。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "4243dc45-5a64-486d-ae2a-11448db00dcf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "初级试验的组合1比二级试验的组合2减少了15%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            15,
            16
        ]
    },
    "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "二级试验的1组具有比初级试验的1组更长的中间PFS。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "f616e3d8-6c1a-4b99-ac79-ea87895e37b7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "初级试验的组合2是控制组,次级试验的组合1是控制组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "2f700407-8baf-4e5f-8fc0-378a294512f5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "护理患者不符合初级试验或次级试验的资格,因为研究干预可能对父亲造成伤害。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            19
        ]
    },
    "cebee448-235d-49ff-8e87-56639399548b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "知情同意是入学初审的可选。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "18岁以上的女性,其最后一个月经在随机调试前2年,有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "因植入装置的存在而出现的疮是初级试验中常见的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "af677d94-a376-42ea-93fe-91963a071199": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "患有 dysphagia 的患者不能参加二级试验,但可能有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            26
        ]
    },
    "6579e25e-8dcf-44b5-a50d-7c84672cba89": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "只有以前被诊断出患有癌症并目前正在接受其主要肿瘤的持续治疗的人才有资格参加初级试验,只要他们超过20岁。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "1ac9c526-91e6-4e0d-8570-0a78e3ec78db": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "初级试验的1和2组记录了每个类型的不良事件的完全相同百分比。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "79c07f36-daf9-4844-ad8a-f362fbbaaf81": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "初级试验的两组报告患者在试验期间呕吐的比例相同。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "bced9c90-5ce0-416c-a168-f9e74359b332": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "初级试验中的Exemestane组比Abiraterone Acetate + Prednisone组具有更好的中等肿瘤响应,但最大TR的患者属于Abiraterone Acetate + Prednisone组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "ce88c763-0062-48dc-b5e1-f81af32f2628": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "HER2 负 BC 患者可参加初级和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "982469a3-2fc1-40b4-92a9-d531b6c0ab5d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "初级试验将尿素/乳酸奶制剂局部施用,每天两次,并每天一次口服安慰剂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "无论是初审还是次审都没有年龄限制。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "e6901a45-4c97-4618-bfcb-6f6dd046ef0c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "在初级试验中,Exemestane组的最大和最低记录TTP之间的差异不到3个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e94ea1b1-1816-4bac-b1ca-f6d66b95702a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "大多数初级试验参与者在研究周期8后经历了3级或以上的心脏毒性事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "0e3c62f7-a152-4370-9d09-b69a715c0a21": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01216319",
        "Secondary_id": "NCT03346161",
        "Statement": "二级试验和初级试验正在评估患有乳房切除手术的乳房重建手术。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7191b5e9-4f29-4261-8a64-51653ee151fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Statement": "在初级试验中,Dasatinib,70毫克,每日两次结果比Dasatinib,100毫克,每日更好的中位PFS。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "639ccada-370d-4709-bdd7-1b29bbcc8769": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG > 1和12周以上的预期寿命是参加初级试验所必需的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5
        ]
    },
    "8c6e6c06-c409-4c42-b195-e9d2a1065b97": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "初级试验中的所有患者都有最低的胃炎症状和正常饮食。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "b5183c1c-adb5-4877-b061-50a16d6a5b52": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "初级试验中的任何患者都没有自杀,但在二级试验中有一个这样的案例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "69f57cdb-22e9-4a3a-8f19-6095c66c6497": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "二级试验使用临床效益(CBR)作为结果衡量,这与用于初级试验的病理完整反应率的参与者的比例不同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "ea505463-c509-416e-ad88-11576764b734": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "具有 ECOG 值 < = 1 的日本参与者有资格参加二级试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "81669281-db01-4493-a797-0d60f448f706": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "总体上,初级试验中最常见的不良事件是脱水。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "40dbf023-ead5-45fc-bdce-bf40e1955578": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "无论是初级试验还是次级试验都没有使用低剂量氧化物、高剂量氧化物或莫米塔森在他们的干预中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b64ae9c9-956a-421e-a41f-1886408fec2a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "在初级试验中的一个群体中,超过5%的患者经历了副作用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            11,
            12
        ]
    },
    "e0980234-0611-44de-9165-54bdd086663d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "初级试验使用局部干预,二级试验使用口服和静脉注射治疗的组合。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3366c10a-3d41-48ae-bfa8-26b9e655761e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "初级试验的群体2中有8例喉咙炎。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "be29030a-98e8-40ad-9138-90076fdb50d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "初级试验的凝聚体1记录了比凝聚体2更多的白细胞相关不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "a31298d5-20ae-4a3d-a57b-e97288fff6c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Statement": "每个初级试验的患者在2年内至少经历了1次治疗新兴不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "54e93334-0f21-4ea2-b0f2-34473385da53": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "在初级试验的两组中,最常见的不良事件是Anafilaksis,影响不到1%的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "fbedd8fc-05e8-4438-b780-d7483aed3b45": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "不正常的LVEF,怀孕或哺乳自动排除患者参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            22,
            28,
            29
        ]
    },
    "4bd9f061-6420-443d-8f84-b703733644ac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "在初级试验中,百分之百的患者遭受了危及生命的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "e6d3354b-b36a-42b9-b406-61a9af594686": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "初级试验的1号群体每天服用120毫克金戈比洛巴两次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "62b3d09e-6b2a-4827-8ceb-96ccafca18d4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "初级试验中的患者不需要先前在转移或辅助环境中进行激素治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "065a6cfe-3991-4dd5-8a55-22b9b31d1fc3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "初级试验的参与者必须年满18周岁,有历史证实的乳腺癌的第3阶段或以上,ECOG<2和预期寿命超过6个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            6,
            7,
            8
        ]
    },
    "85c315e5-7ae4-4764-8b02-87d36f67a159": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine 在初级试验中不使用,并且仅在次级试验的其中一个手臂中使用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "497188e0-9d88-406f-b163-c154516cb12c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "在小组2中,不良事件的病例比初级试验中小组1的病例多10%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ]
    },
    "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "患有BUN < 20 mg/dL,血小板数: < 90,000/mm3,白细胞数 5,000/mm3 至 8,000/mm3 可能有资格参加初级和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "f26fb90b-a9a5-4614-9680-2e9f6f0ba649": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "初级试验和次级试验的患者没有出现相同的副作用,除了超管外发症,这在两项试验中是最常见的事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "90dd042b-c16c-4ea7-b360-625bd5e64590": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "一名75岁的女性患者,其ECOG值为1并预期寿命超过1年,可以参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            11,
            12,
            13
        ]
    },
    "9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "在初级试验中,Afatinib单独治疗的客观反应(OR)参与者的百分比低于Afatinib和Paclitaxel或Vinorelbine组合治疗组的13%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "20cc98f8-a71a-466d-a39c-735899791613": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR 等于或高于 1.5 是参加初级试验的义务,不需要参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fa1c6f63-ae37-4c18-918b-7b9ba445fd81": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "总共在初级试验中发生了32例发烧性中性衰竭。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            12,
            14
        ]
    },
    "6d0b2acc-11f4-479f-9a86-004e2f5f7599": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "IV被用作初级试验和次级试验中的干预方法。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7e9c3980-9f12-40c7-920e-76594db26fd1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "初级试验中的群体之间的差异是,一旦群体接受了安慰剂和其他低剂量的欧米茄3脂肪酸,而二级试验的差异则是患者的特征。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c83e003d-d12d-4f72-ab1f-c39f3a13326b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "为了符合二级试验和初级试验的资格,患者必须是女性,18岁以上,ECOG <2,并具有 histologically 确认的HER2负性乳腺癌。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            10,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "cae58656-76e7-447a-940e-dfcc78159173": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "初级试验监测贫血在其不良事件的发生。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "94c4c3fc-7bcb-407b-86b5-6699305d3dbd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "初级试验中没有发生过多次的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "103fbaa8-1852-402a-9368-36bbf6c747b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "主要试验中最多有3名患者患有中性衰竭。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "731dc36f-983d-4d4c-97ac-6e3eeee23a40": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "左侧乳腺癌患者和ECOG值为3被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            8,
            14,
            17
        ]
    },
    "b2883781-f4e9-405e-9231-7a07e46c35b0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "在初级试验中,只有一个群体在每公斤4毫克时服用了特拉斯图苏马布。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "932c2135-381a-4675-a782-e683eca8d935": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "初级试验和次级试验都使用基于疫苗的干预措施,但这在不同的间隔和不同的时间。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6461007d-fc18-43e2-a797-11cb0a4512ce": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "初级审判时间比二级审判更短。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "819e85b0-2d4e-4535-b920-4e18868da883": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "在中枢神经系统中放射性确认甲状腺的患者均被排除在二次试验和初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            14
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "cc0d6fe8-69c4-49d3-b321-00e47c155db6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "在那里,初级试验的3队的结果是毫无结论的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0fbb4fb4-620b-4ee9-aaa8-956992026cef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "初级试验中1和2组患者中不到一半的患者经历了不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "69b12ff4-6bb4-4207-b400-67795709c3c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "初级试验的Palbociclib+Letrozole 澳大利亚群体中的每个患者都经历了治疗突发不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            14,
            15,
            16,
            17,
            8,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "患有3级或4级周边神经病的女性患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            12
        ]
    },
    "9872cf9f-6f43-44d3-97ce-e205e0e5fc6c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "安娜是一名57岁的女性,ECOG为0,被诊断为乳房侵入性腺癌,IHC结果为1+.她有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            15,
            16,
            17,
            18,
            19,
            10
        ]
    },
    "efc15257-5e19-4b7e-8b51-da94840784d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "初级试验记录了1名血小板缺陷的患者,而二级试验共记录了6名血小板缺陷的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "二级试验中有1957%的患者出现了饮食障碍,初级试验中没有出现这种情况。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "初级试验的1号群体的死亡人数比2号群体高得多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10,
            13,
            23
        ]
    },
    "e4961c1a-83e2-40ed-93ac-64d5cef1f84a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "所有初级试验参与者必须在整个研究期间减少饮食中的卡路里数量四分之一。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9cb1c975-0d49-4437-af56-1a4f97e30aef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "没有确定参加初级或次级试验的最高或最低年龄。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            16,
            17,
            18
        ]
    },
    "51699ae8-d297-4635-95c1-4ed38c8706c3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "马克在过去一个月中遭受了两次反射性疮,因此他被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            14
        ]
    },
    "c2c73b99-f89c-4dd3-8362-295f9a7965f3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "为了满足初级试验的纳入标准,患者必须在研究入学前接受无效的 aromatase 抑制剂 (AI) 治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "180d7b66-9ee9-40fb-b4c7-a6060e6f67b7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "初级试验的1号群体的死亡率比2号群体高得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10,
            13,
            23
        ]
    },
    "949ac54b-a871-4134-a507-c98a4de55720": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "初级试验记录了安aphylaxis和脊椎压缩骨折的病例,二级试验中都没有观察到这些病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "02407f87-235d-4240-98fe-498b352cce75": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "患者必须有人类表皮生长因子受体2(HER2)过度表达肿瘤才能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "61a524d4-1697-4a10-b36a-a0c6cda79526": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "患有I级、II级、III级或IV级三负乳腺癌的患者不适合参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            13
        ]
    },
    "304977b6-9742-4c3b-84fd-e5ef1737a143": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG < 2 和预期寿命超过 12 周是参加初级试验所必需的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5
        ]
    },
    "87c65217-85d9-4f05-87aa-f4dfacd9f25a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "以Phosphoinositide 3-kinase抑制剂为基础的治疗的患者不符合初级试验的条件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6
        ]
    },
    "19e89ebc-a417-47a8-bfa7-1778baead178": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "在二级试验中使用了安慰剂治疗,但在初级试验中只有一个试验组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "561a0631-1eb3-48d1-baa2-81eb3fa79b98": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "初级试验记录了患有胸部疼痛的患者,而次级试验观察到患有腹部疼痛的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "bc617e84-a0c1-400b-9ad5-88b56d1805e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "初级试验的1组1组中的42名患者失明。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "具有突发双边乳腺癌(T3 N1 M0)的成年患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            3,
            4,
            5
        ]
    },
    "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "接受初级试验的干预1的患者获得比西姆瓦斯塔丁更高的阿纳斯特罗佐尔剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b059e44b-9830-4c45-858e-ebd007fbaf69": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "初级试验的1和2组记录了相同数量的发烧中性衰竭患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "fec065ca-fbde-476d-ab0d-7e7054e29858": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "患有脊椎脊椎上超过20度的Cobb角度或前期脊椎外科手术的患儿被排除在初级试验中,因为这些会干扰研究所需的CT和MRI扫描。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            39,
            40,
            41
        ]
    },
    "ea3bd229-001c-487f-9cda-edf2e699dbb2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "在初级试验中,患者以相同的频率、剂量和通过与二级试验相同的服用途径接受了vorinostat。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "576e519a-1ef3-43e5-a13c-6058ad71f388": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "已接受先前放射治疗的患者,以治疗当前的乳腺癌,在研究入学前的最后两周有资格参加初级试验,但被排除在次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8,
            10
        ],
        "Secondary_evidence_index": [
            8,
            9
        ]
    },
    "699d0cb5-1ebb-441d-aa7e-041a48923b00": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "接受凯拉丁的初级试验受试者在大约3至6周内每日两次局部服用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "患有 T1N1M0, T2N1M0, T3N1M0 和 TxN1M0 肿瘤的患者适合进行初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "6e882de6-e55f-40a4-95a1-bdb176e68a18": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "初级试验的1组患者中没有出现急性 vestibular 或急性冠状动脉综合征。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "525ed182-07e9-4548-87b3-c831e0b7389e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "患有淋巴嫩症的患者可以参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18
        ]
    },
    "233d2ec1-1383-4088-90af-c5a948847631": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "初级试验和次级试验都报告了他们的病人患有 Pseudomonal Sepsis的病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            12
        ]
    },
    "8e3fe244-d47d-48ce-ab29-4a5226024aad": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "在初级试验中,在各群体中出现了相同数量的发烧性中性衰退、白血病和中性衰退。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "670443b0-89bf-4af4-a9ab-4cdff26d09a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T4 N3 M0乳腺癌可接受初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "455748bf-8e12-4834-8126-ab77cab16200": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "所有初级试验参与者都接受了相同的Letrozole剂量,仅在次级试验中给出Exemestane的某些患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "d29bd9dd-b52e-4b18-82ea-e2914dfb9579": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "初级试验 接受Neratinib Plus Capecitabine的患者平均(95%信任间隔)进展自由存活时间比服用Lapatinib Plus Capecitabine的患者长2个月以上。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2649c857-f98d-4529-9a4a-4f8b17813cb8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "第一组患者的平均总存活时间比初级试验的第二组患者长44天。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0a6e8720-ea47-4520-bd02-e0eb8fcd880f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "初级试验中 ZA 4 mg 组的单一 IV 注射与 Odanacatib 5 mg 组相比,Urinary N-telopeptide of Type I Collagen 的基准比例变化较小。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "ce6630d3-d3b7-4870-a486-9b6284a454f0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "与Palbociclib+Letrozole India Cohort的患者相比,初级试验中的Palbociclib+Letrozole Australia Cohort的更多患者经历了治疗突发不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "27e31574-5a73-4a68-997d-daa84797a65a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "初级试验和次级试验都至少部分通过静脉注射进行干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e21171de-ad49-4fc5-9c5d-aa362ca61c8a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "初级试验的一组报告2/680名患者经历与眼睛相关的不良事件,而两组报告41名患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "初级试验的2组是控制组,因为有资格的乳腺癌患者每28天接受GnRHa治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "38f47a03-f71d-4072-a005-b954fb6069da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "初级试验的A臂患者在没有恶化的情况下生活的平均时间为半年。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e41917b8-d921-4797-b845-0121a75104a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "在初级试验中,超过2%的患者经历了喉咙背部的临床显著炎症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "初级试验中的1组患者的存活时间几乎是2组患者的2倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "二级试验的凝聚体1记录了比初级试验的凝聚体1更多的腹泻和口臭病例,这是由于凝聚体大小的显著差异。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8
        ]
    },
    "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "初级试验中的 Gemcitabine 组中,Kaplan-Meier 预测的无进展生存率比 Carboplatin 组低了 83%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "6214280f-f665-48d3-b33f-9d798deff71f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "二级试验使用总生存率(OS)作为结果测量,这与用于初级试验的病理完整反应率的参与者的比例不同。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "108b54a9-b5cc-4f31-956f-e4e2e653d756": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "总的来说,初级试验中有更多参与者没有肿瘤响应,而不是部分响应,0名参与者有完整响应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "662f4992-0155-4a82-926f-b1821539aab7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Secondary_id": "NCT00617942",
        "Statement": "在初级试验的1组患者中,有57%的患者在手术中有病理完整反应率,而在次级试验的1组患者中有60%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "398f744b-97cf-4f95-b162-99ec6652d327": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "在初级试验中,贫血和白血病的病例比二级试验的病例多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "43421f19-878e-46f7-b456-8031835af649": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "初级试验使用每日Lapatinib的固定剂量为1000mg,而卡佩西塔宾剂量与身体表面面积发生变化。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "13fa44e7-38be-48fb-a0eb-6b212549f526": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "达到完全反应(CR)或部分反应(PR)的参与者的百分比在HER2阳性组在初级试验中比在ER+和/或PR+组更低。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "12ae2315-cc50-43ac-a595-762c85c1ec58": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "没有基于神经肿瘤脑转移反应评估(RANO-BM)响应标准(CR)或(PR)的初级试验1组的参与者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "11403f92-661b-4334-8dfb-098586610ec6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "在主要试验和次试验中,大多数患者中观察到呼吸道疾病。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "2823adfc-b3a4-4626-9690-0c292aa8da04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "初级试验是第二阶段的试验,所有参与者将在两周内每天两次服用0.05%的局部液化素面霜。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "1cda051f-27d0-4027-94cf-7b5340173ca2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02504424",
        "Secondary_id": "NCT03708393",
        "Statement": "初级试验和次级试验不具有相同数量的研究组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "最短PFS的患者在二级试验中只有5天,最长的PFS记录在初级试验中78个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1e91c023-96e8-459b-9070-02df13339617": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "在初级试验中,FEC-75 然后 Paclitaxel/Trastuzumab 组比 Paclitaxel/Trastuzumab 然后 Trastuzumab/FEC-75 组产生更好的病理完整反应率(pCR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "a15b4c0c-232b-4209-bf60-35d160e41d2c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "初级试验中的一名患者经历了疮事件,这种情况与高程度的发病率和死亡率有关,然而,最常见的不良事件是贫血。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "795d634a-9f9c-49a2-a4e7-ec99bd3600f2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "初级试验是测试基于网络的教育工具,而次级试验是测试更年期后女性的医疗设备。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e2d4c56c-a68f-4751-907d-9c2355c9528b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "与初级试验相比,二级试验中患者的感染比例显著高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Secondary_id": "NCT00232479",
        "Statement": "患者必须年满18岁,预期寿命超过6个月,才能参加初级或次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            11,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "9ad3444c-143d-4c28-a08a-e0c9cda44900": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "初级试验和次级试验在他们的患者中没有观察到任何相同的不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2
        ]
    },
    "43061a8b-c1b2-4b5e-b935-73733d674fb4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "初级试验将具体的干预措施分配给其患者,取决于其肿瘤反应,完全响应的患者将被分配给A群组和B群组中的所有其他人,而次级试验则随机分配干预措施。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "fc7369dc-0fc5-4823-a8eb-5ac85188fd60": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "患有卵巢或肺癌的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            13
        ]
    },
    "25ec56f0-e472-4423-92ae-8d4840b067b5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "主要试验的参与者根据其预诊断获得不同的干预措施,而二级试验的所有患者都接受了相同的干预措施。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2c9e9407-e990-41bd-a87b-9d294c78f727": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "初级试验是测试一种名为PET/CT的新型放射追踪器,以评估其用于可视化HER2+损伤的使用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f3cebdf7-be0c-45ad-85bd-bde827524e20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "初级试验记录不到5个不同的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b5c7bfd2-d491-400c-8444-8bc424cd5dbf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "初级试验中的一名患者患有肾结石。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            14
        ]
    },
    "53c62057-d6ea-4639-adaf-98cb1544a394": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "接受初级试验介入1的患者进行21天的治疗周期,总共6次,但如果他们患有疾病进展或发生不可接受的毒性,则会更早停止。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "599b37cd-f380-48ac-864d-e766a7af963e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "初级试验和次级试验监测他们6岁以下DFS患者群的百分比。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c428ec76-4d22-4d2d-8c06-1675bd431d41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "初级试验的参与者必须是夫妇,乳腺癌幸存者和护理人员,双方都必须是西班牙裔。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Statement": "初审有两个群体。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a9d5c664-896f-4bb1-95e7-1deaa88848ef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "阿加莎上周过了53岁生日,她有乳腺腺癌,没有转移性疾病的证据。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "62b5fe62-470d-46e3-82a6-d57cd6cab452": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "胃肠道出血在初级试验的1组患者中比次级试验的1组患者更常见。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "de349a2d-80ee-4c34-ab9f-38eb467c77d7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "初级试验和次级试验不研究患者的PFS、ORR或DLT。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0d37bf26-bc74-4a01-9bc9-61e2fa3051da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "初级试验和次级试验在他们用于干预的药物中没有重叠。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "69f7a93d-7134-40ec-aff3-50acd7119d2c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "二级试验和初级试验都测量了他们的患者群体的PFS。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8de31b0f-7127-4c8b-b5e0-060e7a83fae5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "乔有已知的肝炎病史,但由于他18岁以上,仍然有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "207a1d82-a61b-4b5f-bebf-0706def6729d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "总体而言,二级试验只记录了比初级试验更多的粘膜炎症病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "968aeaf1-44b9-4454-8c99-e3c207037485": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "初级试验的1组中有4例发烧性中性衰竭和心力衰竭。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            5
        ]
    },
    "2b79f9cc-4262-4353-ad28-91cda07a9b9a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "患者必须具有 AST、ALP 和 ALT 低于 1.5 ULN 才能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            20
        ]
    },
    "d56ffd81-4007-477b-b3c3-0fdb89806931": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "糖尿病患者不适合进行初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "f62e6c20-862b-4ce3-9121-0d93ff050839": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01373671",
        "Secondary_id": "NCT00686127",
        "Statement": "Lidoderm产品用于二次试验的干预臂1中,而一款FFDM产品用于初级试验的臂1中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "833eeb4b-4921-468a-947d-bacfc7816ae6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Secondary_id": "NCT02131064",
        "Statement": "初级试验和次级试验调查其干预对患者TPCR的影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "二级试验记录了几次胃肠道不良事件,而初级试验没有记录任何 GI不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9
        ]
    },
    "c317750d-6ef7-494d-8040-2c7fa3d777fb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "二级试验和初级试验都使用MRI进行干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "87eca8d2-72fe-4285-9884-6d2ec7bae6df": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "初级试验的两群群体中有完全相同的贫血的比例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            12,
            14
        ]
    },
    "7a87c605-fc41-4d0a-9291-85e88f6eb510": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01000662",
        "Secondary_id": "NCT02413008",
        "Statement": "二级试验是测试在阴道内应用的 Gel,而主要试验是测试需要每天辐射乳房的干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fbb853c9-bed4-4cde-a283-2d91b23d35bf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "初级试验和次级试验都报告了侵入性疾病的病理证据,在他们的干预后,使用不同的结果测量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c3cc3621-a8ce-4f0d-a150-7e627f36e7c5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "QT间隔超过半秒的患者被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            29
        ]
    },
    "84aa97cf-efce-484e-825e-5af509e5988f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "初级试验的1组患者可以接受Afatinib单药剂量逐渐增加,高达起始剂量的160%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a40e172a-8839-499d-896d-be71a7ca4905": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03076190",
        "Secondary_id": "NCT03196635",
        "Statement": "分子乳房成像不适用于初级试验或次级试验干预,但所有参与这些研究的参与者都需要接受干细胞移植。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9e972e33-9ecd-4a8b-8337-7bee209f790b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "初级试验的群体1和群体2之间的区别是通过超声波评估,并为群体2的患者插入额外的负压排水。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            5,
            10,
            5
        ]
    },
    "f29768ba-5d79-4528-839f-933ab13faaa1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "初级试验和次级试验的所有受试者将接受4mCi Tc-99m sestamibi,并接受分子乳房成像。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "343e0a32-aebe-4bbb-97c0-b2c597c36802": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "初级试验记录了两种不同类型的疼痛在其不良事件,在腹部和胸部区域,二级试验没有记录任何类型的疼痛在其参与者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "4d51608c-b0d8-4019-9b9a-34cf1c3d5087": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "所有初级试验的参与者都接受了Lapatinib 1500 mg PO QD和Pazopanib 800 mg。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7bb88699-1536-4fdc-9cb2-c5ef350d559b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": "trastuzumab用于初级试验和次级试验的干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c86ef61b-7565-465a-82ba-25e7ac050ccc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "在初级试验中有1例出血病例,而在次级试验中没有记录病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "58dec898-e0af-41c1-96f9-7163d3e3e855": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "初级试验和次级试验记录了三种相同类型的不良事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "5cf74526-9f91-498d-a13a-6393dcd45b7b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "初级试验中的一个患者患有肝脏的炎症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "154caa20-3be1-4cee-a838-2d90b44566c4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "初级试验没有使用PFS来评估其干预的表现。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c40d8532-4e66-4eef-9644-91f20a02066d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "在初级试验中没有记录食管腺癌的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "3d450be5-4587-48e5-ae2e-745623606631": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "初级试验和次级试验都给他们的试验组每两周服用口服Carboplatin。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3
        ]
    },
    "fa28753a-aa3b-4642-9fd4-a2414fd8a472": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "初级试验中患者QTcF间隔的平均持续时间从基准的变化在第三周期的第1天,T-DM1静脉注射(IV)后达到最高水平。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "5e700303-cd26-4024-a260-62f6a1c297ed": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01000662",
        "Secondary_id": "NCT02413008",
        "Statement": "二级试验是测试将 Gel 应用于乳房,而初级试验是测试需要每天辐射乳房的干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4c4c191c-de68-44c8-a23c-2455acc43d46": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "在初级试验和次级试验中观察到的不良事件之间没有重叠。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "e5a4cb11-2a00-4144-93ba-f5462d7efbf0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "在初级试验和次级试验中,唯一口服的药物是萨拉卡蒂尼布和维利帕里布。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "初级试验的参与者比二级试验的患者获得了更多的阿纳斯特罗佐尔、莱特罗佐尔和埃克塞梅斯坦。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "27a4d1a8-185b-4483-85ce-0fbb3d323b99": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "初级试验中Talazoparib组中最短的PFS比研究持续时间长了一个多月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ff797dd4-0b4d-42fc-808d-27c439563ce2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "到初级试验的第48周,没有患者有完全响应,7患者有部分响应,15患者有进展性疾病。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "9f666667-0fde-4d79-b53c-33c0ffbbed90": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "保拉最近从楼梯上摔下来,骨折了臀部,她被排除在初审中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "47084742-d031-4e59-865c-d8687282c782": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "波拉最近心脏病发作,她被排除在初审中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "ae583ea3-36a5-472c-acda-825cd7d513b6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "在初级试验中,在1或2组中没有发生心肌梗塞。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "a18c447b-de08-48ef-8e65-0ecaa775c2b0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "初级试验中的一名患者患有阴道真菌感染。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "18b900fb-b071-43df-b37d-c68a89ef78c0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": "具有四个或多个轴心淋巴结转移的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "ebdf2841-b5e0-431a-8dc7-e100c5d27ccf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "患有三级外围神经病症或以上的患者被排除参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            16
        ]
    },
    "d56745c3-ba0b-4b42-b3cf-ac060f658d83": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "急性冠状动脉综合征是初级试验中最常见的不良事件,除了 Thrombocytopenia 。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "0ef77b5d-684a-4a87-bf61-8d4bc9975b7f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "初级试验仅在其两群组中共有6名患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "03c7f31f-788c-4edb-a885-b6cb0fca05da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "在初级试验中,对照组的患者有0.037的Z分数,高于测试组的分数。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "e43c01e9-20a2-4435-a32b-224d5f460d7c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "初级试验1组患者的最小无进展生存期为1.6个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c55f34ab-b883-465e-89dc-75bbeb8afa77": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "初级试验中的一个患者有确认的肿瘤部分反应,二级试验中的没有患者对肿瘤反应进行了评估。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0ee36ceb-5790-440e-b6ad-10a0b7a23f43": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "初级试验的群体1的参与者接受乳房检查,而次级试验的群体1的患者接受6mg的雌激素,没有乳房检查。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2535da13-e0f7-44df-aa02-89765d8d51cb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "HER2 + 乳腺癌 1-4 阶段的患者有资格参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "94fc6e05-8a73-43d9-a48c-531d36dfbbcd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "初级试验中的大多数乳腺癌患者在12周后获得了至少接近完全的病理反应,或者更好。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "0057172f-d019-401b-a516-993a7b46a67b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "初级试验中的群体1的参与者比群体2的参与者接受了更多的Dasatinib。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "bb23e8b8-c7d6-4e58-80a2-0555db5645e9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "女性患者最近处方Rapamycin不符合初级试验的条件,但可能有资格参加二级试验,只要他们有第1阶段至第2阶段的管道癌在现场,并能说英语。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c4588d2c-b0d4-428d-a958-29787b9d4ec5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "只有初级试验的2组接受了Bevacizumab,但两组都接受了内分泌治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "具有临床意义的3级PVD的患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18
        ]
    },
    "00466f98-52b8-41f3-9bf1-2edaad950be9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02504424",
        "Secondary_id": "NCT03708393",
        "Statement": "初级试验和次级试验都要求患者通过远程控制激活干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "50a524ae-2135-45f7-ae9b-515fd4e2e404": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "在初级试验中,超过一半的患者经历了不良事件,而在二级试验中,100%的患者没有出现不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b2062e01-0ea6-4ee8-94a1-b59dc40901d3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": "患者必须具有 histologically 或 cytologically 确认的 ERBB2+ 侵入性乳腺癌, 主要肿瘤 直径 > 2 cm 才能参与初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4dbce51b-1cfc-4d5f-82bb-ce9319ace3af": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "初级试验的1和2组接受不同剂量的不同药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "43a9cc96-4020-459c-8fa4-4bbde7173f7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "在初级试验中,11名患者出现严重不良事件,没有患者出现严重的药物不良反应,超过一半的患者死于意外不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "ff319fa6-89b6-4f1a-871d-456edb91b69b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "沙龙在3周前接受了臀部更换,她不能参加初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            6
        ]
    },
    "a321acf0-2296-4588-bf96-85b22bf1420f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "在两群群体的初级试验中,总共发生了14例与中性热症相关的不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "b841dfd8-4676-4d3c-a57d-6ba1055b8597": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "一名患者接受了6个月的Pertuzumab治疗,该治疗在研究入学前2个月中止,患者已经完全康复,因此该患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            25
        ]
    },
    "1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "在初级试验中观察到的 1-Pemetrexed-d-tryptophan (indoximod) 的最大容忍剂量(MTD)为 800 mg。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "48d40c7e-3514-43c3-a31a-7b391727f012": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "在初级试验中使用的MM-121剂量较低,而不是在2试验中,Paclitaxel剂量对于两组均相同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "dd98fca1-27a7-41c2-ba0c-3ff90aceab54": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "患者必须呈现IHC 3+或FISH增强结果,以参加初级试验,这意味着他们的癌症已被 histologically确认为HER2阳性。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "b975dc12-757e-4ef5-af33-83dfce12e6cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "初级试验仅记录GI不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "2c4254c9-9c40-492f-aa45-2a9ab47579b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "女性患者LVEF > 50% 之前曾接受过特拉斯图苏马布 emtansine 或 lapatinib 治疗仍然符合次级试验的条件,但被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "e140b055-b7fc-4802-a79b-9dfe7d136876": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "初级试验和次级试验正在测试完全不同的干预方式。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0a6418c8-63a6-4900-bfc9-1659acbe1ad7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "初级试验中至少有8名参与者中枢神经系统(CNS)无进展生存期(PFS) >=3个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "2db9e0c7-d94b-47d2-a61f-55a0896d714e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "二级试验报告了更多 Haematemesis 病例,但初级试验有更多的 Sinus tachycardia 病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "3129e58d-0c16-42a5-90b4-f26e048dfe58": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "在整个初级试验中,一组1的患者出现了视力问题。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "7be7cecb-d265-4098-9969-a40555702573": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "初级试验中的1名患者被诊断为流感。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            12
        ]
    },
    "5b0d3709-7879-4dea-96c3-29178cd9f162": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "初级试验的两组报告了在试验期间呕吐的患者数量相同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "af70a3a9-d2d0-4d65-81fe-15a1becb5e95": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "初级试验和次级试验都具有控制臂和几个测试臂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a378f448-eef0-465a-abc0-8b4dd1156bb5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "HER2阳性乳腺肿瘤的患者有资格参加初级试验和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "f30182a1-b82a-497c-885c-9bd2e805db62": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "所有初级试验的患者都必须喝237毫升水,无论是碱性水还是蒸水,取决于他们所处的群体。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ae87e5a3-fdd8-4003-ae80-4b370cade158": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "2 %的初级试验患者有3年以下的无复发生存期。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "9f3062db-16fb-41b8-ac10-f205f66070c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "大多数在初级试验中用Dasatinib和Letrozole治疗的患者有超过2年的无疾病间隔(DFI)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "a1c5685a-8e6e-4733-aa8b-7040bac1a397": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "初级试验中没有任何一群患者有超过6个月的PFS。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "d58683e2-d276-4184-a8e9-c9df6ffd8047": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "初级试验参与者最多服用萨拉卡蒂尼布PO 28 天。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "28d8f88a-e8cb-40c0-a12b-ef555f83ff59": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "患者必须有 LVEF < 50% 才能符合初级试验和次级试验的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "0ee4c935-18bd-4807-a2af-041a3d84e125": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie已经和她的男朋友住了2个月,她有资格参加初审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            6
        ]
    },
    "355fb813-cbe0-44f5-b04a-87813e060d54": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "患者必须有Eceptorsestrogen受体(ER) - progesterone受体(PR) - 和人类表皮生长因子受体2(HER2) - 乳腺癌,以及没有 dysphagia。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            8,
            12
        ]
    },
    "274d9d2b-9227-4496-a525-d5477b0003ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "二次试验组 1 中的更多患者患有肢体肿胀,而不是初级试验组 2 的患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "3ab9c66c-06fc-4bc5-b504-d9193efa8701": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "在初级试验中,来自不同种族的参与者接受了不同的干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "d39078d9-9bc3-4b91-a012-e95f14813c9a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "菲奥娜的妹妹34岁被诊断患有通道癌症,因此菲奥娜可能有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "02538194-97ac-4749-9301-83f108927478": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "具有 ER 阳性、PR 阳性或 HER2 阳性肿瘤的患者可能有资格参加二级试验或初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            14,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            14,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            14,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42
        ]
    },
    "6d9113b4-9d18-4a1b-bc78-cc3ac1150876": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "每个患者在初级试验中接受3种不同的药物,而在次级试验中,患者接受2种可能的药物中的1种。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "99599b71-85d7-4c15-8d23-4294732f87cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "所有初级试验的参与者都接受了Lapatinib 1500 mg PO QD。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "adbc193f-ffd6-49ce-9acd-7b1675adf0c0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "雷切尔19岁,皮肤溃和对三克洛桑过敏反应,她不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            4,
            8,
            9
        ]
    },
    "c476f92a-a450-4e5c-9688-6557ff3d822b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "患者必须有健康的肾脏、肝脏和卵巢才能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "39d685a4-b179-4687-a273-2a44e675f2c6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "初级试验中的两组接受了相同的药物治疗,但第二组获得了两倍的剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c66963b9-19e0-4c0f-bb65-2fec15e60b8f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "在初级试验中最常见的副作用是感染和胃炎,共影响14名患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f541ce25-c43e-496b-98e6-8470fe23f840": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "总体而言,二级试验的1组不良事件比初级试验的2组不良事件多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            14,
            15
        ]
    },
    "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "初级试验的干预2导致乳腺密度比干预1的比例较低。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "24d81b18-ce9c-4927-9386-9ebef969a159": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "在初级试验中,治疗时间是二级试验中的一半。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0046e113-8ac5-4725-a285-e78b8c26f825": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "为了满足初级试验的纳入标准,患者必须在研究入学前接受阿罗马达酶抑制剂(AI)治疗,导致肿瘤完全响应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "e90f7748-f4b4-4822-8768-586c3f2f9980": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "为了符合二级试验和初级试验的资格,患者必须是女性,18岁以上,ECOG <2,并具有HER2 +乳腺癌的 histologically确认。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            10,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "fb8f09d6-c393-4943-bc67-fa0f0a6bdd86": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "更年期后患者被排除在二级试验中,但有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3c3fb5e3-1994-455a-bae4-6d267c5c89d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "患有I级外围神经病症或以上的患者被排除参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            16
        ]
    },
    "2ecd62df-f5ea-417d-8783-2174a6d77087": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "初级试验的参与者必须在干预期间至少进行一次MRI和严格的化疗团,而在二级试验中,患者必须使用Fitbit。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "b43c02bf-c4b0-495f-b7ba-879f409cb685": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "初级试验中的所有受试者都必须遵守定期的练习时间表。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "fdff0cf1-a0a2-4516-bdf7-109ac7adb266": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "只有在出生时被分配为女性的患者才有资格参加二级试验和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            6,
            7
        ],
        "Secondary_evidence_index": [
            18,
            38
        ]
    },
    "6babfc60-5043-4f2b-9605-3e44744265e9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "初级试验中的80%的患者没有出现任何不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "5ca02204-6120-4b02-bf3b-fba94d6fac4f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "在初级试验中,不超过1%的群体都感到恶心。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            12,
            13,
            25
        ]
    },
    "625c2690-ec9e-4ecc-85c0-9b5ca8467848": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "患者不能根据性别或种族被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "c28ad685-4c91-492a-85ab-180f37d9cef5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "在初级试验中记录了1个GU和3个GI不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "52e8d676-1744-4fdb-bab4-a553874329bd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "外部神经病症>0的女性患者被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            12
        ]
    },
    "beff8878-9405-412d-af3a-0f2720275bf3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "初级试验和次级试验都使用皮下注射作为其干预的服用途径。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "96f41881-6ba5-4688-8471-9462fc727919": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "在初级试验中的平均1组参与者中,脊椎骨矿物密度增加,而在2组参与者中,矿物密度增加。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9dbf55d5-6af3-4250-b5cb-97799cdf778a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "初级试验中没有发生脑内出血的情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e8ce8686-8d5f-4d31-b442-0cb52b7b2bec": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "初级试验的参与者服用比莱特罗佐尔更高剂量伊马蒂尼布梅西拉特,但服用莱特罗佐尔的频率是两倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d72709fd-e94e-4c27-bf56-3f028c0bbd3f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "大多数初级试验参与者达到CR或PR。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "最佳总体响应(BOR)在初级试验的群体1中比群体2中高出不到10%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "49f44497-2382-4658-b716-38e66c5c52b7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Cohort B的干预被描述为阿法提尼布50mg,口服,为研究的每一天。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4a6dc84a-3afd-4060-b8c5-981895f31099": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "心肌病和凝血障碍的病例仅在初级试验的1组中观察到。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "11e84dc4-6573-4ad7-b2d9-cfc66b626e1c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "初级试验1组中的四分之一以上的患者经历了不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "f1f2e066-a016-422f-8627-d0e477933352": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "在初级试验的患者群体中,观察到3种不同类型的感染。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "efbd87d7-f8ac-42c6-ac9a-e3a35d354885": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "具有94%的卡诺夫斯基状态的患者有资格参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            16
        ]
    },
    "a604244f-789f-4c12-8c5a-96c86d1b976e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "在初级试验中观察到的第 4 周血清 Beta C 终端交叉链接型 I 胶原蛋白(betaCTX)的变化最大是 AZD0530 175 mg 组中的患者,与初级试验相比发生了 -75.9% 的变化。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2b543cc7-e295-4dc6-ad04-a2e43e9b3d97": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "初级试验中的2组患者中发生了两种不同类型的心脏病。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            22,
            23
        ]
    },
    "987b1da5-0276-417d-a659-8e298529ccac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "在初级试验中,在服用100mg与125mg口服PD-0332991的剂量限制性毒性参与者数量/百分比中没有记录的差异。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b9e8a0b3-574f-4079-9191-214af99e97a8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "T1-4N1-3M1 早期入侵性乳腺癌的更年期妇女有资格参加初级试验,T4-4N1-3M1 早期入侵性乳腺癌的妇女有资格参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2
        ]
    },
    "0151d1fa-05c8-45a0-b21e-f08478ea5110": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil,酮和循环磷酸胺(FEC)在二次试验的两组中使用,但不是在初级试验的一组中使用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Secondary_id": "NCT00290758",
        "Statement": "在初级试验和次级试验中观察到几个不同的心理健康问题。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "b838a265-99e4-42f0-bd72-b4f72d7eb16e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "一名患者接受了6个月的Pertuzumab治疗,该治疗在入学前不到1个月中断,患者尚未完全康复,因此该患者有资格参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            25
        ]
    },
    "240e9cb0-3e40-4478-9d2c-fb4ff22e1e21": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "患有呕吐的患者仍然有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            26
        ]
    },
    "a1644573-fba8-4598-8353-a40d3ef1968c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "以前用化疗治疗4级癌症的患者不符合初级试验或次级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            26
        ]
    },
    "ba533122-db9d-49e1-a2d1-936c8fdfdd00": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "初级试验1组中超过15名患者经历了不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "f20cd859-7159-457a-a1cb-56bdb01d521b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "在两群团体的初级试验中共有7例胃炎病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "d33df923-6c12-4135-b339-5cefdd240985": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "初级试验中的任何一个群体都没有超过5%的患者出现副作用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            11,
            12
        ]
    },
    "0f49a1ec-ed73-465b-be20-b70fe990b1f0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "在初级试验中记录了几起凝血不良事件,但在次级试验中没有一个。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "7370c10d-f6e7-4153-9649-9d2598ce1ed7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03196635",
        "Secondary_id": "NCT01943916",
        "Statement": "初级试验和次级试验都评估成像技术。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "3f89537a-479e-4314-b9de-4caf845850fc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "在初级试验中观察到的第 4 周血清 Beta C 终端交叉链接类型 I 胶原蛋白(betaCTX)的变化最大是Zoledronic Acid 4 mg 组中的患者,与初级试验相比,变化为 -73,0%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "8e9f417a-dc0f-4c20-9cf7-5f8586c23df2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "患者将不得不接受脊椎的MRI扫描,在进入前进行二级试验和初级试验,对于初级试验的患者还需要进行脑部MR和PET成像,研究入学后。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            2
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "8ba451be-606a-4a57-a85e-82b5e5b286fc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "3/49的初级试验参与者HER2表达的转移性和/或不可转移性乳腺癌的QTcF的最大变化从基线超过30ms。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "46906361-5133-4db9-b9e5-b9b7f80a8666": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "初级试验和次级试验记录了患有恶心症的患者比例相同。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            7
        ]
    },
    "ab17f223-3f70-4b63-bfc5-1fca5d6ec05d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "为了有资格参加初级试验,患者必须没有先前的辐射,安特拉西克林或系统性抗癌治疗,并且必须有T1-3,N0和M0乳腺癌。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            13,
            14,
            15,
            19
        ]
    },
    "3320983d-55cb-49f9-9265-ca4e77acf62a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "在过去一个月内注射了关节注射的患者不符合初级试验的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "6c57e451-a706-4b32-ae71-254e9d0e04de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "初级试验中的任何患者都没有患有 Thrombocytopenia、心力衰竭、pancytopenia、急性冠状综合征或疮。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            7,
            9,
            10,
            11
        ]
    },
    "73a5f715-6d4c-43f3-ace4-9f1217d3d0c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "初级试验不是测试基于药物的干预,而是测试一种名为Flexitouch的医疗设备。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "83883edd-ea16-4b20-8a97-2a545f957add": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "二级试验只记录胃肠道不良事件,而初级试验没有记录任何 GI不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "ad0628ef-be51-4d54-a5c6-7608df258629": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "对于接受初级试验的患者,橙汁是禁止的。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "619d88fd-cef5-4f1a-83dc-3cc710c1c93d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "在初级试验中,不到30%的患者至少经历了1次不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "42d6a15e-fa43-4ebc-b627-70f4dd0233f8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "初级试验的2号群体接受了比1号群体更高的Ixabepilone剂量,但服用了相同的Epirubicin剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fc60c272-ceeb-47b5-b25b-dca832a2a57e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "实验室生物标志物分析和问卷在二级试验和初级试验中使用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "dfe1236f-ac29-4c1c-a287-6f46abb7703d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "皮肤感染在二级试验的2组患者中比初级试验的1组患者更常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            13,
            21
        ]
    },
    "b1060434-0f7c-4c4a-bcff-53c3124bb51e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "初级试验的1号群体产生了比2号群体更好的客观响应率结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "e2862bbf-562f-4c96-abf1-fc9f07655b46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "不幸的是,患有膜转移的女性被排除在初级试验中,因为这会使神经学和其他不良事件的评估变得复杂。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18,
            19
        ]
    },
    "aed75656-1594-4d99-be42-7097f7926c18": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "至少有一名初级试验参与者在不到100天内死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "6ce5a9d7-5793-43b0-92ed-980cca3be02b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "初级试验报告了总共3例皮肤发出,Astenia和Gastritis在1组合。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            8,
            9
        ]
    },
    "b2a4f905-c6b5-4977-95de-5aa6424a5bb6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "为了被纳入初级试验,患者必须至少有1个单维可测量的损伤,没有资格的尺寸限制。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5,
            8
        ]
    },
    "a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "在初级试验的1组中记录了4种不同的消化肠道不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            6,
            7,
            8
        ]
    },
    "4db02d9b-d96e-4ced-947c-71cebcccc933": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "系统性疮患者被排除在初级试验中,但仍然有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            24,
            32
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35
        ]
    },
    "cfb07772-e485-491c-8ae3-9009e3d04415": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "初级试验中的一个患者的WBC数值远低于正常水平。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "a283b69c-0f36-4773-a711-9e6088a8ee63": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "初级试验中的2组患者接受纳普罗克森的频率与第二组试验中的2组患者接受Pilocarpine的频率相同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "8d90d538-3b56-48dd-bd58-007d266c923c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "初级试验中唯一发生心脏问题的病例发生在1组中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "fa0fe1a0-2b89-4b78-8fdb-04dee84b4421": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "患者不需要性活跃才能接受初级试验干预,但这是次级试验的要求。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "8502cb9e-e382-41bc-b547-02d2d7beb381": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "初级试验测试了两个不同的乳房成像模式,即X射线和伽马成像。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f6c64bb3-1836-4685-8541-8856f003524b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "患有不可测量的疾病的患者仅有资格参加初级试验的第一阶段。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6
        ]
    },
    "79272218-91b9-4331-ba44-6a3709a13f62": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "二级试验和初级试验研究了参与者的进展自由生存率(PFS),但他们使用不同的衡量单位。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            9,
            10
        ]
    },
    "97e3b0d7-3320-4eb5-bc42-5031db87692e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "初级试验和次级试验都报告了患者的客观反应率(ORR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "83251670-803e-4fec-a5cf-50f052932752": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "在初级试验中,所有患有疾病进展的参与者(经过16周的治疗)都服用了阿法提尼布50毫克与莱特罗索尔组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "初级试验中的1名患者突然失去心脏功能。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "在初级试验中,最常见的不良事件是发烧性中毒性(42.86%),而在次级试验中,排泄率下降(4.95%)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "97812fde-57f3-4299-be34-dd436757adde": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "癌细胞在颈椎上方的淋巴结中的患者不能进入初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "f37774f4-db96-4aa6-b3a1-626953faeecf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "适当的血液,肾脏和肝脏功能是必要的参加二级试验,但这种情况在初级试验中没有指定。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            7
        ]
    },
    "4fef4cdf-53bf-4239-9d31-4710fd3edc6f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "初级试验中的Ridaforolimus + Dalotuzumab + Exemestane组中间PFS超过38.43个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "在初级试验中使用的干预措施之间的唯一区别是患者的位置。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a577e819-c928-4217-8743-f4809e852919": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "患者必须有白细胞数超过1500/mm,才能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18
        ]
    },
    "bd073d05-3ba2-4898-9d86-a51951a7ad1f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "初级试验和次级试验都使用肿瘤客观响应率来衡量其不同干预的效果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    }
}